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Colorectal cancer remains a significant cause of morbidity and mortality worldwide. Half of all patients 
develop liver metastases, presenting unique challenges for their treatment. Irinotecan is a 
topoisomerase I inhibitor used to treat metastatic colorectal cancers. Its use is limited by severe dose-
limiting toxicities and heterogeneity in its clinical response. Moreover, the clinical use of the active 
metabolite (7-Ethyl-10-hydroxycamptothecin, SN-38) is significantly limited due to poor solubility, 
instability and a short elimination half-life. Thus, the shortcomings of conventional chemotherapy 
have encouraged the exploration of nanomedicines; the application of nanotechnology in the 
diagnosis and treatment of disease. 
This thesis describes the development of SN-38 loaded nanoparticles for use in the treatment of 
colorectal cancer, particularly advanced stage metastatic disease, to improve both the safety and 
effectiveness of available therapies. For screening purposes, a robust and sensitive liquid 
chromatography-tandem mass spectrometry assay for the detection of irinotecan, SN-38 and SN-38 
glucuronide was developed and colorectal cancer spheroids were characterised for their use in 
assessing cytotoxicity. Several polymer nanomaterials were thereafter screened for drug release, 
cytotoxicity and macrophage uptake. Subsequently, the pharmacokinetic profiles of the best 
candidates were compared to free SN-38 and irinotecan in vivo. In the final year of the PhD, the world 
was afflicted by the COVID-19 pandemic, which resulted in a change of focus towards assessing 
potential drug repurposing opportunities for SARS-CoV-2 antivirals. 
As demonstrated in chapter 2 the liquid chromatography-tandem mass spectrometry assay was fully 
validated to FDA guidelines in PBS and mouse plasma. In chapter 3 the physiological relevance of 
spheroids was shown, with their ability to mimic the in vivo/clinical environment better than 
monolayer cultures. In particular, drug sensitivity and uptake differed between culture systems, due 
to the arrangement of cancer cells in spheroids i.e. the outer rim of actively proliferating cells, a middle 
viable layer of quiescent cells and an internal necrotic core. Therefore, such properties of spheroids 
meant they would represent a more robust tool for drug screening purposes. A panel of polymer 
nanomaterials were screened in chapter 4. Formulations SB1 and CA16 were selected on the basis 
that they showed a slower sustained release profile, adequate cytotoxicity against colorectal cancer 
cells and minimal macrophage uptake. However, when given in vivo both formulations did not lead to 
the prolonged circulation of SN-38. In comparison to irinotecan, significantly lower concentrations of 
SN-38 released from nanoparticles were present in the plasma (p ≤ 0.001 for SB1 or CA16 versus 
irinotecan). The data indicated possible non-specific uptake of the nanoparticles within other organs. 
The analysis for drug repurposing to target COVID-19, included in appendix A, highlighted the 
importance of taking into account the achievable plasma pharmacokinetics as an indicator of antiviral 
activity. Several drug candidates were identified (13 drugs showed plasma exposures above that 
required for an antiviral activity) and were recommended for further investigation. 
In conclusion, despite promising in vitro data SN-38 loaded nanoparticles did not display better 
pharmacokinetic properties (AUC and Cmax) over the parent drug irinotecan in vivo. However, areas 
warranting further investigation to improve translation, such as nanoparticle biodistribution and 
potential toxicity, were demonstrated. Furthermore, to address the challenges of targeting metastatic 
tumours with nanotechnology, it is necessary to combine the rational design of nanoparticles with the 
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DAB  3,3’-Diaminobenzidine An organic compound that is used in the staining of 
nucleic acids and proteins 
dH20  Deionised Water Water that has been treated to remove all ions 
DMEM  Dulbecco's Modified Eagle Medium Cell culture medium 
DMSO  Dimethyl Sulfoxide A colourless organosulfur solvent, which dissolves both 
polar and non-polar compounds 
DNA  Deoxyribonucleic Acid A double-stranded polymer containing four bases 
tethered to a sugar-phosphate backbone 
DTT  Dithiothreitol A reducing agent  
ECM  Extracellular Matrix A three-dimensional network of extracellular 
macromolecules that provides structural and biochemical 
support  
EGFR Epidermal Growth Factor Receptor A type of receptor tyrosine kinase involved in cell 
signalling pathways that control cell division and survival 
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EMA European Medicines Agency A decentralized agency of the EU responsible for the 
scientific evaluation, supervision and safety monitoring of 
medicines 
EPR  Enhanced Permeability and 
Retention Effect 
A phenomena governing the transport of macromolecules 
and drug-delivery systems to the tumour site 
FA  Folinic Acid A form of folic acid that acts as a chemoprotective agent 
and a type of chemosensitising agent 
FAP  Familial Adenomatous Polyposis An autosomal-dominant, precancerous condition of the 
colon  
FBS  Foetal Bovine Serum Growth medium additive 
FDA Food and Drug Administration An agency of the United States Department of Health and 
Human Services whose principal purpose is to enforce the 
Federal Food, Drug and Cosmetic Act 
Fu  Fraction Unbound  The fraction of drug in plasma that is not bound to a 
carrier protein or other molecule, which generally is 
pharmacologically active 
H&E  Haematoxylin and Eosin Staining technique 
HGF  Hepatocyte Growth Factor A protein that regulates cell growth, cell motility and 
morphogenesis  
HSC  Hepatic Stellate Cells Liver-specific mesenchymal cells that play vital roles in 
liver physiology and fibrogenesis 
HTS  High Throughput Screening A drug discovery process that allows automated testing of 
large numbers of chemical and/or biological compounds 
for a specific biological target 
IC50  Half Maximal Inhibitory 
Concentration 
The concentration of a chemical required to exert an 
inhibitory effect on 50% of the population 
IF  Immunofluorescence A technique that uses a detector antibody or an antigen 
labelled with fluorescent dyes 
IS Internal Standard A chemical substance that is added in a constant amount 
to samples 
IV  Intravenous Solutions administered directly into the venous 
circulation 
KC  Kupffer Cells A macrophage present within the liver sinusoids 
LC-
MS/MS  
Liquid Chromatography Coupled 
with Tandem Mass Spectrometry 
Analytical chemistry technique 
LDS  Lithium Dodecyl Sulphate Sample buffer used to prepare proteins 
LLOQ  Lower Limit of Quantification Lowest analyte concentration that can be quantitatively 
detected 
LSEC  Liver Sinusoidal Endothelial Cells Form the wall of the liver sinusoids 
LYVE-1 Lymphatic Vessel Endothelial 
Hyaluronan Receptor 
A type I integral membrane glycoprotein that binds to 
hyaluronan 
MCRC  Metastatic Colorectal Cancer Cancer cells which have spread beyond the colon to other 
organs 
MMR  Mismatch Repair Repairs mismatches induced during replication 
MOI  Multiplicity of Infection Number of virions that are added per cell during infection 
MPS Mononuclear Phagocytic System Class of cells that occur in widely separated parts of the 
human body and that have in common the property of 
phagocytosis 
MRM Multiple Reaction Monitoring A highly specific and sensitive mass spectrometry 
technique used to selectively quantify compounds  
MSI  Microsatellite Instability A change that occurs in certain cells in which the number 
of repeated DNA bases is different from what it was when 
inherited 
MW  Molecular Weight The sum of the atomic masses of all atoms in a molecule 
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NK Natural Killer Cells A type of immune cell that has granules with enzymes that 
can kill tumour cells or cells infected with a virus 
NME  New Molecular Entity An active ingredient that contains no active moiety that 
has been previously approved 
NO  Nitric Oxide  A toxic compound that acts as a vasodilator 
NP  Nanoparticles A wide class of materials that are smaller than 1000nm 
NPC Non-parenchymal cells Specialised cells that interact with hepatocytes to form a 
functional hepatic unit 
NSAID  Non-Steroidal Anti-Inflammatory 
Drugs 
A class of drugs that are widely used to relieve pain and 
reduce inflammation 
OS  Overall Survival The length of time from either the date of diagnosis or the 
start of treatment for a disease 
OTC  Over-The-Counter A drug classified safe and effective for use by the general 
public without a doctor's prescription 
PBPK Physiologically Based 
Pharmacokinetics 
A mathematical modelling technique for predicting the 
absorption, distribution, metabolism and excretion of 
drugs 
PBS  Phosphate-Buffered Saline A buffer solution 
PCR  Polymerase Chain Reaction A technique that enables the amplification of small 
amounts of DNA 
PEG  Polyethylene glycol A linear synthetic polyether 
PFA  Paraformaldehyde Tissue fixative 
PPI  Protease and Phosphatase Inhibitor A reagent used for protein sample protection for cell and 
tissue lysates 
QC  Quality control  
RIPA  Radioimmunoprecipitation Assay  A lysis buffer used to lyse cells and tissues 
ROS Reactive Oxygen Species A type of unstable molecule that contains oxygen and that 
easily reacts with other molecules in a cell 
RPMI  Roswell Park Memorial Institute Growth medium 
RT  Room Temperature  
SARS-
CoV-2  
Severe Acute Respiratory Syndrome 
Coronavirus 2 
The strain of coronavirus that causes coronavirus disease 
2019 
SD  Standard Deviation  
SDS  Sodium Dodecyl Sulfate Anionic surfactant 
SN-38G  SN-38 Glucuronide Metabolite of irinotecan 
T1/2  The time required to reduce the plasma concentration to 
half of its initial value 
Tmax  The time taken to reach the maximum concentration 
TNM  Tumour Node Metastases Cancer staging system 
TOP I  Topoisomerase I An enzyme that reduces supercoiling in DNA  
UGT  Uridine Diphosphate 
Glucuronosyltransferase 
An enzyme responsible for the formation of glucuronides  





Chapter 1: General Introduction 
1.1 Introduction  
Cancer is one of the foremost causes of death globally. According to the World Health Organization's 
World Cancer Report, in 2018 there were an estimated 18 million new cases of cancer with a reported 
10 million deaths worldwide. The predicted global burden is expected to double to about 29–37 
million new cancer cases by 2040 (World Health Organization, 2020). Cancer is a complex disease that 
arises from the transformation of normal cells into tumour cells in a multistage process. The 
complexity of cancer pathophysiology requires much efforts to identify the best approach for its 
successful management. Despite attempts to mitigate risk factors, the prevalence of cancer is 
continuing to increase. Over the next decade, cancer will be diagnosed in about 200 million people 
who will require care (World Health Organization, 2020). Treatment must, therefore, be improved and 
capacity scaled up. 
Current standards of care combine precise staging of cancer with chemotherapy, radiotherapy and/or 
surgical resection. Radiotherapy and chemotherapy are known for significant adverse effects, with 
most methods targeting non-specifically any rapidly dividing cells irrespective of whether they are 
tumourous or not. Furthermore, poor pharmacokinetic characteristics of anticancer drugs arising from 
poor solubility, stability and metabolism pose challenges relating to toxicity, inefficacy and limited bio-
distribution. Thus, it is imperative to develop effective therapies that can address these challenges 
and provide selective targeting of tumour sites. In particular, nanomedicines are being studied to 
achieve effective drug delivery, establish novel in vitro diagnostics, and develop nano-based implants. 
In the past decade, approximately 12,000 reports on the topic of nanomaterials as drug carriers in 
cancer treatment have been published (Z. Li, Tan, Li, Shen, & Wang, 2017). The design and synthesis 
of a library of nanomaterials, precise control over their physicochemical properties and ease of their 
surface functionalisation, has brought nano-based formulations to the forefront of medical research, 
emerging as potential tools for cancer treatment and its management.  
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1.2 Colorectal Cancer and its Treatments 
Colorectal cancer (CRC) is the third most common cancer worldwide, with more than 1.8 million new 
cases diagnosed in 2018 (10.2% of the total number of cancers diagnosed; (Bray et al., 2018). In the 
United Kingdom, CRC is the fourth most common cancer amongst men and women with over 41,000 
people being diagnosed annually, a trend that has gradually increased over the last 50 years (Cancer 
Research UK, 2018). Metastatic disease often occurs for patients with CRC and the lungs, liver, 
peritoneum and brain are primarily involved. For instance, at diagnosis, 14–20% of patients present 
with hepatic metastases (synchronous), and up to a third of patients will subsequently develop hepatic 
metastases (metachronous) during their disease (Adam et al., 2015). Survival is greatly dependent on 
the stage of cancer and the five-year overall survival (OS) for metastatic CRC (mCRC) remains low; less 
than 10% in recent reports (Cancer Research UK, 2018). This results in CRC being a leading cause of 
cancer deaths and represents a significant burden on patients, families and the healthcare system. 
Metastatic disease often occurs for patients with CRC and the lungs, liver, peritoneum and brain are 
primarily involved. For instance, at diagnosis, 14–20% of patients present with hepatic metastases 
(synchronous), and up to a third of patients will subsequently develop hepatic metastases 
(metachronous) during their disease (Adam et al., 2015). Survival is greatly dependent on the stage of 
cancer and the five-year OS for metastatic CRC (mCRC) remains low; less than 10% in recent reports 
(Cancer Research UK, 2018). This results in CRC being a leading cause of cancer deaths and represents 
a significant burden on patients, families and the healthcare system. 
1.2.1 Surgery 
In general, patients with mCRC who go untreated have a median survival of 5–6 months. Several 
treatment options are available for patients with colorectal liver metastases (CLM), with 
chemotherapy and surgical resection forming the backbone of treatment in these patients. Surgical 
resection is the only treatment that offers a potential chance of cure and long-term survival with 5-
year survival reported to be over 50% in recent studies (Aloia et al., 2006; Donadon, Ribero, Morris-
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Stiff, Abdalla, & Vauthey, 2007; Fernandez et al., 2004). The overall median survival following liver 
resection in patients with CLM is reported to be 3.6 years. Patient selection is fundamental and several 
factors must be considered, including medical tolerability and technical/oncologic feasibility. Only 20% 
to 30% of patients with CLM are suitable for hepatic resection (Folprecht, Grothey, Alberts, Raab, & 
Kohne, 2005; Nordlinger et al., 2009). 
Not all patients undergoing resection experience long-term benefit – around 30% develop recurrence 
and 15% succumb to their disease a year after surgery (Jones et al., 2012). This is because surgery 
leaves small clusters of tumour cells that cannot be removed or detected on scans or other tests. Some 
months after surgery, these cancer cells can proliferate again. Hence, long term survival is still only 
possible in a small minority of patients with mCRC. Therefore, to increase OS in this setting, several 
licensed agents are normally used to complement surgery. 
1.2.2 Radiotherapy 
Radiotherapy uses ionising radiation to eliminate cancer cells and is often used as a palliative 
treatment. Radiotherapy is less common for colon cancers but is utilised for rectal cancers. The 
indications for radiation in rectal cancer are to reduce the risk of local recurrence and to shrink locally 
advanced tumours to facilitate successful resection. In a Cochrane review, it was concluded that 
preoperative radiotherapy reduces the risk of local recurrence compared with surgery alone and 
overall mortality is marginally improved (R. K. S. Wong, Tandan, De Silva, & Figueredo, 2007). 
1.2.3 Chemotherapy 
The use of chemotherapy for advanced and mCRC was introduced by Charles Heidelberger with the 
discovery of 5-fluorouracil (5-FU), an antimetabolite that interferes with deoxyribonucleic acid (DNA) 
biosynthesis through the inhibition of thymidylate synthase (Heidelberger et al., 1957). It was later 
detected that the addition of folinic acid (FA) potentiated the effects of 5-FU, by stabilising the binding 
of 5-FU to thymidylate synthase to further enhance its inhibitory effect (Ullman, Lee, Martin, & Santi, 
1978). Hence 5-FU/FA regimens gained acceptance in the early nineties in both the adjuvant and 
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metastatic setting (Poon et al., 1989). However, major advances in the evolution of chemotherapy for 
CRC were not achieved until the early 2000s when irinotecan (topoisomerase I inhibitor), oxaliplatin 
(a platinum-based alkylating agent) and the 5-FU prodrug capecitabine were introduced and 
combination therapies were formed (Gustavsson et al., 2015). Combination regimens have since 
become standard practice following their introduction and include; 
• FOLFOX (folinic acid, 5-fluorouracil and oxaliplatin) 
• FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) 
• FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan and oxaliplatin) 
• XELOX (capecitabine, oxaliplatin) followed by FOLFIRI. 
Both combination therapies (FOLFOX, FOLFIRI) have become standard cytotoxic combination 
regimens for the treatment of mCRC. Several trials (GERCOR and GOIM studies) showed similar 
efficacy for the FOLFIRI and FOLFOX regimens in patients with advanced CRC (Colucci et al., 2005; 
Tournigand et al., 2004). Both FOLFIRI and FOLFOX have been stated to enable a resection rate of 9-
40% amongst patients with initially unresectable CRC liver metastases (Nordlinger et al., 2007). 
Combination chemotherapy, however, is not indicated as a first-line systemic treatment in all patients. 
A preference of combination or single-agent therapy as first-line treatment is dependent on patient 
and tumour-related factors and the fundamental aim of the therapy. Combination treatment choice 
is further based on differences in toxicity profiles between these regimens i.e. additional 
gastrointestinal side effects with FOLFIRI, whereas increased thrombocytopenia and neurotoxicity are 
present with FOLFOX (Colucci et al., 2005). 
1.2.4 Targeted Therapy 
In recent years, the development of novel pharmacological agents targeting molecular pathways 
known to play a vital role in carcinogenesis has shown significant improvement to the clinical outcome 
of mCRC patients. Vascular endothelial growth factor (VEGF) is a crucial mediator of angiogenesis. 
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Upon binding to its associated receptor on endothelial cells, VEGF activates cascades of signalling 
pathways to promote the growth and migration of endothelial cells. This leads to the formation of 
new blood vessels to supply oxygen, growth factors and cytokines to the tumour site (Ferrara, 2004). 
In 2004, Hurwitz et al. were the first to demonstrate that the addition of bevacizumab, a humanized 
monoclonal antibody that targets VEGF, to first-line FOLFIRI resulted in an improved OS (20.3 versus 
15.6 months) (Hurwitz et al., 2004). Epidermal growth factor receptors (EGFR) are also involved in 
promoting the proliferation of malignant cells during carcinogenesis. Upon activation by its ligands, 
activation of two signalling pathways (RAS/RAF-MAPK for proliferation and PI3K-Akt/mTOR for 
survival) facilitate the growth of tumours (Normanno et al., 2006). Cetuximab, a chimeric monoclonal 
antibody, and panitumumab, a humanized monoclonal antibody, are two monoclonal antibodies 
targeting EGFR to reduce or delay the growth of cancer. These monoclonal antibodies extended the 
median OS to 20–30 months (7-8%) when used in combination with first-line FOLFOX or FOLFIRI 
chemotherapy regimens (Bokemeyer et al., 2011; Douillard et al., 2013; Van Cutsem et al., 2011). 
However, their use is limited to patients with wild-type KRAS. More recently, additional agents with 
antian¬giogenic effects such as aflibercept and regorafenib have been developed in attempts to 
maximise anti-VEGF targeting. Despite this, they have only displayed small survival benefits and 
treatment led to significant toxicities (Phase III CORRECT trial and Phase III VELOUR trial) (Grothey et 
al., 2013; Van Cutsem et al., 2011). Nevertheless, the efficacy of these newer approaches remains very 









1.3 Nanomedicine in Cancer Therapy 
Nanotechnology involves the use of nanometer-scale materials and systems by controlling the matter 
on the nanometre length scale. The applications of such approaches in various disciplines are 
becoming increasingly common. In particular, the medical application of nanotechnologies termed 
nanomedicine was defined by the National Institutes of Health of the United States and the European 
Science Foundation, as the “science that uses nanomaterials to the development of diagnosis, 
treatment and prevention of specific medical application” (Foundation, 2004; Oberdorster, 2010). An 
extensive variety of nanocarriers or nanoparticulate systems, composed of different materials have 
been proposed in the biomedical field. As current advances in biotechnology and related areas are 
aiding the discovery and rational design of many new classes of drugs, it is crucial to improve specific 
drug delivery methods by utilising nanotechnology, to turn these new advances into clinical 
effectiveness.  
Nanoparticles (NP) are submicron-sized particles with diameters ranging from 10 – 1000nm (Parveen 
& Sahoo, 2008). NP-based systems possess unique physicochemical properties and their size, shape 
and surface properties can be tuned to modify the fate of both the NP and loaded drug (Shi, Kantoff, 
Wooster, & Farokhzad, 2017). Hence, the application of NPs in cancer therapy has been explored more 
widely than in any other disease, and their potential for optimising the pharmacokinetics of 
chemotherapeutics and selectively accumulating high concentrations of cytotoxic agents within 
tumours have been reported (Cheng et al., 2007; Jain & Stylianopoulos, 2010; Koo et al., 2011; 
Senapati, Mahanta, Kumar, & Maiti, 2018). 
Drugs including small molecules, peptides, proteins and nuclear acids can be loaded in/onto NPs by 
various means, such as physical entrapment (encapsulating anti-cancer drugs within their cores), 
covalent linking or surface attachment i.e. polymeric micelles and polymer conjugates. As such, NPs 
designed to preserve the drug in its active conformation could provide significant clinical benefit as it 
has the potential to overcome problems such as insolubility of hydrophobic drugs, protecting a drug 
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from degradation in harsh physiological environments, enabling control of drug release kinetics and 
increasing drug uptake by cancer cells. Their surfaces can be additionally modified to incorporate 
specialised coatings or long-chain polymers (polyethylene glycol; PEG) to impart increased stability 
and an enhanced circulatory half-life (Knop, Hoogenboom, Fischer, & Schubert, 2010). Attaching 
targeting moieties including antibodies, nucleic acids, peptides, recombinant proteins and aptamers 
can further improve their selective accumulation (Rosenblum, Joshi, Tao, Karp, & Peer, 2018). On top 
of the mentioned physiological advantages of NPs, the tumour’s pathophysiology offers ample 
opportunity for NP-based drug delivery. In comparison to healthy tissues, solid tumours exhibit a 
morphologically irregular and abnormally acidic microenvironment. As a result, NPs due to their small 
size tend to preferentially accumulate and localise within the tumour microenvironment, due to the 
hyper permeable vasculature and dysfunctional lymphatic drainage within tumours - referred to as 
the enhanced permeability and retention (EPR) effect which is discussed in more detail in section 1.3.3 
(Kobayashi, Watanabe, & Choyke, 2014; Matsumura & Maeda, 1986). Therefore, the unwanted side 
effects and the toxicity of the therapeutic agent is reduced and the therapeutic efficacy is enhanced 
(Yih & Al-Fandi, 2006). NPs are opening new therapeutic opportunities for therapeutic agents that 
cannot be utilised effectively as conventional drug formulations because of poor bioavailability or drug 
instability. The various advantages of NPs are summarised in the table below. 
Table 1.1 Summary of the advantages of NPs 
Increase the aqueous solubility of the drug 
Protect the drug from degradation 
Produce a prolonged release of the drug 
Improve the bioavailability of the drug 
Provide a targeted delivery of the drug 
Decrease the toxic side effects of the drug 
Offer appropriate form for all routes of administration 





Figure 1.1 Schematic diagrams of several nanotechnology-based nanocarriers 
 
1.3.1 Advantages of Nanotechnology in Drug Delivery 
Nanotechnology in medicine is increasingly being viewed as a promising tool that will eventually 
surpass conventional chemotherapy. Several different nanocarriers are being investigated as 
controlled drug delivery vehicles for cancer therapy. These include carbon nanotubes, dendrimers, 
liposomes, micellar systems, NPs, and synthetic polymers (Mody, Tekade, Mehra, Chopdey, & Jain, 
2014). These nano-sized drug carriers offer a versatile platform to which many properties can be 
added and modified, with the overall aim of improving therapeutic effectiveness and specificity. 




Table 1.2 Selected nanomedicines that have been approved or are in clinical development 











HIV associated Kaposi’s -
sarcoma 
Multiple myeloma 
FDA (1995)  
EMA (1996) 
Enhanced circulation time and up to 









Metastatic breast cancer EMA (2000) Better toxicity profile than free Dox 
(decreased occurrence of cardiac 
events and congestive heart failure) 
(Anselmo & 
Mitragotri, 2016; 




























Enhanced tumour distribution 
Reduced toxicity present 
Cremophor-free 









Acute myeloid leukaemia FDA (2017) 
EMA (2018) 
Improved overall survival (Jazz 
Pharmaceuticals, 
2019) 
      
NK012 
(Nippon Kayaku) 
Polymeric micelle of SN-38 
(PEG–PGA) 
~20nm 
Small cell lung cancer 
Metastatic colorectal 
cancer 
Phase II  (Kayaku, 2019; 
Nakajima, 
Yasunaga, et al., 
2008; Takahashi 








Advanced solid tumours 





Polymer drug conjugate of Irinotecan 
(PEGylated) 
Metastatic breast cancer  
Ovarian cancer  
Colorectal cancer 












Small cell lung cancer 
Phase II  (Svenson, 
Wolfgang, 




∼20 to 30nm  
AZD2811 
(AstraZeneca) 
Polymeric nanoparticle containing an 
aurora kinase B inhibitor 
(PEG-PLA) 
80-130nm 
Advanced solid tumours 
Haematological tumours 







SMARTICLES® based liposomal 
nanoparticle encapsulating CEBPA-
targeting saRNA  
Liver cancer 
 









Advanced colon cancer 
Solid tumours 
Phase I/II  (LipoMedix, 




1.3.2 The Mononuclear Phagocytic System  
Systemic delivery via intravenous injection is the only route that has been successfully employed to 
deliver therapeutic NPs for cancer. Generally, complex NP therapies involving nanocarrier systems are 
difficult to deliver via other routes because they do not readily cross biological barriers in an intact 
form. Intravenous delivery is generally considered to be reliable and minimally invasive for cancer 
therapy, but NPs are subject to numerous physiological barriers within the circulatory system itself. 
The mononuclear phagocytic system (MPS), consisting of phagocytic cells located within organs 
including the bone marrow, spleen, liver and lymph nodes, sequesters and clears NPs from the 
systemic circulation (W. Jiang et al., 2017). Numerous serum proteins, in particular, opsonisation by 
complement factors (C3, C4 and C5), fibrinogen, albumin, apolipoprotein and immunoglobulins, are 
adsorbed onto the surface of circulating NPs (Nguyen & Lee, 2017). This typically triggers the 
recognition of opsonised NPs by specialised receptors, resulting in NP clearance from circulation by 
the MPS. Examples of phagocytic cells comprising the MPS include blood circulating monocytes, 
splenic red pulp and marginal zone macrophages, hepatic Kupffer cells (KC) and liver sinusoidal 
endothelial cells (LSEC), along with bone marrow macrophages (Davies, Jenkins, Allen, & Taylor, 2013; 
Y. N. Zhang, Poon, Tavares, McGilvray, & Chan, 2016). Given that premature elimination from the 
circulation obstructs NPs from accumulating in tumours, research has focussed on the design of NP 
surface chemistries to minimise clearance via the MPS. 
The most common technique involves functionalisation of the NP surface with PEG, through a process 
called PEGylation. PEG molecules form a closely associated hydrating layer around the NP, impeding 
protein adsorption and subsequent clearance. In doing so, NPs are said to gain a “stealth” attribute 
and can remain in circulation for longer periods, increasing their chances of reaching target sites. This 
feature was best demonstrated by Doxil, whereby PEGylation extended the half-life from minutes to 
hours (Gabizon, Shmeeda, & Barenholz, 2003). The impact of PEGylation varies for NPs differing in 
shape, size and surface charge. PEGylation of smaller NPs results in a higher surface PEG density (larger 
hydrodynamic volume), meaning they are more readily able to evade clearance by the MPS (Alexis, 
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Pridgen, Molnar, & Farokhzad, 2008; Walkey, Olsen, Guo, Emili, & Chan, 2012). To specifically study 
the effect of surface charge on MPS uptake, Xiao et al. were able to demonstrate that NPs with high 
negative or positive charges were taken up by murine macrophages in vitro as well as in vivo (K. Xiao 
et al., 2011). Other surface modifications have included zwitterionic ligands, hydrophilic sugar coatings 
(dextran10) and the use of biological proteins (Abraxane® and INNO-206), but PEG remains the most 
widely used conjugation technique. Several PEGylated NPs loaded with chemotherapeutic agents have 
displayed selective tumour accumulation and enhanced inhibition in various xenografted models of 
CRC liver metastases (B. L. Chen et al., 2016; Luo et al., 2018; Pohlen, Buhr, & Berger, 2011; H. Zhang 
et al., 2015). Such results demonstrate the advantages of PEGylated over non-PEGylated drug delivery 
systems for cancer therapy. Of note, EZN-2208 is a PEGylated prodrug loaded with SN-38 that showed 
prolonged circulation in various preclinical tumour xenograft models in comparison to free drug. PEG 
was attached in a manner that stabilised the drug, maintaining its active conformation (Gritli et al., 
2016; Sapra et al., 2008). However, when given to patients with advanced CRC in a randomised clinical 
study, EZN-2208 did not demonstrate superior efficacy in terms of OS in comparison to irinotecan 
(Garrett et al., 2013). Possible reasons for this were thought to be due to poor tumour drug 
distribution and pharmacokinetics. Therefore, even after NPs have successfully evaded clearance by 
the MPS, they still need to be able to effectively extravasate towards and penetrate the tumour 
microenvironment. 
1.3.3 Targeting Approaches; Active and Passive Targeting 
Alongside the MPS, both passive and active targeting plays a key role in assisting NP delivery to tumour 
sites - as depicted in Figure 1.2. Large fenestrae of 100–200nm (increases to 400-600nm in some liver 
diseases) and an absence of an organised basement membrane are features of the liver sinusoids 
(Aird, 2007). Hence, they can facilitate passive liver targeting through the widely reported EPR effect. 
This effectively builds up a high local concentration of NPs in the perisinusoidal space of Disse, 
whereby diffusion towards the malignant tumour cells can occur. Since the EPR effect is evident within 
tumours, it results in the preferential uptake and retention of NPs (Maeda, Wu, Sawa, Matsumura, & 
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Hori, 2000). Excessive pro-angiogenic signalling within the tumour microenvironment leads 
collectively to the production of immature blood vessels that are heterogeneous, poorly perfused and 
disorganised. The lymphatic systems of tumours are also abnormal, causing fluid retention and high 
interstitial pressure whilst leakage results from large inter-endothelial cell junctions, all of which 
favour the retention of NPs. These mechanistic features underpin the EPR effect and have been greatly 
exploited as a strategy to passively deliver NPs into tumours. It was established that NK012, a 
polymeric micelle formulation of SN-38, enhances its anti-tumour activity through the EPR effect. By 
using a VEGF-secreting tumour model, significantly enhanced accumulation of NK012 within tumours 
was demonstrated, augmented by the hypervascularity and hyperpermeability induced by VEGF 
(Koizumi et al., 2006). Similarly, in a phase II clinical trial the accumulation of the liposome, CPX-1, in 
CRC lesions was attributed to EPR-based accumulation (Batist et al., 2008; S. Goel et al., 2011; 
Golombek et al., 2018). Despite the benefits of passive targeting, major limitations still exist. 
Heterogeneity within tumours and between the primary and metastatic tumours often causes the 
non-uniform delivery of NPs (Adua et al., 2017). Additionally, passive delivery of NPs can result in drug 
exposure to healthy tissues and cells i.e. passively targeted NPs release their payload into the tumour 
microenvironment rather than within tumour cells. This can reduce therapeutic effectiveness, 
promote drug resistance, and promote off-target toxicity (W. Jiang et al., 2017). A possible solution to 




Figure 1.1 Schematic representation of passive and actively targeted NP delivery systems. By taking advantage 
of the EPR effect, non-targeted NPs can passively extravasate through the leaky vasculature and accumulate 
within the tumour (upper). Alternatively, the surface of NPs can be conjugated with targeting moieties to actively 
bind with a cell-specific target (lower). This allows for enhanced cellular uptake inside the tumour. 
  
As mentioned earlier the limitations for chemotherapeutic treatments in mCRC are many, with the 
most common being the non-specific distribution of chemotherapeutic drugs. This poor specificity 
leads to a plethora of toxicological problems as well as drug resistance, which are the major concern 
and the primary reason for the failure of chemotherapy (C. Liu et al., 2009). A targeted approach may 
therefore be applied, to advance the pharmacological properties and reduce the toxicities associated 
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with the treatment of mCRC. Active targeting requires the conjugation of recognition molecules that 
can promote retention of NPs specifically at the tumour site. It is generally achieved by targeting 
surface molecules or receptors overexpressed on either the tumour cells, microenvironment or its 
vasculature. Careful selection of the targeting moiety is needed, and the target should be highly and 
preferentially expressed at the tumour site. Moreover, the targeting moiety should have strong and 
specific binding affinity to the intended target and be well suited to chemical modification by 
conjugation. However, to take advantage of this increased affinity, actively targeted NPs must first 
reach the target site. Effective passive targeting is therefore essential for these NPs to increase their 
accumulation and distribution at the tumour site. Recently, Sharma et al. demonstrated that NPs 
functionalised with folic acid displayed preferential in vivo uptake in colon tissue (Cisterna et al., 2016). 
Similarly in an mCRC experimental model, folate conjugated pRNA NPs were found to be specifically 
retained in liver metastases, without any untargeted uptake in other organs (Rychahou et al., 2013). 
Other investigations have shown that using hyaluronic acid as a targeting ligand on the surface of NPs, 
resulted in increased CRC targeting when compared to the non-targeted NPs (B. Xiao et al., 2015). 
Further, widely explored cellular targets for CRC include CD44, ASGPR, VEGFR, EGFR, TfR1, DR-5 
carcinoembryonic antigens, TAG-72, integrin α5β1 and A54 peptide surface markers (Cohen & Margel, 
2012; Schmid et al., 2014; Y. N. Zhang et al., 2016). Presently, methods to prime the tumour 
microenvironment are being reviewed to enhance NP delivery by normalising the tumour 
microenvironment (Jain & Stylianopoulos, 2010; Khawar, Kim, & Kuh, 2015; Stylianopoulos, Munn, & 
Jain, 2018). Despite the enhanced efficacy demonstrated in various studies, factors including; 
immunogenicity and stability of the targeting moiety leading to premature NP clearance, uneven 
exposure to chemotherapy - bringing about tumour recurrence, drug resistance and loss of activity 
due to receptor mediated endocytosis, severely hinder the application of targeted NPs. Research 
conducted by Wilhelm et al. highlighted this point, as they showed that active targeting only slightly 




A hallmark of cancer cells is their ability to activate invasion and metastasis (Hanahan & Weinberg, 
2011). Metastasis, a multistage process, concerns the spread of malignant cells from a primary tumour 
to distant organs. Joseph Claude Récamier in 1829 was the first to reference and document metastasis 
- “métastase”, which he described as the haematogenous spread of disease (Pienta, Robertson, 
Coffey, & Taichman, 2013). This profound observational study initiated investigations into the 
mechanisms of metastasis in cancer (Talmadge & Fidler, 2010). Stephen Paget's seed and soil theory 
of metastases, stating that a permissive microenvironment (the soil) promotes the growth of the 
disseminated tumour cell (the seed), remains the basis of research to date and is widely accepted to 
explain the mechanism of metastasis (Paget, 1989). In a complementary hypothesis, James Ewing 
proposed in 1928 that cancer cells were directed to that site by the direction of lymphatic and 
circulatory systems (Ewing, 1928). Recent advances in our understanding of the metastatic process 
have led to the development of the concept of “pre-metastatic niche formation”. Here, changes at the 
cellular and molecular level are thought to occur in target tissues before the tumour cells leave the 
primary site. As a result, this renders the target site susceptible to metastatic cells (Psaila & Lyden, 
2009). Continuous efforts to uncover the metastatic process will ultimately provide unprecedented 









1.4 Irinotecan: A Key Chemotherapeutic Drug for Colorectal Cancer  
1.4.1 Discovery 
Irinotecan (Camptothecin-11, CPT-11, Campto®, and Camptosar®) is a semisynthetic water-soluble 
derivative of the natural alkaloid camptothecin (CPT). The origin of irinotecan dates back to the late 
1950s when a screening program of natural products was conducted by the United States Department 
of Agriculture (Wall & Wani, 1995). An extract of Camptotheca acuminate (family Nyssaceae), a plant 
native to China and Tibet was shown to have cytotoxic anti-tumour activity against lymphoid 
leukaemia cells, L-1210. Subsequent studies conducted at the National Cancer Institute demonstrated 
that CPT was the active constituent. CPT has a pentacyclic structure (rings A-E) and is insoluble in 
virtually all organic compounds except dimethyl sulfoxide (DMSO) in which it exhibits moderate 
solubility (Wall & Wani, 1996). The first soluble derivative was a sodium carboxylate form, but this 
achieved only low response rates and high toxicities (Moertel, Schutt, Reitemeier, & Hahn, 1972). It 
was, therefore, necessary to develop a soluble analogue able to exist in the active lactone (closed ring) 
form. Irinotecan, developed jointly by Daiichi Pharmaceuticals and Yakult Honsha in Japan, was the 
first water soluble CPT analogue to undergo extensive clinical evaluation and obtain regulatory 
approval. Irinotecan became commercially available in Japan for the treatment of ovarian, cervical, 
gastric, and lung cancers in 1994. In the mCRC setting, irinotecan obtained FDA monotherapy approval 
as a second-line treatment in 1996 (for patients refractory to 5-FU monotherapy), and in combination 
with 5-FU and folinic acid (as in the FOLFIRI regimen) as a first-line treatment for mCRC in 2000 
(Cunningham, Falk, & Jackson, 2002; Douillard et al., 2000; Rougier et al., 2002; Vanhoefer et al., 
2001). By 2006, the drug was approved in more than 100 countries and sold in 88.  
1.4.2 Pharmacokinetics 
Irinotecan is the prodrug for SN-38, which inhibits topoisomerase I (TOP I), an enzyme involved in DNA 
replication. SN-38 is 100- to 1000-fold more cytotoxic than irinotecan, and its exposure is highly 




Irinotecan is a hydrophilic compound with an estimated volume of distribution up to 400L/m2 at 
steady state. At physiological pH, the lactone-rings of irinotecan and SN-38 can be hydrolysed into a 
carboxylate isoform. As a result, a pH-dependent equilibrium exists such that, an acidic pH promotes 
the formation of the active non-ionic lactone form, while a more basic pH favours the inactive anionic 
carboxylate form. As only the lactone form has antitumour activity, a small change in pH could adjust 
the pharmacokinetics and efficacy of irinotecan and SN-38. Additionally, the lactone and carboxylate 
forms express distinctive affinities for transporters and disparities are seen in pharmacokinetic profiles 
in animals versus humans. Within plasma the carboxylate form of irinotecan and the lactone form of 
SN-38 dominate (Sasaki et al., 1995). Studies have shown this to be due to a higher tissue distribution 
of irinotecan lactone and the preferential binding of SN-38 lactone to plasma proteins (M.-C. Haaz, 
Rivory, Riché, & Robert, 1997; Xie, Mathijssen, Sparreboom, Verweij, & Karlsson, 2002). Both 
irinotecan (30-68%) and SN-38 (  ̴95%) are highly bound to albumin (Burke & Mi, 1994). In blood, SN-
38 is almost completely bound, with two-thirds located in platelets and, predominantly, red blood 
cells (Combes et al., 2000). 
1.4.4 Metabolism 
The carboxylesterases (CES1 and 2) and butyrylcholinesterase enzymes can hydrolyse the prodrug 
irinotecan into its active metabolite SN-38. CES1 and CES2 are localised in liver, colon, kidney and 
blood cells, while butyrylcholinesterase is predominantly found in plasma (Rudakova, Boltneva, & 
Makhaeva, 2011). Conversion by these esterases mainly occurs intra-hepatically and is a relatively 
slow and inefficient process as only 2–5% of irinotecan converted into SN-38 (G. Chabot et al., 1995; J 
Greg Slatter, Su, Sams, Schaaf, & Wienkers, 1997). The affinity of CES2 for irinotecan is 12.5-fold 
greater than CES1, whilst in the blood, butyrylcholinesterase has a 6-fold higher activity than CES 
(Bencharit et al., 2002; Laurent P Rivory, Bowles, Robert, & Pond, 1996; Rudakova et al., 2011). 
Following this conversion, SN-38 is actively transported into the liver by OATP1B1 (SLCO1B1), ABCB1, 
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MRP1 (ABCC1), MRP2 (ABCC2), and MXR (ABCG2). In particular, ATP-binding cassette (ABC) 
transporter ABCB1 located on the bile membrane is involved in the secretion of SN-38 into the liver.  
Irinotecan is also metabolised by intrahepatic cytochrome P450 (CYP) enzymes, i.e. CYP3A4 and 
CYP3A5, into inactive metabolites — APC (7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] 
carbonyloxycamptothecin) and NPC (7-ethyl-10-[4-(1-piperidino)-1-amino] 
carbonyloxycamptothecin) (Santos et al., 2000). NPC can further be metabolised into SN-38 by CES1 
and CES2 in the liver, but to a lower degree as compared to irinotecan (Dodds, Haaz, Riou, Robert, & 
Rivory, 1998). APC is poorly converted to SN-38 by CES2 and is also at least 100-fold less active than 
SN-38. 
SN-38 is detoxified in the liver to SN-38G by uridine diphosphate glucuronosyltransferase (UGT) 
enzymes and excreted into the intestinal lumen via the bile duct (M. C. Haaz, Rivory, Jantet, 
Ratanasavanh, & Robert, 1997). This inactivation route involves the transfer of the glucuronic acid 
from the cofactor UDP-glucuronic acid to the SN-38, causing the formation of 10-O-glucuronyl-SN-38 
(SN-38G), an inactive water-soluble and glucuronidated metabolite. SN-38G is formed directly after 
SN-38 formation, hence accounting for the short half-life of SN-38. Moreover, SN-38G can be 
deconjugated into SN-38 by (bacterial) β-glucuronidases produced by intestinal bacteria, which could 
result in the enterohepatic circulation of SN-38 and its reabsorption (Cole, Fuller, Mallet, & Rowland, 
1985; Fujisawa & Mori, 1997; Sperker, Backman, & Kroemer, 1997; Younis, Malone, Friedman, Schaaf, 
& Petros, 2009). Several UGT subtypes are involved in the hepatic (UGT1A1, UGT1A9) and extrahepatic 
(UGT1A1, UGT1A7, UGT1A10) conversion of SN-38, of which UGT1A1, UGT1A7 and UGT1A9 are the 
major isoenzymes (Ciotti, Basu, Brangi, & Owens, 1999; Hanioka et al., 2001; L. Iyer et al., 1998; 
Strassburg, Oldhafer, Manns, & Tukey, 1997; Tallman, Ritter, & Smith, 2005). Reports have shown the 
UGT1A7 isoform to be approximately 20 times more active at physiological pH when compared to 
UGT1A1 (Ciotti et al., 1999). Furthermore, patients genetically predisposed with decreased UGT1 
activity (Gilbert’s syndrome) have an increased risk of irinotecan-associated adverse events 
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(Wasserman et al., 1997). The most common UGT1A1 polymorphisms are UGT1A1*6 and UGT1A1*28. 
Both polymorphisms produce increased systemic exposure to irinotecan and SN-38 in patients 
homozygous for these variants (Lalitha Iyer et al., 1999; Y. Wang et al., 2012).  
1.4.5 Elimination 
The clearance of irinotecan is mainly biliary (66%) with the remainder undergoing urinary excretion 
(32%) (Mathijssen et al., 2001). Irinotecan is transported into the bile by several ABC transporters (i.e. 
ABCB1, ABCC2, and ABCG2). All metabolites, except SN-38G (primarily excreted in urine), are 
predominately excreted in faeces, although they are also detectable in urine.  
1.4.6 Mechanism of Action 
The primary therapeutic target of SN-38 is DNA TOP I. TOP I is critical for cell growth proliferation and 
repair, as it makes a transient single-stranded break in the DNA duplex, which allows for the unwinding 
of supercoiled DNA, enabling the replication fork to process in duplicating the DNA. When inhibiting 
TOP I, SN-38 triggers several events, interfering with the replication fork and the nicking-ligation 
reaction of TOP I. After TOP I-mediated DNA cleavage, SN-38 binds to and stabilises the TOPI-DNA 
cleavable complex, thereby preventing re-ligation of the DNA strand. Subsequent accumulation of 
cleavable complexes results in double-stranded DNA breaks that inhibit DNA replication, triggering 
apoptotic cell death and transient cell cycle arrest (Pommier, Pourquier, Fan, & Strumberg, 1998). SN-
38 is considered an S-phase-specific antitumour drug since it needs ongoing DNA synthesis to exert its 
cytotoxic effects. 
Two recent publications suggest that SN-38 may not uniquely target TOP I. One study refers to the 
interaction of SN-38 with the E3 ligase MDM2 (a ligase of tumour suppressor protein p53) and the 
anti-apoptotic protein Bcl-xL (B. Lee et al., 2019). This suggests that SN-38 acts as a selective protein 
binding inhibitor. Another study put forward the idea that SN-38 inhibits human FUBP1 (Far Upstream 
Element (FUSE) Binding Protein 1) activity. FUBP1 is a multifunctional DNA- and RNA-binding protein 
and SN-38 prevents binding of FUBP1 to its single-stranded DNA target. This induced deregulation of 
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FUBP1 target genes in hepatocarcinoma cells (Khageh Hosseini et al., 2017). Nevertheless, these 
different studies suggest that SN-38 may have targets other than TOP I, which is a plausible hypothesis 
because it is known that other CPT analogues can regulate gene expression independent of TOP I 












Figure 1.3  Schematic summarising the metabolism of Irinotecan 
Irinotecan is metabolised into its active metabolite SN-38 via carboxylesterases. SN-38 is then inactivated into its glucuronide conjugate, SN-38G, by the uridine diphosphate 
glucuronosyltransferases. Hepatobiliary excretion occurs then SN-38G is reconverted into active SN-38 by bacterial β-glucuronidases. A second irinotecan detoxification pathway is the 




Administration of irinotecan is limited by severe dose-limiting toxicities with distinct inter-individual 
and inter-ethnic variability. The most common being chemotherapy-induced diarrhoea (CID) and 
myelosuppression; ~35% of the treated patients reported grade 3/4 diarrhoea and ~14–47% reported 
grade 3/4 neutropenia (Hoskins, Goldberg, Qu, Ibrahim, & McLeod, 2007; Richardson & Dobish, 2007). 
Such toxicities decrease therapeutic benefit by preventing dose intensification and efficacy in up to 
40% of treated patients (Maroun et al., 2007). The manifestation of both severe diarrhoea and 
neutropenia (~10%) is associated with a greater risk of death (~3.5%) for patients (Ducreux, Kohne, 
Schwartz, & Vanhoefer, 2003; Rothenberg, Meropol, Poplin, Van Cutsem, & Wadler, 2001). Moreover, 
acute CID occurs following 1–24 h of administration. It can be life-threatening when it is prolonged, 
owing to the risk of dehydration, imbalance of electrolytes, hemodynamic collapse or severe sepsis 
due to bacterial translocation (Rothenberg et al., 2001). 
Irinotecan acutely damages the intestinal mucosa, causes the mitotic arrest of crypt cells and increases 
apoptosis. The severity of irinotecan-induced gastrointestinal toxicity and histological damage is 
associated with the intestinal β-glucuronidase activity, the rate of biliary excretion of SN-38 and the 
reconversion of SN-38 from the enteric SN-38G. If the rate of SN-38 glucuronidation in the intestines 
is low, active SN-38 is exposed to the epithelial cells for a lengthier period, resulting in severe diarrhoea 
due to the loss of colonic absorptive capacity. Thus, the glucuronidation of SN-38 is imperative for 
limited gastrointestinal toxicity. The rate of metabolic conversion to the water-soluble derivative SN-
38G depends on polymorphs of the UGT1A1 enzyme and is highly variable among individuals. For 
instance, individuals with the UGT1A1*28 allele have been reported to have a higher risk of 
neutropenia caused by limited metabolism of SN-38. This is due to the reduced expression of UGT1A1 




Other common toxicities observed following irinotecan administration are nausea, vomiting, 
abdominal pain, constipation, anorexia, asthenia, fever, decrease in body weight and alopecia (Bast, 
2016). Rare, but life-threatening non-haematological toxicities include interstitial lung disease and 
hypersensitivity reactions. Oxidative metabolic pathways, CYP2B6 and CYP3A4, create inactive 
irinotecan metabolites and increase the potential for drug-drug interactions. Hepatotoxicity is also 
reported, with several observational clinical studies having reported that the inclusion of irinotecan in 
preoperative chemotherapy regimens is associated with the risk to develop steatohepatitis in up to 
50% of cases (Mahli et al., 2018). Furthermore, there is significant evidence that the presence of 
chemotherapy-induced steatohepatitis is associated with increased morbidity and possibly mortality 
following hepatic resection as a result of hepatic insufficiency (Morris-Stiff, Tan, & Vauthey, 2008). 
Details of the mechanisms of irinotecan induced hepatotoxicity remain unclear. However, it is thought 
to involve hepatic changes brought about by liver inflammation, oxidative stress, mitochondrial 












1.5 Nanomedicine for Colorectal Cancer 
The number of patients with CRC has increased markedly over the past 20 years and will continue to 
increase in the future. Despite recent advances in chemotherapy, chemotherapeutic treatments for 
CRC are not as effective as for some other cancers, because of the difficulty of delivering drug at 
effective concentrations to the target site. To maintain therapeutic concentrations at the tumour site, 
chemotherapeutic drugs must be administered at high doses and this causes serious toxicity to normal 
(non-cancerous) tissues and organs i.e. due to the non-specific distribution of chemotherapeutic 
drugs. In many cases, the failure to achieve effective doses at the tumour site leads to the failure of 
chemotherapy, cancer recurrence and reduced patient survival. 
As discussed above irinotecan has several well-established limitations. Although SN-38 is up to a 1000-
fold more potent than irinotecan, its clinical use is limited by its poor solubility and chemical instability 
of its pharmacologically active lactone ring (G. G. Chabot, 1997). It is practically insoluble in water (11–
38μg/ml) and is not solubilised at 0.5% (w/w) in most pharmaceutically acceptable solvents and oils, 
limiting the direct formulation as a solution dosage form (Williams et al., 2003). The active, closed-
ring structure (lactone) of SN-38 is stable at pH ≤ 4.5 and hydrolyses completely to form the open-ring 
structure (carboxylate) at pH > 9.0 (L. P. Rivory, Chatelut, Canal, Mathieu-Boue, & Robert, 1994). At 
pH 6.7 both forms are in equilibrium. The instability of the active drug molecule at physiological pH 
(pH 7.4) is a major hurdle in attaining effective therapy with SN-38, as the open carboxylate form of 
SN-38 has no therapeutic effect resulting in low anti-tumour activity. Other limitations include fast 
reversal of the trapped TOPI-DNA cleavage complex following drug removal and drug resistance 
mediated by the ABC transporters. In addition, the conversion of irinotecan into SN-38 is often 
inefficient in humans and leads to variability in SN-38 exposure (Hsiang et al., 1989). Alongside this, 
the narrow therapeutic index of irinotecan presents further challenges for its use as an anti-cancer 
therapeutic in the clinic. 
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The transport of drugs by NPs has shown great promise in terms of improving drug distribution and 
bioavailability, increasing tissue half-life and concentrating anticancer molecules in the tumour mass, 
providing optimal drug delivery to tumour tissue, and minimising drug toxicity, including those effects 
associated with pharmaceutical excipients. Similarly, NPs may interact with key drug-resistance 
molecules to prevent a reduction in intracellular drug levels. Recently published data have provided 
convincing pre-clinical evidence regarding the potential of active-targeted nanotherapeutics in CRC 
therapy, although, unfortunately, only a few of these therapies have been translated into early-phase 
clinical trials. Thus, incorporating SN-38 into a pharmaceutical formulation with an adequate solubility 
and stability profile might be attractive for cancer therapy. As a result, some of the limitations and 
challenges mentioned may be overcome by using a nanomedicine-based approach, leading to a more 
efficient chemotherapeutic option. 
Various polymer-based structures have been used in cancer treatment and established excellent 
therapeutic potential at both preclinical and clinical development stages. The high rate of irinotecan 
toxicity has prompted the development of alternative treatment strategies to reduce the drug’s 
serious side effects. This includes the use of encapsulated drug delivery by various nanocarriers, 
including liposomes (Onivyde), polymeric nano-conjugates (NKTR102) and micellar formulations 
(NK012). 
1.5.1 Irinotecan-based Nanocarriers 
1.5.1.1 Onivyde 
The liposomal carrier, Onivyde (also known as PEP02 or MM-398), was approved in 2015 for 
combination with 5-FU and folic acid as a second-line therapeutic option for patients with metastatic 
pancreatic ductal adenocarcinoma, after disease progression following gemcitabine-based therapy (H. 
Zhang, 2016). Onivyde liposomes are unilamellar lipid bilayer vesicles with a mean diameter of ~110 
nm. The vesicle is composed of distearoyl phosphatidylcholine, cholesterol and DSPE-PEG2k in the 
ratio of 3:2:0.015, which encapsulates more than 90% of the drug (X. Liu, Tang, Wainberg, & Meng, 
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2020; Tran et al., 2017). This liposomal encapsulation helps protect irinotecan from early conversion 
into its active metabolite SN-38. Onivyde displayed a much slower clearance, a prolonged terminal t1/2 
of circulating total irinotecan (25.8 hours), and more favourable pharmacokinetics of SN-38 were 
observed in comparison to free drug-treated patients (Chiang, Chang, Shan, & Chen, 2016; Roy et al., 
2013). The dose-normalised AUC0-∞ value of active SN-38 was approximately five times higher for 
Onivyde than that of irinotecan (Chiang et al., 2016; Roy et al., 2013). However, Onivyde’s approval 
was accompanied by a “black box” safety warning from the FDA, referring to the likelihood of severe 
diarrhoea (grades 3–4, 13%) and severe and life-threatening neutropenia (grades 3–4, 27%) 
(Barenholz, 2012). Although Onivyde demonstrated antitumor efficacy and improved safety in a 
subcutaneous CRC model in nude mice (Wolfram et al., 2015), the advantages of encapsulated drug 
delivery could not be demonstrated in CRC patients in a phase II clinical trial, and the effort was 
abandoned. Despite this, Onivyde is currently being investigated in a variety of solid tumour types, 
including lung and breast cancer.  
1.5.1.2 Etirinotecan pegol  
Etirinotecan pegol (NKTR-102 or Onzeald), is a long-acting topoisomerase-I inhibitor that was designed 
to improve the pharmacokinetics of irinotecan. Structurally, etirinotecan pegol contains a large-chain 
PEG core to which four molecules of irinotecan are attached via a cleavable ester-based linker (Hoch 
et al., 2014). This linker is slowly hydrolysed in vivo to subsequently release irinotecan. The high 
molecular weight of etirinotecan pegol (22 kDa) limits its ability to freely cross intact vasculature into 
healthy tissues, but promotes extravasation via the EPR effect. In an initial phase 1 study, the mean 
half-life of SN-38 was prolonged from 2 days following administration of conventional irinotecan to 50 
days with etirinotecan pegol. Additionally, fewer cases of early-onset cholinergic diarrhoea and 
neutropenia were seen (Jameson et al., 2013). A randomised phase 2 study assessing two schedules 
of etirinotecan pegol (145 mg/m2 every 14 or 21 days) reported that the drug produced substantial 
antitumour activity in patients (Awada et al., 2013). Subsequent phase 3 clinical studies in patients 
with advanced metastatic breast cancer (Tripathy et al., 2019) and advanced breast cancer with brain 
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metastases (Perez et al., 2015), did not achieve statistical significance. No improvement in overall 
survival was present in patients receiving etirinotecan pegol, and, as a result, development activities 
came to an end. 
1.5.1.3 DEP irinotecan 
Starpharma's DEP irinotecan is a PEGylated polylysine dendrimer with SN-38 conjugated to the surface 
via a hydrolytically labile linker. The incorporation of the active metabolite, SN-38 avoids the need for 
hepatic conversion and thereby minimises variability in SN-38 levels. In preclinical studies, DEP 
irinotecan has shown to be well tolerated in animals (Kelly et al., 2020). Efficacy assessments have 
been conducted, using a range of xenograft cancer models (SW620, HT-29, MDA-MB-231 and CAPAN-
1). These studies demonstrated significant efficacy and survival benefits of DEP irinotecan compared 
to standard irinotecan. DEP irinotecan, alone and in combination with Lynparza, showed significant 
anti-tumour efficacy and synergy compared with standard irinotecan and Lynparza (olaparib) in an 
irinotecan-refractory human colon cancer model (Starpharma, 2019). Treatment with DEP irinotecan 
provided a significantly greater level of inhibition – 62% for low dose and 97% for high dose. DEP 
irinotecan is currently in a phase 1/2 adaptive trial to evaluate its safety, tolerability and 
pharmacokinetics, and to determine anti-tumour efficacy in various tumour types. 
1.5.1.4 NK012 
NK012 is an SN-38-loaded polymeric micelle formulation constructed in an aqueous milieu by the self-
assembly of an amphiphilic block copolymer, consisting of PEG and partially SN-38–bound 
polyglutamate (Koizumi et al., 2006). PEG is hydrophilic and forms the outer shell of the micelle, whilst 
SN-38–bound polyglutamate is hydrophobic and forms the inner core of the micelle. The ester bond 
between glutamic acid and SN-38 is gradually cleaved by hydrolysis under physiological conditions. 
Hence the release of SN-38 is not dependent on metabolic conversion by enzymes. NK012 has a 
particle size of 20 nm and shows high colloidal stability due to the hydrophobicity of SN-38, as well as 
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π–π stacking of the drugs inside the micelle (Y. Li, Zhang, Liu, & He, 2019). It is thought that NK012 
accumulates in tumour tissue by utilising the EPR effect.  
NK012 is proposed to be a promising agent for clinical applications given that its ability to suppress 
tumour cell growth in vitro and its antitumor effects in animal models are greater than those of 
irinotecan in various cell types, including several human tumours. In addition, NK012 has been found 
to accumulate in high concentrations in tumourous mouse models (Nakajima, Yanagihara, et al., 2008; 
Sumitomo et al., 2008). A phase I study was launched to evaluate the tolerability, pharmacokinetics, 
safety, and recommended phase II dose of NK012 in 38 patients with advanced cancer. Accordingly, 
the recommended dose was determined to be 28 mg/m2. In a second phase I study, NK012 showed 
high plasma levels with a terminal t1/2 of approximately 210 hours (Hamaguchi et al., 2010). NK012 
was well tolerated, and the antitumor activity showed partial responses and several occurrences of 
prolonged stable disease condition, such as a reduction of tumour size. In addition, a multicentre 
open-label phase II study was launched to evaluate the efficacy and safety of NK012 in 58 patients 
with unresectable metastatic CRC. In this trial, the presence of febrile neutropenia and grade ≥ 3 
neutropenia, indicated that NK012 at 28 mg/m2 may be too high for CRC patients pretreated with 
oxaliplatin (Hamaguchi et al., 2018).  Since November 2017, no further reports of development have 
been presented within the literature. 
Therefore, the polymers employed in NP formulations make them ideal drug delivery systems, and 
they could play an important role in improving the bioavailability of the anticancer drugs and the 





1.6 Hyperbranched Polydendrons 
When developing a highly efficient therapeutic, many issues need to be considered. The ideal system 
should be able to overcome the biological barriers, distinguish the tumour tissues from the normal 
cells, target specific sites and release an efficacious dose. The advantages of using polymeric 
nanostructures are based upon the flexibility of their modified structures. This yields materials with 
various compositions, sizes and surfaces, thereby allowing for tuneable properties.  
Hyperbranched polydendrons are dendrimer-like materials that mimic the surface functionality of a 
dendrimer (repetitively branched monomers with a large number of adjustable peripheral groups) 
with a much greater molecular weight and size than conventional dendrimers (Hatton et al., 2015). 
This technology allows drug encapsulation within polymer NPs and henceforth the dispersion of poorly 
water soluble compounds. These novel materials are intended to offer benefits as nanomedicines 
through their increased stability, encapsulation properties, enhanced bioavailability and decreased 
drug toxicity structure. They also present high densities of surface functionality that could be applied 
for a more targeted approach. 
The materials which were made use of in this thesis comprised of a branched polymer and either a 
block copolymer or a linear dendritic hybrid. It is useful to be able to control the properties of such 
materials including for example their size, size distribution, surface functionality (active targeting and 
incorporation of acid degradable branching units to saturate drug at tumour site), 
hydrophobicity/hydrophilicity (i.e. hydrophobic core for encapsulation of hydrophobic drugs), variety 
of drug loadings and behaviour in systems of use, e.g. in aqueous systems in the case of biological 
applications. Hyperbranched polydendrons offer enormous flexibility in the customisation of NPs in 
drug delivery, and thereby represent a promising opportunity for the in vivo diagnosis and treatment 
of CRC liver metastases. However, with so many parameters capable of being altered, a process of 




1.7 Aims and Objectives  
This thesis aimed to characterise bespoke polymeric NP formulations loaded with SN-38 and evaluate 
their prospective use in the treatment of CRC liver metastases. It was hypothesised that incorporating 
SN-38 into these nanomaterial’s could improve the treatment outcomes of CRC by augmenting drug 
retention and enhancing SN-38’s bioavailability. The experimental objectives for which the chapters 
are based are as follows: Chapter 2 details the development and optimisation of a liquid 
chromatography-mass spectrometry assay for the detection of irinotecan, SN-38 and SN-38G in 
various matrices. Chapter 3 outlines the development and characterisation of CRC spheroids using 
both human and mouse cell lines. Responses to both irinotecan and free SN-38 are investigated. 
Chapter 4 describes the analysis of various polymer nanomaterial’s using an in vitro tiered screening 
system to select out the most effective candidates. Properties such as drug release and retention, 
disposition, cytotoxicity and pharmacodynamics were investigated. The plasma pharmacokinetic 











Chapter 2: Development and Validation of an LC-MS/MS Assay for the 





Irinotecan is a chemotherapeutic agent used in the treatment of metastatic colorectal cancer. The 
work presented throughout this thesis required the development of a liquid chromatography-tandem 
mass spectrometer bioanalytical assay. A method was therefore optimised to quantify irinotecan, its 
active metabolite SN-38 and SN-38 glucuronide (SN-38G) in different matrices (mouse plasma, PBS 
and DMEM growth medium). A 100μL of the sample was prepared after protein precipitation with 
centrifugal evaporation and analysed on a C18 column (SynergiTM Hydro-RP 80A) using 0.1% formic 
acid in water and 0.1% formic acid in acetonitrile as mobile phases. The mass spectrometer worked 
with multiple reaction monitoring in positive scan mode with a 5.50-minute analytical run time. The 
method was validated according to the bioanalytical guidelines defined by the Food and Drug 
Administration. The standard curves were linear (R2≥0.99) over a concentration range of 4-1024ng/mL 
for irinotecan, 2-512ng/mL for SN-38 and 2-512ng/mL for SN-38G across all matrices. Intra-day and 
inter-day variations (precision and accuracy) observed during the validation for all analytes, were 
found to be within the set limit of 15%. The developed method was successfully used to quantify 
irinotecan, SN-38, and SN-38G and applied to a pharmacokinetic study in BALB/c mice. Results from 










2.1 Introduction  
Irinotecan (Camptosar®, CPT-11) is a chemotherapeutic drug used in the treatment of colorectal 
cancer, most often in combination with other chemotherapeutics (folinic acid and 5-fluorouracil) or 
targeted (cetuximab and bevacizumab) therapies. Irinotecan is cleaved into the primary active 
metabolite SN-38 (7-ethyl-10-hydroxycamptothecin), primarily by liver carboxylesterases (CES) 
(Senter, Beam, Mixan, & Wahl, 2001). SN-38 is 100–1000 times more potent than its parent drug, but 
as it’s poorly soluble it cannot be administered systemically, hence irinotecan is currently used as a 
prodrug in clinical applications (Humerickhouse, Lohrbach, Li, Bosron, & Dolan, 2000; Kaneda, Nagata, 
Furuta, & Yokokura, 1990; Marangon, Posocco, Mazzega, & Toffoli, 2015). It is necessary to 
simultaneously monitor for the prodrug and its main metabolites to resolve the issues around the 
inter-individual variability in the pharmacokinetics and pharmacodynamics of irinotecan, and thus to 
improve colorectal cancer treatment. 
 
Figure 2.1 Chemical structures of irinotecan, SN-38, SN-38G and SN-38-d3 (internal standard) 
The availability of a plethora of completely validated bioanalytical methods has paved the way for the 
characterisation of the pharmacokinetic profile of irinotecan in various preclinical species and human 
subjects. Previously researchers have utilised HPLC coupled parallel to both fluorescence and LC-MS 
detectors, due to the similarity of excitation and emission spectra between irinotecan and its 
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metabolites (de Bruijn et al., 1997; Kurita & Kaneda, 1999; Owens, Dodds, Fricke, Hanna, & Crews, 
2003; X. Yang et al., 2005). For instance, Sai et al set the excitation at 368 nm and emission at 432 nm 
for and irinotecan, SN-38G, APC, NPC and for SN-38 the excitation and emission were set at 368 and 
535 nm, respectively (Sai, Kaniwa, Ozawa, & Sawada, 2002). However, these fluorescence methods 
suffer from several drawbacks such as lengthy preparation times i.e. the need for specific pH, limited 
sensitivity, longer run times, limited dynamic ranges due to saturation and high sample volumes. 
Moreover, fluorescence detection cannot yet provide the required analytical sensitivity and specificity 
for SN-38G. 
Recently, liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) has become a 
favoured analytical tool for the rapid and efficient quantification of drugs, metabolites, and 
biomarkers in different biological matrices due to the unique combination of high specificity, 
sensitivity, and the high throughput of samples. Several methods are currently employed for the 
determination of irinotecan and its metabolites, but only a few methods are available to quantify 
irinotecan, SN-38 (Bardin et al., 2005; M. Chen et al., 2017; Ghazaly, Perry, Kitromilidou, Powles, & 
Joel, 2014; Ramesh, Ahlawat, & Srinivas, 2010) and in particular, SN-38G (Atasilp et al., 2018; Basu, 
Zeng, Yin, Gao, & Hu, 2016; Marangon et al., 2015; Prijovich, Burnouf, & Roffler, 2014) with a high 
degree of sensitivity. Published methods for the direct determination of all three metabolites suffer 
from laborious sample preparation, complicated extraction procedures and long run times (Kurita & 
Kaneda, 1999; Owens et al., 2003; Poujol et al., 2003; Sparreboom et al., 1998). Therefore, we have 
developed and validated an LC-MS/MS method, in accordance with the bioanalytical guidelines 
defined by the Food and Drug Administration (FDA, 2016), for quantifying the levels of irinotecan and 
its metabolites SN-38 and SN-38G in a range of biological materials. The developed method was 





2.2 Methods and Materials 
2.2.1 Materials 
Irinotecan and SN-38 were purchased from Hangzhou J&H chemical company (J&H Chemical, 
Shanghai, China). SN-38G and the internal standard (IS) SN-38-d3 were purchased from Toronto 
Research Chemicals, (Toronto, Canada). Drug-free mouse plasma was purchased from BioIVT (West 
Sussex, UK). All other consumables were purchased from Sigma Aldrich (Dorset, UK) and were of LC-
MS grade or the highest analytical grade commercially available. 
2.2.2 Tuning for Irinotecan, SN-38, SN-38G and IS 
Detection of all compounds was conducted using a TSQ Endura™ Triple Quadrupole Mass 
Spectrometer (Thermo Fisher Scientific, UK). Tuning was performed using direct infusion 
(20µl/minute) of a 500ng/mL stock of each compound with 50% mobile phase A (100% H2O with 0.1% 
formic Acid, LC-MS/MS grade), 50% mobile phase B (100% acetonitrile (ACN) with 0.1% formic acid) 
at a flow rate of 300µl/minute. Ionisation was achieved via heated electron spray ionization in the 
Multiple Reaction Monitoring (MRM) positive mode, at a spray voltage of 3800V. The following 
parameters were optimised to achieve the highest signal intensity: spray voltage, sheath gas and 
auxiliary gas. 
2.2.3 Chromatographic Separation  
Chromatographic separation was achieved using a multistep gradient (Table 2.1) with a Synergi™ 4 
µm Hydro-RP 80 (150*2mm) obtained from Phenomenex (Macclesfield, UK). The assay was conducted 
over 5.50 minutes at a flow rate of 400μl/minute. Data acquisition and chromatographic analysis were 







Table 2.1 The operating chromatographic conditions 
 
 
2.2.4 Preparation of Standards and Controls 
Irinotecan and SN-38 stock solutions were prepared at a concentration of 1mg/ml in dimethyl 
sulfoxide (DMSO). A stock solution of SN-38G was prepared at a concentration of 0.5mg/mL and stored 
in glass vials at −40°C. Working standards of SN-38 and SN-38G were prepared in the appropriate 
matrix via serial dilution ranging from 2 to 512ng/ml; whilst final irinotecan concentrations ranged 
from 5 to 1024ng/ml. Quality control samples (QC) of 5, 100 and 500ng/ml were prepared for SN-38 
and SN-38G and 10, 200, and 1000ng/mL for irinotecan from their respective working solutions. The 
IS working solution (500ng/mL) was prepared by diluting its stock solution with DMSO. All stock 
solutions were stored at −30°C. 
2.2.5 Extraction Procedure  
Extraction was performed using a protein precipitation method. A total volume of 100μl of either 
sample, standards or QCs was transferred to glass vials where 800µl of 100% ACN containing 0.75% 
FA and 500ng/ml of IS was added. Following mixing, samples were centrifuged at 4000 × g for 10 
minutes at 4°C. The supernatant fraction was transferred to a fresh glass vial and evaporated to 
dryness using a rotary vacuum centrifuge, Jouan RC 10.22 (Thermo Fisher Scientific, UK). The pelleted 
residue was reconstituted with 100μL solution of H2O: ACN (90:10) and vortexed. Subsequently, 80μl 
of the sample was then transferred into 200μl chromatography vials. Thereafter 5μl of each sample 
was injected into the LC-MS/MS system for analysis. 
 
Time (minutes) Mobile Phase A (%) Mobile Phase B (%) 
0.0 90 10 
0.1 90 10 
0.5 14 86 
3.0 8 92 
3.1 5 95 
4.0 5 95 
4.0 90 10 
5.5 90 10 
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2.2.6 Assay Validation 
The assay was validated according to the most recent FDA guidelines (FDA, 2016). The following 
criteria were assessed: linearity, recovery, selectivity, accuracy, precision and inter-assay as well as 
intra-assay variability.  
2.2.7 Linearity 
Linearity was assessed by three independent preparations of a calibration standard curve for each 
analyte. The calibration curve was obtained by plotting the ratio of peak area of the analyte to the 
peak area of IS. Maximum allowed deviation of standards was set at 15% of the stated value, excluding 
the lower limit of quantification (LLOQ) where deviation was set at no more than 20%.  
2.2.8 Recovery  
Recovery experiments were performed by comparing the results for extracted samples of each 
compound at three concentrations (same as high, medium, and low QCs) with non-extracted 
standards that were taken to represent 100% recovery. 
2.2.9 Selectivity  
The degree of interference from the matrix (due to potential interfering substances including 
endogenous matrix components, metabolites, and decomposition products) was assessed via 
comparison of extracted blank samples with the lowest point of the standard curve, the LLOQ. The 
LLOQ was a minimum of five-times greater than the background signal. 
2.2.10 Accuracy & Precision 
The intra-day and inter-day precision and accuracy of the method were determined with QC samples 
at three different concentrations (three injections for each concentration) on the same day and three 
different days. The calculated average concentration relative to the nominal concentration was used 
to express accuracy (% variability of accuracy = error/stated value*100). The relative standard 
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deviation was calculated from the QC values and used to estimate the precision (%variation of 
precision = standard deviation/average assay value*100). Acceptable variation for accuracy and 
precision was set at 15% and 20% for the lower concentrations. 
2.2.11 Stability 
Stability of irinotecan, SN-38 and SN-38G stock solutions were evaluated by repeated injection of 
standards (low, medium, and high) after 3 freeze-thaw cycles. Each analyte was considered stable at 
each concentration when the differences between the freshly prepared samples and the stability of 
testing samples did not deviate more than 15% from the nominal concentrations. 
 
2.3 Application of the Method 
2.3.1 Animals 
All animal experiments were performed in accordance with criteria outlined in a Home Office UK 
approved project licence (PPL 70/8563/OWEN) granted under the Animals (Scientific Procedures) Act 
1986 and approved by the Animal Ethics Committee at the University of Liverpool. Male BALB/c mice 
weighing between 20-25g were purchased from Charles River Laboratories (Margate, UK) and housed 
in a licenced specified pathogen-free establishment. Mice were given free access to food and water 
and housed at a temperature between 19°C and 23°C under a 12-hour light-dark cycle. 
2.3.2 Pharmacokinetic Study 
The developed LC-MS/MS method was used to study the plasma concentration-time profile in mice. 
Mice (n=3) were injected intravenously (tail vein) with irinotecan at a dose of 40mg/kg and blood was 
collected in heparinised tubes following cardiac puncture at 0.083, 0.25, 0.5, 2, 2.5, 3, 4 and 5 hours 
after dose administration. Samples were centrifuged at 10,000 rpm for 10 minutes to separate plasma 
and stored at −40°C un l analysis. 
2.3.3 Statistics  




2.4.1 Method Development  
Various preliminary experiments were carried out to develop the analytical method for the detection 
of irinotecan, SN-38 and SN-38G. LC-MS/MS conditions were optimised so that good symmetrical 
peaks and resolution were achieved. The optimised global settings were positive ion 3800V, sheath 
gas 50, aux gas 30 and sweep gas 0. Mass parameters were fine-tuned for maximum sensitivity, and 
parent ion transitions (MRM mode) were selected to afford the best response for the spectrum 
analysis as shown in Table 2.2. 
Table 2.2 Optimised tuning setting for the detection of the compounds 
Parameter Optimised Setting 
Positive Ion (V) 3800* 
Sheath Gas 50 
Aux Gas 30 
Sweep Gas 0 
Ion Transfer Tube Temperature (°C) 375 
Vaporiser Temperature (°C) 375 
*The spray voltage was time-dependent – divert valve was switched on between 2.2 to 3.2 minutes 
To improve the specificity, the MRM scan type was used. The MRM transitions from precursor ions to 
product ions were optimised based on their most abundant precursor ions and corresponding product 
ions. These parameters for irinotecan, SN-38, SN-38G and the IS are summarised in Table 2.3 and 
Figure 2.2. 
Table 2.3 The parent mass, product ion and collision energy for each of the compounds 
















Figure 2.2 Representative MS/MS chromatograms of (A) Irinotecan (B) SN-38 (C) SN-38G and (D) SN-38-d3 at 
500ng/ml. 
2.4.2 Chromatographic Separation 
The elution of the analytes was rapid and selective with adequate separation of all the peaks within a 
period of 5.5 minutes. Irinotecan, SN-38, SN-38G and the IS were eluted at approximately 2.78, 2.85, 
2.66 and 2.85 minutes, respectively. No interfering peaks were observed at these retention times, plus 




Figure 2.3 Representative LC-MS/MS chromatogram of Irinotecan (retention time: 2.78 mins), SN-38 (retention 
time: 2.85 mins), SN-38G (retention time: 2.66 mins) and the internal standard SN-38-d3 (retention time: 2.85 
minutes). 
 
2.4.3 Method Validation 
2.4.3.1 Linearity  
Method validation was conducted in blank mouse plasma, phosphate-buffered saline (PBS) and 
Dulbecco's modified Eagle medium (DMEM) growth media. The nine-point standard curves were 
linear in the concentration range for all matrices between 4-1024ng/mL for irinotecan, 2-512ng/mL 
for SN-38 and 2-512ng/mL for SN-38G. Mouse plasma calibration curves for each analyte are shown 
in Figure 2.4. The average correlations of the calibration curve were found to be acceptable (Pearson’s 
coefficient of determination R2>0.99). The peak area ratio (analyte to IS; variation of IS was <15% in 




Figure 2.4 Standard curve generated from extracted mouse plasma standards for (A) Irinotecan, (B) SN-38 and 
(C) SN-38G. Variation in the IS response area used to create the calibration curves is displayed in (D).  
 
2.4.3.2 Extraction Recovery 
The recovery was evaluated using three replicates of QC samples at three concentration levels (the 
same concentrations as QC sample) in mouse plasma, PBS and DMEM. The results showed (Figure 2.5) 
that the recoveries were not less than 70% for all the analytes. The average recovery was in the range 




Figure 2.5 The percentage recovery for (A) Irinotecan, (B) SN-38 and (C) SN-38G at low, medium and high QCs 
in various matrices. Data is shown as an average percentage of unextracted standards ± SD (n=3). 
2.4.3.3 Selectivity 
FDA guidelines require the LLOQ produce a peak area of at least five-fold greater than that observed 
in the blank matrix. The acceptable LLOQ of irinotecan, SN-38 and SN-38G were determined to be 4, 
2, and 2ng/mL respectively and was validated through the analysis of three replicates. Additionally, 
the signal produced by the IS showed no interference with any of the analytes. 
2.4.3.4 Accuracy & Precision 
The variability within and between assays was calculated to demonstrate that the method maintained 
accuracy and precision across repetitions. Table 2.4, Table 2.5 and Table 2.6 shows the variance of 
accuracy and precision calculated from average values of three repetitions of the assay (low QC, 
medium QC and high QC) either from the same experiment (intra-day) or an average of three separate 
experiments (inter-day). For FDA guidance, these results demonstrated that the precision and 
accuracy values were in the acceptance range (<15%). Across all matrices, the intra and inter-day 
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precision consisted of ≤6.49% and ≤11.47% for irinotecan, ≤10.16% and ≤9.24% for SN-38, and ≤8.27% 
and ≤6.68% for SN-38G. Across all matrices, the intra and inter-day accuracy consisted of ≤10.71% and 
























1034.29 ± 15.45 3.43 1.49 1004.09 ± 28.23 0.41 2.81 
Medium 
(200ng/ml) 
221.42 ± 14.38 10.71 6.49 203.67 ± 15.54 1.83 11.47 
Low (10ng/ml) 10.68 ± 0.51 6.82 4.77 11.15 ± 0.81 11.49 7.29 
SN-38 
High (500ng/ml) 488.15 ± 9.96 -4.66 2.04 475.59 ± 24.69 -1.42 3.14 
Medium 
(100ng/ml) 
101.26 ± 0.53 1.26 0.53 106.72 ± 4.49 1.05 8.26 
Low (5ng/ml) 5.14 ± 0.22 7.06 10.16 4.64 ± 0.38 -2.37 4.27 
SN-38G 
High (500ng/ml) 475.59 ± 24.69 -4.88 5.19 486.69 ± 15.72 -2.66 3.23 
Medium 
(100ng/ml) 
106.72 ± 4.49 6.72 4.21 104.80 ± 2.72 4.80 2.59 





Table 2.5 Intra-day and Inter-day accuracy and precision for irinotecan, SN-38 and SN-38G in DMEM (n=3) 
Compound  
Average ± SD 
(ng/ml) 
Intra-day 














1012.6 ±31.2 1.3 3.1 995.4 ± 17.1 -0.5 1.7 
Medium 
(200ng/ml) 
196.2 ± 6.1 -1.9 3.1 199.3 ± 2.9 -0.3 1.5 
Low (10ng/ml) 10.4 ± 0.32 3.9 3.1 10.3 ± 0.1 6.4 3.1 
SN-38 
High (500ng/ml) 498.6 ± 4.9 -0.3 1.0 500.4 ± 0.3 0.1 0.6 
Medium 
(100ng/ml) 
100.2 ± 0.8 0.2 0.8 98.1 ± 2.5 -1.9 2.5 
Low (5ng/ml) 5.0 ± 0.1 0.5 1.6 4.7 ± 2.8 -5.8 5.9 
SN-38G 
High (500ng/ml) 500.7 ± 4.4 0.1 0.9 500.5 ± 2.6 0.1 0.5 
Medium 
(100ng/ml) 
98.8 ± 2.1 -1.2 2.1 103.4 ± 4.9 3.4 4.8 






Table 2.6 Intra-day and Inter-day accuracy and precision for SN-38 in PBS (n=3) 
 
Average ± SD 
(ng/ml) 
Intra-day 
Average ± SD 
(ng/ml) 
Inter day 
Variance of accuracy 
(%) 
Variance of precision 
(%) 
Variance of accuracy 
(%) 
Variance of precision 
(%) 
High (500ng/ml) 500.0 ± 2.6 0.1 0.5 502.6 ± 2.5 0.5 0.5 
Medium 
(100ng/ml) 
100.2 ± 0.7 0.4 0.7 100.8 ± 0.4 0.8 0.4 







Analyte stock solutions were found to be stable following 3 freeze-thaw cycles at −40°C. As seen in 
Table 2.7, a concentration difference of less than 15% was observed across all analytes. The analytical 
method was therefore proved to be applicable for routine analysis over this period. 
Table 2.7 Stability of the working solutions of Irinotecan, SN-38 and SN-38G stored at -40°C over 6 weeks 
  
After 3 freeze-thaw cycles 










High (1000ng/ml) 981.8 ± 
20.1 0.2 -1.8 
Medium (200ng/ml) 198.3 ± 7.7 3.9 -0.8 
Low (10ng/ml) 10.8 ± 1.4 13.1 7.5 
SN-38 
High (500ng/ml) 500.1 ± 
16.6 3.6 0.1 
Medium (100ng/ml) 101.0 ± 3.9 3.8 0.9 
Low (5ng/ml) 4.9 ± 0.3 5.8 -0.4 
SN-38G 
High (500ng/ml) 501.8 ± 
18.1 3.6 0.4 
Medium (100ng/ml) 96.1 ± 8.7 9.1 3.9 
Low (5ng/ml) 4.5 ± 0.6 14.1 -9.6 
 
2.4.4 Method Application 
The validated method was applied to determine irinotecan, SN-38 and SN-38G content in mouse 
plasma after intravenous administration of 40mg/kg irinotecan in male BALB/C mice. Average plasma 
concentrations of irinotecan, SN-38 and SN-38G as a function of time after administration are shown 
in Figure 2.6. As seen from Figure 2.6A, a sharp decline in the plasma concentration of irinotecan was 
observed with time and irinotecan was found to be mostly eliminated from plasma within 5 hours of 
dose administration. The concentration of SN-38 was found to increase initially in the first 30 minutes 
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followed by its gradual elimination from plasma over time (Figure 2.6B). The extent of SN-38 
glucuronidation in mice was assessed by the direct measurement of SN-38G and its levels seemed to 
be maintained (Figure 2.6C). 
 
Figure 2.6 The plasma concentration-time curves of (A) irinotecan, (B) SN-38, and (C) SN-38G following 
administration of irinotecan to BALB/c mice. Pharmacokinetic parameters for each compound were derived and 











The described bioanalytical method, based on simple protein precipitation and LC-MS/MS 
determination, quantifies irinotecan and its main metabolites. The method, which has been 
successfully validated according to the FDA guidance on bioanalytical method validation is highly 
sensitive, precise and accurate. The required sample volume was 100μL and the sample preparation 
was straightforward and efficient, an advantage over some methods (D’Esposito, Tattam, Ramzan, & 
Murray, 2008; Khan, Ahmad, & Ahmad, 2003; L. P. Rivory et al., 1996). The sensitivity of the method 
(LLOQ - irinotecan 5ng/ml, SN-38 2ng/ml and SN-38G 2ng/ml) was better than what has already been 
reported in the literature (Atasilp et al., 2018; X. Chen et al., 2012; D’Esposito et al., 2008; Taneja, 
Gota, Gurjar, & Singh, 2019). Greater LLOQ values had been reported for irinotecan and its metabolites 
by Marangon et al., however, this might be explained by differences (mouse vs. human) in the nature 
of the samples analysed (Marangon et al., 2015). Other advantages include a short analysis time (5.5 
minutes) permitting high sample throughput and good selectivity i.e. negligible matrix effect. The 
analysis time was much quicker in comparison to those published in the literature 18 minutes (Atasilp 
et al., 2018; Marangon et al., 2015) or 12 minutes (Martinez-Chavez et al., 2020). Many of the 
published methods (see cited review) are only able to quantify irinotecan and SN-38 and some use an 
estimate to determine the levels of SN-38G (Ramesh et al., 2010). Here we additionally directly 
quantified the levels of SN-38G, which will give a clear understanding of the clearance and inactivation 
of SN-38. This has clear implications in trying to understand mechanisms for both toxicity and efficacy 
involved in irinotecan pharmacokinetics. 
The LC-MS/MS method was fully validated and applicable to a number of matrices including DMEM 
growth media and PBS, demonstrating its versatility. Only one other publication has detailed the 
quantification of irinotecan and SN-38 in DMEM (Hu et al., 2007) and they were also unable to quantify 
SN-38G within their method. Our method was successfully applied to determine irinotecan and its 
metabolites in mouse plasma. The plasma-concentration time curves, together with the derived 
pharmacokinetic parameters as shown in Figure 2.6D, indicated a short half-life, rapid elimination and 
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low bioavailability of irinotecan within BALB/c mice, corroborating with similar in vivo studies (Basu et 
al., 2016; Prijovich et al., 2014; Taneja et al., 2019). The initial rise in the concentration of SN-38 could 
be explained by the biological conversion of irinotecan into its active metabolite SN-38. This method 
can be used in future PK/PD studies for irinotecan or its novel formulations. A more in-depth 
pharmacokinetic analysis of this data is presented in chapter 4 as part of a larger study. Further 
improvements to the method that could be made would be to include additional irinotecan 
metabolites such as APC and NPC and to take into consideration both the lactone (active) and 
carboxylate (inactive) forms of irinotecan and SN-38. This would provide a more in-depth 
understanding of the inter-conversion and plasma pharmacokinetics of both irinotecan and SN-38. 
 
2.6 Conclusion 
In this chapter, we developed and validated an LC-MS/MS method with acceptable accuracy, 
precision, and extraction recovery with good linearity according to the US FDA guidance on 
bioanalytical method validation. The method was successfully applied to a pharmacokinetic study of 










Chapter 3: Monolayer (2D) and Spheroid (3D) Colorectal Cancer Models as a 
Tool for Assessing and Understanding Chemotherapeutic Effectiveness during 
Pre-Clinical Development  
 
Abstract  
Colorectal cancer, the second most common cause of cancer deaths worldwide, is associated with a 
poor prognosis due to the lack of effective therapies. Most promising pre-clinical drug candidates 
ultimately fail, largely caused by the poor predictive value of pre-clinical models. Over the past decade, 
the evaluation of anticancer drugs using two-dimensional cell cultures has delivered significantly 
useful pharmacological analyses. However, these cultures lack many of the characteristics and 
complexity seen in vivo. This has led to the development of three-dimensional culture systems, which 
have been shown to better mimic tumours and their microenvironment. Consequently, they are better 
placed for the assessment of pharmaceutical candidates. Accordingly, HCT116 and CT26 cells were 
cultured as spheroids and characterised in terms of their growth kinetics, morphology and histology.  
The response of monolayer and spheroid colorectal cancer cell lines to the topoisomerase I inhibitor 
irinotecan and its active metabolite SN-38 treatment were compared. Cell viability, 
immunohistochemistry, immunofluorescence (IF) and subsequent protein expression with Western 
blotting was assessed. Uniform, compact spheroids formed after five days in culture. Results showed 
that cells cultured as spheroids differed significantly from monolayer, in terms of drug response to 
both irinotecan and SN-38. Cell lines in monolayer typically exhibited increased sensitivity (lower IC50 
values at 72hrs) to drugs, as compared to spheroids. Spheroids also showed morphological changes 
such as increased cell size, nuclear changes and a decrease in spheroid diameter. Repeated exposures 
in spheroids, did lead to a reduction in cell viability i.e. spheroids became more sensitive (21-fold 
reduction for HCT116, and a 9- and 3-fold reduction for CT26 in IC50 for irinotecan and SN-38). Notable 
differences between cultures were also observed in protein expression and drug uptake, both of which 
were consistently decreased in spheroids. Taken together, the data indicated that the cellular 
environment in which cells are cultured can considerably influence a drug’s efficacy and mechanism 
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of action. Spheroids are likely to be a better representation of in vivo solid tumours and can provide a 
physiologically relevant model for evaluating the effects of anticancer agents pre-clinically, however, 



















3.1 Introduction  
Despite significant improvements in CRC therapy, there is still a need for innovative drug screening 
methodologies. Patients with advanced CRC are often limited to traditional chemotherapies, as their 
primary therapeutic option. Additionally, patients relapsing after initial chemotherapy is a challenge 
in approximately 30-50% of cases (Broadbridge et al., 2013; Ryuk et al., 2014). Therefore, enabling 
more effective therapies to treat CRC, remains an urgent unmet medical need.  
Three approaches are currently employed in the discovery and development of novel cancer drugs: 
high throughput drug screening (HTS), rational drug design and the development of analogues of 
existing drugs (Colotta, 2008; Schwartsmann et al., 2002). These approaches rely on in vitro assays 
based on clonogenicity, proliferation and cytotoxicity. However, a major problem is that promising 
pre-clinical activity (≤5%) often does not translate clinically into patient benefit (Chabner & Roberts, 
2005). Lack of clinical efficacy and/or unacceptable toxicity profiles are the two main causes of drug 
failure during development. Several factors have contributed to this, specifically pre-clinical models 
failing to adequately recapitulate the complexity and heterogeneity of human cancers. To overcome 
this, many techniques have been developed that attempt to bridge the gap between pre-clinical and 
clinical studies.  
Table 3.1 Summary of the differences in two-dimensional vs. three-dimensional cell culture models 
Characteristic Type of culture Ref. 
2D 3D 
In vivo-likeness 
Do not mimic the natural structure 
of the tissue or tumour mass Resemble organisation seen in vivo 
(Kapalczynska et al., 
2018) 
Proliferation Proliferate rapidly Cells tend to proliferate slower (X. Xu et al., 2012) 
Polarity Partial/forced polarisation Polarisation is conserved 
(Duval et al., 2017; 
Freytes, Wan, & 
Vunjak-Novakovic, 
2009) 
Cell morphology Sheet-like, flat and elongated cells Form aggregate/spheroid structures and contain multiple layers 
(Antoni, Burckel, 
Josset, & Noel, 2015; 
J. B. Kim, 2005; 
Zanoni et al., 2016) 
Gene/protein 
expression 
Display differential gene/protein 
levels compared with in vivo models 
Expression of genes and proteins similar 
to those seen in vivo. 
(Chang & Hughes-
Fulford, 2009; K. J. 
Price et al., 2012; 
Szot, Buchanan, 
Freeman, & Rylander, 
2011)  
Drug responses Offer little resistance to drugs and tend to be more sensitive 
Display more resistance to drug 
treatments and provide a more accurate 
representation 
(Bruningk, Rivens, 
Box, Oelfke, & Ter 
Haar, 2020; Gurski, 
Petrelli, Jia, & Farach-
Carson, 2010; 
Hongisto et al., 2013) 
Culture 
formation Within a few hours Ranges from a few hours to a few days 
(Chaicharoenaudomr




Traditional monolayer cell culture (two dimensional - 2D) techniques have delivered significantly 
useful pharmacological analyses in various disease settings, such as Parkinson's, HIV, diabetes and 
cancer (Breslin & O'Driscoll, 2013). Other advantages involving low cost, ease of application, high 
throughput, and control over microenvironmental features, has meant that 2D cultures are a standard 
method for assessing cellular responses. Despite this, cells cultured in 2D show clear limitations. For 
instance, cells do not grow in a physiological environment that allows them to completely mimic the 
different properties and behaviours observed in vivo. Cells are also forced to polarise and increase 
their exchange area to culture media due to the attachment to rigid and flat substrates (Freytes et al., 
2009). This leads to over-nutrition, increased oxygenation and non-reproducibility of in vivo molecular 
gradients. Additionally, the composition, configuration and production of the extracellular matrix 
(ECM) is considerably altered (Edmondson, Broglie, Adcock, & Yang, 2014). As a result, anticancer 
agents administered to 2D cell cultures reach cells without any physical barrier, whereas the same 
molecules delivered in vivo encounter a differently associated stroma and a range of cell-cell and cell-
matrix interactions, which influence the concentration present throughout the tumour 
microenvironment (Edmondson et al., 2014; Sensi, D'Angelo, D'Aronco, Molinaro, & Agostini, 2018). 
It is, therefore, necessary to improve in vitro testing methods to provide a more informed prediction 
of drug candidate efficacy and safety. As such, there is increasing interest in applying three 
dimensional (3D) in vitro models to enhance the selection of lead candidates for in vivo evaluation. 
3D culture models such as spheroids could serve as an intermediary between 2D cultures and the 
highly complex nature of in vivo tumours. Spheroids are tightly bound, sphere-shaped cellular 
aggregates that have been extensively studied since their development in the 1970s (Mueller-Klieser, 
1987; Sutherland, McCredie, & Inch, 1971). Depending on the cell type and growth conditions they 
can range in size from 20μm up to 1mm in diameter. The increased cell-cell and cell-matrix contacts 
in spheroids not only alters gene expression patterns and resistance to anticancer agents but also 
limits the diffusion of drugs, nutrients, oxygen and waste products into and out of spheroids (as 
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depicted in Figure 3.1). Spheroids have a stratified cellular composition, with an outer layer of 
proliferating cells, a viable layer of quiescent cells in the middle and if large enough (usually larger 
than 500μm) necrotic cells are present in the core of the spheroid (Kunz-Schughart, Freyer, 
Hofstaedter, & Ebner, 2004; R. Z. Lin & Chang, 2008; Mehta, Hsiao, Ingram, Luker, & Takayama, 2012). 
Such cellular heterogeneity is also apparent in non-vascularised tumour regions (Mueller-Klieser, 
2000). 
 
Figure 3.1 Schematic diagram of a spheroid. Spheroids are 3-D microscale tissues that exhibit an inherent 
gradient of nutrients, oxygen and metabolites within themselves. In the proliferative zone, cells receive enough 
oxygen and nutrients to proliferate. The quiescent zone is a region of viable and non-proliferative cells. In the 
necrotic zone, cell death occurs due to an accumulation of toxic waste products and a lack of oxygen and nutrient 
supply. Due to similarities between in vivo tissues and spheroids as well as mass transport limitations, spheroids 
can serve as high throughput screening platforms for drug and carrier effectiveness. Adapted from (Dini et al., 
2016). 
Spheroids are considered an appropriate in vitro model for drug screening in the field of oncology due 
to their ability to better recapitulate the complex architectural, biological and physiological nature of 
the tumour microenvironment in vitro. Spheroids are subjected to different adhesive, topographical 
and mechanical factors, then cells grown in 2D (Baker & Chen, 2012; Ekert et al., 2014; Friedrich, 
Seidel, Ebner, & Kunz-Schughart, 2009; C. Wang et al., 2014). Spheroids maintain many properties of 
their tumour counterparts which are lost in 2D i.e. a higher degree of the structural, morphological 
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and functional differentiation and in vivo like growth kinetics and resistance patterns to 
chemotherapeutics. Additionally, certain components (cell-cell and cell-ECM interactions) are 
expressed to a higher degree in spheroids, hence they can establish physiological drug delivery 
barriers, which are also seen in vivo. Spheroids, therefore, have the potential to serve as an improved 
assay format, relevant to the development of nanomedicines. Previous reports have compared 
anticancer activity in 2D and 3D cell culture models and differential drug sensitivity between cultures 
were observed (Ekert et al., 2014; Harma et al., 2010; Hongisto et al., 2013; Riedl et al., 2017; 
Zoetemelk, Rausch, Colin, Dormond, & Nowak-Sliwinska, 2019).  
Nanomedicines have been largely investigated in 2D cultures, as this model is relatively simple and 
cheap. Tumour spheroids are one of the most popular models of 3D cell cultures used as a more 
advanced system for testing the anticancer effect of nanomedicines in vitro  (Friedrich et al., 2009). 
Tumour spheroids are often used to assess NP penetration and toxicity, as this process mimics one of 
the most important barriers to NP entry into the tumour in vivo. Many factors, such as NP size, shape, 
charge and targeting ability can influence a NPs cellular internalisation and its diffusion inside the 
spheroid (Agarwal et al., 2015). Researchers have developed many different methods for evaluating 
the transport of nanomedicines in 3D cultures. Penetration of fluorescent-labelled nanomedicines or 
those containing fluorescent materials inside may be easily studied both in live or fixed spheroids by 
fluorescent or confocal microscopy (Agarwal et al., 2015; Hornung et al., 2015; Leite et al., 2019). In 
this case, images are usually analysed and the depth of NP penetration together with the amount of 
NPs are estimated. Additionally, Hoechst 33342 has been used to discriminate between cells in the 
core and periphery of spheroids (J. M. Lee et al., 2018; Ozcelikkale et al., 2017; E. Yang et al., 2015). 
Tchoryk et al. used staining with Hoechst 33342 to evaluate doxorubicin and its liposomal formulation 
transport into different layers of HCT116 spheroids (Tchoryk et al., 2019). In the case of doxorubicin 
or other fluorescent substances or NPs, it is possible to analyse its extent of penetration and also 
evaluate its accumulation by mean fluorescence intensity in cells (Hornung et al., 2015; Ma et al., 
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2012). Another method of measuring NP penetration in spheroids involves directly measuring the drug 
released from NPs by utilising chromatographic techniques. Lu et al. evaluated the accumulation of 
albumin-polycaprolactone NPs encapsulating albendazole in pancreatic spheroids (H. Lu, Noorani, 
Jiang, Du, & Stenzel, 2017). Following treatment, they lysed the spheroids, then extracted albendazole 
with acetonitrile and evaluated its concentration by high-pressure liquid chromatography. Therefore, 
spheroids have the capacity of offering more appropriate pre-clinical models for evaluating 
therapeutic candidates, as well as being more efficient in predicting in vivo anticancer activity, 
compared with their monolayer counterparts. We hypothesised that characteristics of spheroids 
would enable them to mimic the in vivo/clinical environment better than monolayer cultures, with 
such properties influencing the therapeutic effect of drugs. 
In this chapter, the generation, growth, and characterisation of CRC tumour spheroids are outlined. 
As it is well known that cells at different tumour stages are exhibiting different sensitivity to drugs, a 
panel of classical CRC cell lines were additionally examined: HCT116, CT26, DLD-1 and LoVo. This part 
of the thesis also systematically evaluated the response of irinotecan and its active metabolite SN-38 
in both 2D and 3D cultures using various molecular biological techniques. Mechanisms relating to how 
cultures systems can influence and differentially modulate response to such treatments was 








3.2 Materials and Methods 
3.2.1 Materials 
All materials used in cell culture were obtained from Sigma-Aldrich (Dorset, UK) and all other reagents 
were purchased from Thermo Fisher Scientific (Loughborough, UK) unless otherwise stated. Patient 
tissue samples (patient-matched healthy colonic mucosa, primary CRC and CRC liver metastasis) were 
obtained through Liverpool Bio-Innovation Hub Biobank, with ethical approval granted by the Biobank 
governance board (LBIH project number: 19-07). 
3.2.2 Cell Lines and Maintenance 
The human CRC cell lines DLD-1 (ATCC®, CCL-221), HCT116 (ECACC®, 91091005) and LoVo (ATCC®, 
CCL-229) and mouse colon cancer cell line CT26 (ATCC®, CRL-2638) were obtained from American Type 
Culture Collection or the European Collection of Cell Cultures. All cells were routinely screened for 
mycoplasma contamination by polymerase chain reaction (PCR). Table 3.2 shows brief information on 
the histology and origin of the cell lines used.  
Table 3.2 Details of Cell Lines 
Cell Line Histology Origin 
CT26 Murine colon carcinoma Induced by the administration of the 
carcinogen N-nitroso-N-
methylurethane to BALB/c mice 
DLD-1 Colorectal adenocarcinoma Adult, Male 
HCT116 Dukes' type D, Primary colon carcinoma 48-year-old Male 
LoVo Dukes' type C, grade IV, colorectal 
adenocarcinoma 
56-year-old Male 
The complete growth medium used for the CT26 cells was Roswell Park Memorial Institute (RPMI) 
culture medium and that for the Human CRC cells was Dulbecco’s Modified Eagle’s Medium-high 
glucose (DMEM). Both mediums were supplemented with 10% heat-inactivated Foetal Bovine Serum 
(FBS), 100U/mL penicillin and 100μg/mL streptomycin. The cells were cultured in 75cm2 Nunclon cell 
culture flasks (VWR, Lutterworth) and incubated in a humidified atmosphere at 37°C, 5% CO2. They 
were grown to 70–80% confluence before being passaged (twice a week) using 0.25% Trypsin-EDTA 
(5 min, 37°C) (Invitrogen, Paisley). Cell density was determined using a haemocytometer. For this, cell 
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suspensions were mixed with an equal volume of 0.4% trypan blue solution. Viable cells at the central 
grid (5x5 squares) were counted using the x20 objective lens of a phase-contrast microscope (ECLIPSE 
TS100/100-F, Nikon). The volume required for the specific cell count was calculated and diluted in 
media for seeding as follows: 
Cells/ml = Number of counted cells x 2 (dilution factor) x 1 x104 (haemocytometer factor) 
3.2.3 Monolayer (2D) Culture 
For the monolayer culture method (2D), 100μL/well of each cancer cell line was dispensed into flat 
bottomed 96 well plates. The optimised seeding densities were as follows: CT26 - 2x103, DLD-1 - 3x103, 
HCT116 - 5x103, LoVo - 5x103 cells/well. The cells were left to adhere overnight (24hrs), before 
conducting any further experiments.  
3.2.4 Spheroid (3D) Culture 
Single-cell suspensions of CT26 (1x103 cells/well) and HCT116 (1.25x103 cells/well) cells at optimised 
densities were grown (100μl total volume) in the ultra-low attachment (ULA) 96-well round-bottom 
plates (Corning, Flintshire). The plates are provided pre-coated with a hydrophilic polymer, that 
prevents attachment and triggers the formation of a single spheroid per well. The cells were spun at 
700 x g for 7 minutes using a plate centrifuge to encourage the formation of a single spheroid and 
minimise cell death. The ULA plates were incubated at 37°C, 5% CO2 for 5 days to allow for the 
development of stable spheroids, before conducting any further analysis. During the growth period, 
the medium was exchanged on day three day by removing 50μl of old media and replacing it with the 
same volume of fresh growth medium. Care was taken not to disturb the spheroids.  
3.2.5 Analysis of Spheroid Growth 
Images of spheroids at different seeding densities were taken up to 16 days after initiation for growth 
determination. A 50% medium replenishment was performed every 48-72 hours using a multichannel 
pipette, to maintain nutrient levels. To examine spheroid growth over time, images (10 spheroids/day 
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using an x4 objective) were captured using a digital camera head (DS-Vi1, Nikon) and a stand-alone 
controller and display unit (DS-L3, Nikon). Images were analysed using the ImageJ software (National 
Institutes of Health, USA) applying an image of known scale as calibration. A published macro (Ivanov 
et al., 2014) was utilised to measure the circularity, radius, diameter, and volume of the spheroids in 
an automated manner. 
3.2.6 Histological Analysis 
3.2.6.1 Spheroid Processing and Embedding  
At predefined time points (days 5, 8 and 11), spheroids (minimum of 24) were transferred from ULA 
plates into round bottom collection tubes using a 200µl pipette tip with the end cut off. All excess 
media was aspirated, and spheroids were fixed with 4% paraformaldehyde (PFA) solution (Merck, 
Germany) for 1 hour at 4°C (using enough PFA to cover the spheroids). The 4% PFA was rinsed off with 
three changes of phosphate-buffered saline (PBS) taking care not to disturb the spheroids (to ensure 
all the spheroids pool to the bottom of the collection tube, they were centrifuged briefly). Following 
the last wash, as much PBS was removed as possible.  
Thereafter molten histogel was covered over the spheroids using a Pasteur pipette (4-6 drops). The 
collection tubes were placed in a fridge (4°C, 5minutes) to allow for solidification. The solidified 
histogel was gently removed from the collection tubes, transferred into labelled processing cassettes 
and left overnight in a container of 70% ethanol. The cassettes were then placed on the histocore 
PEARL tissue processor (Leica Biosystems, Newcastle upon Tyne) and processed using the “biopsy” 
protocol (samples were dehydrated in a series of ethanol solutions with increasing concentrations, 
cleared in xylene and infiltrated with molten paraffin). Processed cassettes were then transferred to 
a Thermo Shandon paraffin-embedding station. With a pair of heated forceps, the sample was 
orientated outwards (spheroids facing towards the surface) and embedded in paraffin wax.  
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3.2.6.2 Spheroid Sectioning and Staining  
Paraffin-embedded spheroids were sectioned into 5μm sections using a Leica RM2235 microtome 
(Leica Biosystems, Newcastle upon Tyne) and mounted onto superfrost plus glass slides. Sections were 
then deparaffinised in xylene and rehydrated with descending ethanol concentrations. Routine 
staining was then performed with Haematoxylin and Eosin (H&E) (Feldman & Wolfe, 2014) and Alcian 
blue pH 2.5 (Lai & Lü, 2012) according to standard protocols. 
For immunohistochemistry (IHC), sections were deparaffinised, rehydrated through a series of graded 
alcohol dilutions and endogenous peroxidase neutralised with a 0.3% hydrogen peroxide blocking 
solution (Abcam, Cambridge) for 10 minutes. Heat-induced antigen retrieval (90°C, 2 minutes) was 
carried out in Coplin jars, using universal HIER antigen retrieval reagent (Abcam, Cambridge). After 
blocking with 10% goat serum for 15 minutes at room temperature (RT), sections were incubated 
overnight (1:200, 4°C) with primary antibodies, Ki-67 (Novus Biologicals, NB110-89717, Oxfordshire) 
and cleaved caspase-3 (Cell Signalling Technologies, 9661S, London). This was followed up by 
incubation with a goat HRP conjugated secondary antibody for 1 hour at RT. Thereafter each section 
was reacted with a 3,3’-diaminobenzidine (DAB) solution (Abcam, Cambridge) per the manufacturer’s 
instructions and counterstained with haematoxylin. The slides were coverslipped with DPX mountant 
and air-dried overnight before being assessed (Ki-67 and cleaved-caspase 3 staining was conducted by 
the Veterinary pathology department, Leahurst Campus, University of Liverpool). 
3.2.6.3 Monolayer Staining 
Cells were cultured on poly-L-lysine coated coverslips and fixed with 4% PFA for 20 minutes at 4°C. 
H&E staining was then performed according to standard protocols. 
3.2.6.4 Imaging 
All stained slides were digitally scanned at ×200 magnification using an Aperio ScanScope CS2 digital 
slide scanner (Leica Biosystems, Newcastle upon Tyne). Images were subsequently taken with Aperio 
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ImageScope viewing software (Leica Biosystems Imaging). Further analysis of positive staining was 
conducted on the software using the Aperio positive pixel count v9 algorithm. 
3.2.7 Drug Treatment 
3.2.7.1 Drugs 
Irinotecan and SN-38 were purchased from Hangzhou J&H chemical company (J&H Chemical, 
Shanghai, China). Stocks solutions for both drugs were prepared in hybri-max sterile filtered dimethyl 
sulfoxide (DMSO) and stored at -80°C. Subsequent dilutions were prepared in pre-warmed culture 
medium, immediately before use. 
3.2.7.2 Monolayer Experiments 
Cells were cultured in monolayer as described in section 3.2.3 After 24 hours, all media was aspirated 
and replaced with 100µL of each concentration of media containing drug (wells were 0.1% DMSO by 
volume). Drug concentrations for each cell line were previously determined in preliminary range-
finding experiments. For irinotecan, the concentrations ranged from 0.01 to 100μM. Each plate 
contained vehicle control wells of 0.1% DMSO in growth media and untreated control cells. The plates 
were incubated with drugs for 72 hours at 37°C, 5% CO2 before further assessment. Cells were treated 
with SN-38 in the same manner, however, the concentrations ranged from 0.5 to 200nM. 
3.2.7.3 Spheroid Experiments 
HCT116 and CT26 spheroids were grown as previously described in section 3.2.4. On Day 5, 50µl of 
growth media was removed without disturbing the spheroids. It was replaced with 50µL of each 
concentration of media containing drug (wells were 0.1% DMSO by volume). For irinotecan, the 
concentrations ranged from 0.01 to 100μM and for SN-38 the concentrations ranged from 0.5 to 
200nM. Each plate contained vehicle control wells of 0.1% DMSO in growth media and untreated 
control spheroids. The plates were incubated with drugs for an initial 72 hours at 37°C, 5% CO2 before 
further assessment. Repeat exposure studies were carried out for a further 72 hours by following the 
same procedure. This is shown in the schematic below (see Figure 3.2). After specific incubation times, 
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a minimum of 24 spheroids were harvested for further analysis. Supplementary repeat exposure 
experiments (drug treatment on day 5, 8, 11, 14 and 17) were also performed to explore the sensitivity 
of the spheroids. Cell viability was measured following drugs exposure for up to 360 hours. 
 
Figure 3.2 Time table for setting up and performing spheroid-based drug assays with established tumour cell 
lines  
3.2.7.4 Determination of Cell Viability Following Treatment 
Cell viability was measured using the CellTiter-Glo luminescent cell viability assay (Promega, 
Hampshire) according to the manufacturer’s instructions. The ATP assay is based on the quantification 
of the amount of intracellular ATP which correlates with the number of metabolically active (viable) 
cells. Briefly, 100µL of CellTiter-Glo reagent was added to each well of the spheroid or monolayer cells 
plates. For cells in monolayer, the plate was agitated using an orbital shaker at 60rpm for 2 minutes 
to induce cell lysis. For spheroids, the plates were agitated at 60rpm for 5 minutes to induce cell lysis. 
Thereafter, the plates were left for 10 minutes to equilibrate at RT and 100 µL lysate was transferred 
to a white opaque walled 96-well flat-bottomed plate. The luminescence was measured at 570nm 
wavelength using a Varioskan flash plate reader. Media alone with CellTiter-Glo reagent was used as 
a blank control and subtracted from sample values. Cell viability was calculated as a percentage of 
untreated vehicle control samples (0.1% DMSO treated). Six replicates were used for each experiment 
(n=6) and at least two independent experiments were conducted. A concentration-response curve 
was plotted and IC50 values determined. 
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3.2.8 Western Blotting 
3.2.8.1 Cell Lysis  
Monolayer cells were seeded on 6 well plates and incubated for 24 hours until sub-confluent. For drug 
treatment, cells were incubated with previously determined IC50 concentrations for 72 hours. 
Following incubation, cell lysates were prepared on ice by washing cells twice with ice-cold 1x PBS and 
then by the addition of 300µL radioimmunoprecipitation assay (RIPA) buffer (150mM NaCl, 1.0% 
IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS), 50mM Tris, pH 8.0) 
supplemented with 1x Halt™ protease and phosphatase inhibitor (PPI) cocktail for 30 minutes. Cells 
were thereafter scraped and transferred into 1.5mL Eppendorf tubes. The lysate was clarified by 
centrifugation (14,000rpm, 20minutes, 4°C) and the supernatant was collected and stored at -40°C. 
Spheroids (minimum of 24, either control or IC50 drug-treated) were collected in 1.5mL Eppendorf 
tubes using a 100µL pipette tip with the end cut off. Tubes were centrifuged gently, and the medium 
was removed. Ice-cold PBS (500µL) was added, and tubes were centrifuged gently again, before the 
removal of the PBS. RIPA buffer containing 1x PPI (150µL) was added and left on ice for 30 minutes. 
Lysates were homogenised via sonication (3 x 10-second cycles at pulse setting 2) using a Microson™ 
ultrasonic cell disruptor XL (Cole Palmer, UK). The lysate was clarified by centrifugation (14,000rpm, 
20minutes, 4°C), and the supernatant was collected and stored at -40°C.  
3.2.8.2 Tissue Lysis 
Tissues of interest were thawed on ice and washed with PBS. A clean scalpel was used to dissect the 
tissue sample, which was then placed into a precooled 1.5ml round bottom Eppendorf tubes 
containing a metal bead. Ice cold RIPA buffer containing 1x PPI (300μL) was rapidly added to the tube. 
Samples were homogenised on a mixer mill MM 400 (Retsch, UK) set at an oscillation frequency of 
30Hz for 2 minutes. All lysate was then placed into a fresh Eppendorf tube, before being clarified by 
centrifugation (14,000rpm, 20minutes, 4°C). The supernatant was collected and stored at -40°C. 
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3.2.8.3 Protein Determination 
The protein content of all samples was determined using the Pierce bicinchoninic acid (BCA) assay 
according to the manufacturer’s instructions. The assay is based on the colourimetric detection of the 
cuprous cation (Cu+). The total amount of protein was quantified from a standard curve, generated 
from known concentrations (20–2000μg/mL) of bovine serum albumin (BSA) made up in RIPA buffer. 
Each standard and unknown samples were analysed at an absorbance of 562nm (Varioskan), with a 
sample to working reagent ratio of 1:8 (25µl:200µl). Volumes of sample and deionised water (dH2O) 
required for western blotting were then calculated.  
3.2.8.4 Immunoblotting 
Protein samples (20μg) were mixed with 10x NuPAGE dithiothreitol (DTT) reducing agent and 4x 
NuPAGE lithium dodecyl sulphate (LDS) sample buffer, and the volume was adjusted to 15μL using 
dH2O. Samples were boiled (90°C, 10minutes) and centrifuged briefly. Together with a molecular 
weight (MW) marker (precision plus protein kaleidoscope pre-stained protein standards) they were 
loaded onto a NuPAGE Novex precast 4-12% Bis-Tris gels and electrophoresed with MOPS SDS running 
buffer under reducing conditions (200V, 50minutes). Antioxidant was included in the running buffer 
to prevent re-oxidation of proteins during electrophoresis. A trans-blot turbo transfer system (Bio-
Rad Laboratories, Hertfordshire) was used to transfer proteins on to 0.2µm nitrocellulose membranes 
(mixed MW protocol: 7minutes, 2.5A, 25V). The membranes were blocked for 2 hours at RT in 5% non-
fat milk in TBS-T buffer (0.01M Tris-HCl, pH 8.5; 0.15M NaCl; 0.1% Tween20), before incubation 
overnight at 4°C with the different primary antibodies (see Table 3.3 for dilutions). All blots were 
washed TBS-T (3 times, 5minutes) before being incubated with the appropriate horseradish 
peroxidase (HRP)–coupled secondary antibody for 1 hour at RT (see Table 3.3 for dilutions). After a 
further 4 washes in TBS-T, the bands were visualised through chemiluminescence detection either in 
an automated manner using a chemidoc MP imaging system (Bio-Rad Laboratories, Hertfordshire), or 
manually by covering the membranes with western lighting plus ECL (Perkin Elmer, Buckinghamshire) 
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and visualising it in a darkroom with Amersham hyperfilm ECL (GE Healthcare, Buckinghamshire). Once 
visualised, densitometry analysis was performed using ImageJ software. To correct for protein loading, 
the quantified protein of interest was related to its corresponding loading control i.e. actin band. The 
untreated control sample within each experiment was assigned an arbitrary value of 1.0, to which 
bands from all other conditions were relatively expressed.  
Table 3.3 Antibodies for western blotting 
Antibody 1° Dilution 2° Dilution 
Actin                                                     
(ProteinTech, 66009-1-Ig) 1:20,000 
1:5000                                           
Mouse 
Carboxylesterase 1                                          
(Abcam, ab45957) 1:1000 
1:5000                                  
Rabbit 
Carboxylesterase 2                                           
(Abcam, ab137606) 1:1000 
1:5000                                           
Rabbit 
MRP2                                                               
(Invtirogen, PA5-4997) 1:1000 
1:5000                                           
Rabbit 
Topoisomerase 1                                        
(Abcam, ab109374) 1:2500 
1:5000                                           
Rabbit 
UGT                                                          
(Cell Signalling Technologies, 4371S) 1:1000 
1:5000                                           
Rabbit 
UGT1A1                                                            
(Abcam, ab194697) 1:1000 
1:5000                                           
Rabbit 
γH2AX                                                                              
(Cell Signalling Technologies, 9718S) 1:1000 
1:5000                                           
Rabbit 
Both primary and secondary antibodies were made up in 2% non-fat milk in TBS-T buffer 
3.2.9 Immunofluorescence 
3.2.9.1 Monolayer 
Monolayer cells (HCT116 and CT26) were grown on poly-L-lysine coated coverslips as previously 
described in section 3.2.6.3. Cells were treated for either 0.5, 1, 3 and 24 hours with irinotecan or SN-
38 IC50 concentrations and fixed for 15 minutes at 4°C in 4% PFA. A permeabilisation step was 
performed with 0.25% Triton X-100 in PBS for 15 minutes at 4°C. To render the DNA-protein crosslinks 
more accessible to antibody, the coverslips were incubated in 1% SDS at RT for 5 minutes. Coverslips 
were then washed three times with PBS and blocked in IF blocking buffer for 2 hours at RT (PBS with 
1% glycerol, 0.1% gelatin from cold-water fish, 5% normal goat serum, 0.1% BSA and 0.4% sodium 
azide). Coverslips were incubated overnight at 4°C with primary antibodies (dilutions are shown in 
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Table 3.4) in IF blocking buffer. They were then extensively washed with PBS over 20 minutes and 
stained with fluorochrome-conjugated secondary antibody (Alexa Fluor 488 or 568) diluted 1:1000 in 
IF blocking buffer for 1 hour at RT. After further extensive washes with PBS, coverslips were 
counterstained (cell nuclei) with 1μg/ml Hoechst 33258 in PBS. Coverslips were mounted on 
superfrost glass slides using prolong gold antifade reagent and sealed using clear nail polish. Images 
were captured on a Zeiss inverse Axio observer confocal microscope (Zeiss LSM 710, Carl Zeiss) using 
an x20/x40/x63 objective with apotome. IF was also performed on cells in the absence of either 
primary or secondary antibodies as a control measure. Drug treatment with gemcitabine or 0.1% 
DMSO was also used as a negative control. 
3.2.9.2 Spheroid Sections 
Spheroids (HCT116 and CT26) were grown and treated for 24 hours with irinotecan or SN-38 
predetermined IC50 concentrations. Subsequently, spheroids were processed and sectioned as 
described in section 3.2.6.1 and 3.2.6.2. Heated (50˚C, 10minutes) spheroid sections were dewaxed 
with xylene, before being rehydrated with a series of ethanol solutions of descending concentrations 
(100-25%) and then rinsed in dH2O. A pap-pen (Abcam, Cambridge) was used to create a hydrophobic 
ring around the spheroids and slides were permeabilised, blocked and incubated as per section 
3.2.9.1. 
3.2.9.3 Whole-mount spheroids 
Spheroids (HCT116 and CT26) were grown and treated for 24 hours with irinotecan or SN-38 at 
predetermined IC50 concentrations. Spheroids were transferred from ULA plates into round bottom 
collection tubes using a 200µl pipette tip with the end cut off and fixed in PFA for 1 hour at 4°C. 
Spheroids were then permeabilised, blocked and incubated with the same reagents as per section 
3.2.9.1. However, following counterstaining with 1μg/ml Hoechst 33258, a fructose-glycerol clearing 
solution (100µl) was added for 20 minutes at RT (Dekkers et al., 2019). A pap pen was used to draw a 
circle onto superfrost glass slides. Spheroids were then picked up (using pre-coated (IF blocking buffer) 
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200ul tips with the end cut off) and placed within the circle. A coverslip was lowered on top of the 
spheroids and slight pressure was applied, prior to sealing with clear nail polish. Thereafter maximum 
intensity projection images of spheroids were taken using a Zeiss inverse Axio observer confocal 
microscope using an x20/x40 objective with apotome.  
Table 3.4 Antibodies for immunofluorescence 
Antibody Dilution 
Alexa Fluor 488 goat anti-mouse IgG 
(Invitrogen, A-11001) 1:1000 
Alexa Fluor 568 goat anti-rabbit IgG  
(Invitrogen, A-11001) 1:1000 
α-TopoIcc                                                                        
(Merck, MABE1084) 
0.67:1000                                                            
(0.67μg/ml) 
γH2AX                                                                    
(Cell Signalling Technologies, 9718S) 1:400 
3.2.10 Statistical Analysis 
Unless otherwise stated, all reported values are the average with their respective standard deviation 
(SD). The number of replicates is always indicated in the figure legends. Quantitative experiments 
were conducted at least in biological triplicates and datasets were analysed with SigmaPlot version 
14.0 (Systat Software, Inc., San Jose California USA). A two-way analysis of variance (ANOVA) with 











3.3.1 Analysis of Spheroid Growth Kinetics - Spheroid Formation and Cultivation 
To optimise spheroid culture conditions, different seeding densities which may affect spheroid 
formation and growth were investigated over 16 days. HCT116 cells were seeded at 1250, 2500 and 
5000 cells/well and CT26 cells at 500, 1000 and 2500 cells/well. The dependence of spheroid size on 
seeding density is illustrated in Figure 3.3a and Figure 3.4a where the spheroid diameter is plotted 
against time. All seeding densities resulted in the formation of spheroids varying in size, with cells 
aggregating to form a single spheroid within 3 days. Initially, all spheroid diameters increased 
exponentially, the rate of growth thereafter started to decrease i.e. spheroid growth plateau. As seen 
in Figure 3.3b and Figure 3.4b higher seeding densities resulted in irregularly-shaped (ellipsoidal) 
structures, the formation of large dark regions (quiescent/dead cells) and greater size variations, 
following five days in culture. A seeding density of 1250 or 1000 cells/well for HCT116 and CT26 
spheroids respectively, formed spheroids that displayed a compact cellular assembly with a circular 
structure. This compaction led to the formation of distinct dark borders around spheroids. As a result, 
these seeding densities (1250 or 1000 cells/well for HCT116 and CT26 spheroids respectively) were 
chosen for all subsequent experiments. 
With the optimal seeding density, the average diameter of HCT116 spheroids was 374 ± 16.6μm and 
CT26 spheroids 350 ± 26.1μm after five days of culture. Spheroid shape and diameter was further 
monitored over time and spheroids maintained their uniform shape over a 16-day culture period (see 
Figure 3.3c and Figure 3.4c). HCT116 spheroids increased in diameter over the 16-day culture period 
from 253 ± 20.6μm to 739 ± 7.18μm. Similarly, CT26 spheroids increased from 210 ± 34.7μm to 805 ± 
2.70μm. No substantial morphological changes were observed i.e. cell detachment or budding of 
secondary spheroids. These spheroids were therefore deemed suitable for long term experiments, 




Figure 3.3 Effect of cell density on HCT116 spheroid formation (a) Spheroid diameter of HCT116 cells seeded 
at three densities (1250, 2500 and 5000 cells/well) cultured for 16 days. (n=10, data shown as average ± SD) 
(b) Representative phase-contrast images (x10 objective) of each density shown at day 5. Scale bar is 100μm 
(c) Representative phase-contrast images (x4 objective) of HCT116 cells seeded in ULA plates at an optimised 
density of 1250 cells/well. Scale bars represents 100μm (n=3 using 6 technical replicates, data shown as 





Figure 3.4 Effect of cell density on CT26 spheroid formation (a) Spheroid diameter of CT26 cells seeded at 
three densities (500, 1000 and 2500 cells/well) cultured for 16 days. (n=10, data shown as average ± SD) (b) 
Representative phase-contrast images (x10 objective) of each density shown at day 5. Scale bar is 100μm (c) 
Representative phase-contrast images (x4 objective) of CT26 cells seeded in ULA plates at an optimised 
density of 1000 cells/well. Scale bars represents 100μm (n=3 using 6 technical replicates, data shown as 





3.3.2 Immunohistological Characterisation of Spheroids  
To gauge the applicability of the spheroids, sectioning and immunohistochemistry were performed 
for further characterisation. From Figure 3.5a, H&E staining of HCT116 spheroids revealed a compact 
internal arrangement, densely packed with cells. As the spheroids grew in diameter the H&E staining 
became less intense. Clearly defined cell boundaries were seen over the culture period, with staining 
consistent with the formation of central areas of necrosis emerging at day 11. The proliferative cell 
marker, Ki-67, showed proliferating cells (Ki-67+) throughout HCT116 spheroids on day 5 of culture 
(0.567), as seen by the homogenous brown staining (peroxidase). At later time points, the proliferating 
cells were more concentrated towards the outermost layer of the spheroid (Day 8 and 11). Similarly, 
the amount of Ki-67+ cells decreased to 0.357 on day 8 and 0.196 at day 11. The apoptosis marker, 
cleaved caspase-3, was not identified (negligible amount of brown staining) in any of the HCT116 
spheroids. Alcian blue staining which indicates the presence of acidic sulphated muco-substances was 
only observed on day 11 of culture (see black arrows in Figure 3.5d).  
CT26 spheroids were also characterised in the same manner (see Figure 3.6). As per the above, CT26 
spheroids also exhibited a highly organised 3D tissue-like structure with tightly compacted cells. 
However, on day 11, necrosis seemed to be apparent in the centre of spheroids (as seen by the 
presence of lighter pink - stained only with eosin). The amount of Ki-67 expressing cells markedly 
decreased over time (0.074 to 0.015), in a similar manner to the HCT116 spheroids. When comparing 
both cells lines at day 5 in culture CT26 spheroids displayed a lower proliferative activity (lower 
concentration of DNA in the S phase). However, this could have been due to CT26 cells proliferating 
much quicker initially, which would have been visible at an earlier time point. Low levels of active 
caspase-3-mediated apoptosis were found to be induced in the core of the CT26 spheroids (day 11), 





Figure 3.5 Immunohistological assessment of HCT116 spheroids. HCT116 spheroids at Day 5, 8 and 11 were 
processed, sectioned (5µm) and stained with (A) H&E: for morphology (B) Ki-67: a proliferation marker, (C) 
Caspase-3: a marker of apoptosis and (D) Alcian Blue: for acidic mucins. Images were analysed using the Aperio 
positive pixel count v9 algorithm. The values for positivity represent an average of three spheroids. Scale bars 





Figure 3.6 Immunohistological assessment of CT26 spheroids. CT26 spheroids at Day 5, 8 and 11 were processed, 
sectioned (5µm) and stained with (A) H&E: for morphology (B) Ki-67: a proliferation marker, (C) Caspase-3: a 
marker of apoptosis and (D) Alcian Blue: for acidic mucins. Images were analysed using the Aperio positive pixel 





3.3.3 Chemosensitivity of Monolayer and Spheroids Following Drug Treatment 
The viability of cells in the 2D culture systems exposed to various concentrations of irinotecan or SN-
38 was determined by an ATP assay following 72 hours of treatment. The quantitative data was 
statistically analysed and the IC50 values were determined. A concentration-dependent reduction in 
ATP cell viability was observed in all monolayer cells, in response to both drugs as seen in Figure 3.7. 
DLD-1 cells were seen to be the most sensitive cell line to irinotecan and CT26 cells the least sensitive. 
With SN-38, the LoVo cell line was the most sensitive and CT26 cells again displayed the lowest 
sensitivity. From calculated IC50 values, SN-38 was seen to be between 50-500-fold more potent than 
its parent prodrug irinotecan (see Table 3.5). 
Figure 3.7 Concentration-response curves for cells grown in 2d. ATP levels were measured in monolayer (2D) 
cells treated with (a) irinotecan [µM] or (b) SN-38 [nM], for 72 hours (n=3 using 6 technical replicates, Average 
± %SD). Cell viability was calculated as a percentage of untreated vehicle control samples (DMSO – 0.1%). The 
dashed horizontal line represents the half-maximal inhibitory concentration (IC50). 
The measurement of drug sensitivity was repeated for HCT116 and CT26 spheroids. Cell viability was 
measured in spheroids at time points of 72 hours or 144 hours. After 72 hours, HCT116 spheroids 
exhibited a concentration-dependent reduction in ATP cell viability, however, they also demonstrated 
a lower sensitivity to both drugs in comparison to 2D cells. Following 144hrs (i.e. two repeated drug 
treatments on day 5 and day 8), the spheroids showed greater sensitivity, as revealed by the 





Figure 3.8 Concentration-response curves for HCT116 cells grown in 2D vs. 3D. ATP levels were measured in 
HCT116 cells treated with (a) irinotecan [µM] or (b) SN-38 [nM], for 72 hours in 2D and 72/144 hours in 3D (n=3 
using 6 technical replicates, average ± %SD). Cell viability was calculated as a percentage of untreated vehicle 
control samples (DMSO – 0.1%). The dashed horizontal line represents the half-maximal inhibitory concentration 
(IC50). Statistical analysis was performed using a two-way ANOVA followed by Holm-Šídák multiple comparison 
post-hoc test. A P-value of *P < 0.05 for each drug concentration between 2D and 3D cultures, was considered 
significant. 
A similar pattern was present in CT26 spheroids, with spheroids displaying a lower sensitivity to both 
drugs, as compared to responses seen in monolayer (as depicted in Figure 3.9). CT26 cells overall in 
both 2D and 3D cultures were seen to be less sensitive than HCT116 cells. 
Figure 3.9 Concentration-response curves for CT26 cells grown in 2d vs. 3d. ATP levels were measured in CT26 
cells treated with (a) irinotecan [µM] or (b) SN-38 [nM], for 72 hours in 2D and 72/144 hours in 3D (n=3 using 6 
technical replicates, average ± %SD). Cell viability was calculated as a percentage of untreated vehicle control 
samples (DMSO – 0.1%). The dashed horizontal line represents the half-maximal inhibitory concentration (IC50). 
Statistical analysis was performed using a two-way ANOVA followed by Holm-Šídák multiple comparison post-




The above results (Figure 3.8 and Figure 3.9) showed that the efficacy of the irinotecan and SN-38 was 
lower in HCT116 and CT26 spheroids, than in monolayer culture (data for LoVo and DLD-1 spheroids 
is in the appendix Figure B.3). Consequently, the IC50 values determined in spheroids at 72 hours was 
significantly higher than those obtained in monolayer cultures, with enhanced sensitivity being 
observed in spheroids following repeated exposure (144 hours) (see Table 3.5). 
Table 3.5 The comparative IC50 values calculated from cell lines treated with irinotecan and SN-38 in 2D and 3D 
cell culture 
Cell line 










































(±1.48) - - ** 
8.97 
(±11.46) 
Values shown are the average (±SD) n=3 
**IC50 value was not determined 
- Not tested 
 
3.3.4 Monitoring the Effect of Repeated Chemotherapeutic Exposure in Spheroids 
Predicting cytotoxicity after repeated exposure to drugs or chemicals is important for drug 
development and safety assessment, yet it remains impractical using conventional 2D in vitro systems 
due to the requirement of maintaining a relevant cellular phenotype for an extended duration. To 
further investigate the sensitivity of spheroids, HCT116 and CT26 spheroids were subjected to a three-
week assay, involving five repeated treatments, with either irinotecan, SN-38 or 0.1% DMSO control. 
As seen in Figure 3.10 with each subsequent repeated exposure, HCT116 spheroids produced a 
significantly more potent response with an IC50 of 206.16μM and 7.75nM respectively for irinotecan 
and SN-38 at 360 hours (five repeated exposures). Under the same treatment conditions, the IC50 of 
CT26 spheroids was 6005.30μM and 117.90nM respectively for irinotecan and SN-38 (Figure 3.11). 
However, both spheroid cultures when repeatedly treated with SN-38 displayed a limit of sensitivity 
as subsequent exposures after 144 hours, did not significantly impact the IC50 values (see Table 3.6). 
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Morphological changes of the spheroids following drug treatment displayed spheroid shrinkage, as 
seen by the reduction in spheroid diameter. Also, the loss of spheroid integrity (spherical nature) and 
blebbing on the spheroid surface, was evident following repeated drug exposures. Cell death and 
induction of apoptosis at higher drug concentrations were evidenced by the shedding of dead cells 
and loss of cellular cohesion. In summary, the sensitivity of spheroid cultures was further elevated by 
extending drug exposure duration.  




HCT116 Spheroids CT26 Spheroids 
Irinotecan SN-38 Irinotecan SN-38 
72 ** 170.38 (±38.94) 55687.30 (±212.04) ** 
144 4479.9 (±323.55) 10.87 (±4.75) 16418.90 (±247.12) 374.42 (±39.81) 
216 727.73 (±87.43) 8.72 (±1.98) 11962.65 (±512.79) 158.04 (±15.94) 
288 669.13 (±54.19) 8.65 (±2.32) 11707.20 (±178.16) 141.77 (±12.46) 
360 206.16 (±112.32) 7.75 (±2.64) 6005.30 (±790.43) 117.90 (±27.71) 
Values shown are the average (±SD) n=3 




Figure 3.10 The effect of repeated drug treatment on HCT116 spheroids. ATP levels were measured in HCT116 
spheroids repeatedly exposed to (a) irinotecan [µM] or (b) SN-38 [nM] (n=3 using 6 technical replicates, average 
± %SD). Cell viability was calculated as a percentage of untreated vehicle control samples (DMSO – 0.1%) and 
concentration-response curves were plotted. The dashed horizontal line represents the half-maximal inhibitory 
concentration (IC50). (c) Typical phase-contrast images (x10 objective) of HCT116 spheroids following repeated 
drug exposures with irinotecan or SN-38. The dashed circle represents the size of the control spheroid (0.1% 
DMSO) which is reported as a visual guide. Diameters are shown as an average ± SD (n = 3, using 6 technical 
replicates). The scale bars represent 100μm.  
81 
 
Figure 3.11 The effect of repeated drug treatment on CT26 spheroids. ATP levels were measured in CT26 
spheroids repeatedly exposed to (a) irinotecan [µM] or (b) SN-38 [nM] (n=3 using 6 technical replicates, average 
± %SD). Cell viability was calculated as a percentage of untreated vehicle control samples (DMSO – 0.1%) and 
concentration-response curves were plotted. The dashed horizontal line represents the half-maximal inhibitory 
concentration (IC50). (c) Typical phase-contrast images (x10 objective) of CT26 spheroids following repeated drug 
exposures with irinotecan or SN-38. The dashed circle represents the size of the control spheroid (0.1% DMSO) 
which is reported as a visual guide. Diameters are shown as an average ± SD (n = 3, using 6 technical replicates). 
The scale bars represent 100μm.  
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3.3.5 Effect of Drug Treatment on Spheroid Histology  
Spheroids were exposed to fixed concentrations of irinotecan (100µM) or SN-38 (200 or 400nM) for 
72 hours. Previous results displayed that exposure of HCT116 and CT26 spheroids to irinotecan or SN-
38 caused a dose-dependent reduction in cell viability in both types of spheroids. HCT116 spheroids 
were more sensitive to the cytotoxic effects of both drugs, compared to the CT26 spheroids (Table 
3.6). To assess the effect of the drugs on spheroids, H&E staining was done to initially examine the 
morphology of the cells. To further assess the mechanism of cell death/reduction cleaved caspase 3+ 
and Ki-67+ staining was carried out. 
Initial examination of morphological characteristics using H&E staining showed that specific 
differences between the treatment groups and controls could be easily identified. In particular, 
evidence of necrosis and vacuole formation in spheroids was noted. Cells within both irinotecan and 
SN-38 treated spheroids (Figure 3.12a and Figure 3.13a) were enlarged and swollen, with paler 
cytoplasms (indicated by arrows). Pyknosis of cells with nuclear condensation, together with nuclear 
fragmentation and a dilated cytoplasm was also evidenced (indicated by arrowheads). Cells in both 
HCT116 and CT26 spheroids appeared to be less organised with more acellular gaps present, as 
compared to controls. Additionally, cells grown in 2D that were also treated with SN-38 showed similar 
characteristics i.e. swollen, elongated cells with nuclear condensation present. These images have 
been included in the appendix (Figure B.2). Drug treatment caused a marked decrease in the number 
of Ki-67+ cells in both HCT116 and CT26 spheroids (see positivity values). Interestingly, no significant 
increase in caspase-3 activation was present in HCT116 spheroids following drug treatment. In 
contrast, CT26 spheroids showed an increase in the number of cleaved caspase-3+ cells following both 
irinotecan and SN-38 treatment. Results suggested that drug-induced apoptosis was predominantly 




Figure 3.12 Histological assessment of HCT116 spheroids following drug treatment. HCT116 spheroids at Day 5 
were treated with irinotecan [100µM], SN-38 [200nM] or 0.1% DMSO for 72hrs. Spheroids were sectioned (5µm) 
and stained with (a) H&E, for morphology (arrows indicating features of necrosis) (b) Ki-67, a proliferation 
marker and (c) Caspase-3, a marker of apoptosis. Slides were scanned using the Leica Aperio CS2 slide scanner. 
Images were then processed using the ImageScope software. Images were analysed using the Aperio positive 





Figure 3.13 Histological assessment of CT26 spheroids following drug treatment. CT26 spheroids at Day 5 were 
treated with irinotecan [100µM], SN-38 [400nM] or 0.1% DMSO for 72hrs. Spheroids were sectioned (5µm) and 
stained with (a) H&E, for morphology (arrows indicating features of necrosis) (b) Ki-67, a proliferation marker 
and (c) Caspase-3, a marker of apoptosis. Slides were scanned using the Leica Aperio CS2 slide scanner. Images 
were then processed using the ImageScope software. Images were analysed using the Aperio positive pixel count 










3.3.6 Detection of Topoisomerase I-DNA Covalent Complexes  
The mechanism of action of both irinotecan and SN-38 causes them to bind and stabilise the TOPI-
DNA cleavage complex, thus leading to DNA damage when replication or transcription occurs. These 
agents induce their cytotoxicity by stabilising TOPI-DNA covalent complexes, which in turn interacts 
with advancing replication forks or transcription complexes to generate lethal lesions. Such complexes 
could act as surrogate markers for drug uptake/penetration. IF was therefore used to detect these 
complexes both in monolayer and spheroid culture (α-TopoIcc). Besides the presence of the DNA 
damage marker, γH2AX was also investigated as a marker of efficacy. In both 2D and 3D cultures, 
previously determined IC50 or maximal concentrations as indicated were used (see Table 3.5). 
As seen from Figure 3.14 and Figure 3.15 HCT116 and CT26 cells grown in monolayer showed 
detectable TOPI-DNA covalent complexes following 24 hours of drug treatment with irinotecan or 1-
hour drug treatment with SN-38. This was displayed by small areas of punctate staining (green foci) 
throughout the nucleus. The 0.1% DMSO treated and gemcitabine treated negative controls 
demonstrated the specificity of the staining for TOPI-DNA covalent complexes. The induction of γH2AX 
(red foci) was also observed following drug treatment. A further time course experiment was 
performed with SN-38 in both cell lines in monolayer (see appendix Figure B.4 and Figure B.5). HCT116 
and CT26 cells were treated with SN-38 for 30 minutes, 1 hour, 3 hours and 24 hours and were then 
processed for IF. Staining for α-TopoIcc was detectable after 30 minutes and peaked at 1 hour, before 
then diminishing. Evidence of DNA damage via the marker γH2AX was also detectable at 30 minutes 




Figure 3.14 Detection of topoisomerase I-DNA covalent complexes by fluorescence microscopy following 
irinotecan treatment in 2D. After treatment for 24 hours with irinotecan at previously determined IC50 
concentrations (A) HCT116 and (B) CT26 cells were fixed, permeabilised, incubated with SDS and stained with 
α-TopoIcc antibody (green), γH2AX (red) and Hoechst 33258 (blue). (C) CT26 cells treated with 100µM 
gemcitabine were used as a negative control. (D) HCT116 cells treated with 0.1% DMSO were used as an 
additional negative control. Images were taken on a Zeiss inverse Axio observer confocal microscope (Zeiss LSM 
710, Carl Zeiss) using an x63 objective with apotome. Scale bars represent 10μm. 
 
Figure 3.15 Detection of topoisomerase I-DNA covalent complexes by fluorescence microscopy following SN-38 
treatment in 2D. After treatment for 1 hour with SN-38 at previously determined IC50 concentrations (A) HCT116 
and (B) CT26 cells were fixed, permeabilised, incubated with SDS and stained with α-TopoIcc antibody (green), 
γH2AX (red) and Hoechst 33258 (blue). Images were taken on a Zeiss inverse Axio observer confocal microscope 
(Zeiss LSM 710, Carl Zeiss) using an x40 objective with apotome. Scale bars represent 20μm.  
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Further analysis on spheroid sections or whole mount cleared spheroids, showed TOPI-DNA covalent 
complexes and induction of DNA damage to be present within spheroids following SN-38 drug 
treatment and consistent with the histology previously, more prominent levels of γH2AX were present 
towards the outer surface. Additional IF images of spheroid sections are provided in the appendix 
(Figure B.6) and γH2AX’s proximity to the outer surface was further demonstrated in irinotecan 
treated spheroids. Even though both TOPI-DNA covalent complexes and γH2AX appeared detectable, 
observations remained unclear due to the lack of clear punctate staining. In summary, the reduced 
apoptotic levels in 3D systems further support the hypothesis of poor in vitro tumour penetration and 
increased drug resistance.  
 
Figure 3.16 Detection of topoisomerase I-DNA covalent complexes by fluorescence microscopy following SN-38 
treatment in 3D. After treatment for 24 hours with SN-38 at previously determined IC50 concentrations or a 
nominal concentration of 200nM. HCT116 and CT26 spheroids were fixed, permeabilised, incubated with SDS 
and stained with α-TopoIcc antibody (green), γH2AX (red) and Hoechst 33258 (blue). (A)/(B) are images of 5µm 
spheroid sections, whilst (C)/(D) are images of whole-mount spheroids. Images were taken on a Zeiss inverse 
Axio observer confocal microscope (Zeiss LSM 710, Carl Zeiss) using an x40/x20 objective with apotome. Scale 
bars represent 20μm. 
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3.3.7 Differential Expression of Proteins in Monolayer Cell Cultures 
Four CRC cell lines were investigated to gain an understating of the expression of key proteins involved 
in the uptake, metabolism and clearance of irinotecan and SN-38. Cell lines were either treated with 
0.1% DMSO (control) and to demonstrate the influence of irinotecan and SN-38 treatment on the 
proteins of interest, each of the four CRC cell lines were treated with previously determined IC50 
concentrations for 72 hours (see Table 3.5). Western blot analysis (Figure 3.17) showed that all cell 
lines expressed MRP2 (ABCC2), a gene involved in the transport of irinotecan and SN-38, to a similar 
degree. TOP I expression was greatest in HCT116 cells, with the other three cell lines showing similar 
levels of expression. Following drug treatment, all cell lines showed a marked decrease in TOP I 
expression, relative to each respective control. The UGT1A1 protein, which plays a role in the 
inactivation of SN-38 was found to be absent in HCT116 cells. Its level of expression followed the 
following trend CT26>LoVo>DLD-1 and drug treatment did not impact UGT1A1 levels. Both CES1/2, 
which are involved in the hydrolysis of irinotecan, were present in all cell lines to varying levels, with 
greater heterogeneity present in CES2 expression. Moreover, the expression of γH2AX was enhanced 
following the administration of either irinotecan or SN-38, conforming to the IF results seen previously 
in Figure 3.14 and Figure 3.15. Overall 2D immunoblotting data demonstrated that the differential 
sensitivity of the CRC cell lines to either irinotecan or SN-38 could be attributed to the metabolism and 




Figure 3.17 Western blotting of proteins in CRC cancer cell lines grown in monolayer (2D). CRC cells grown in 2D 
were treated with control (0.1% DMSO) or previously determined irinotecan and SN-38 IC50 concentrations for 
72 hours. (a) Lysates were subjected to immunoblot analysis (b) The bands from three independent experiments 
were evaluated densitometrically and the average values ±SD were plotted after being normalised loading 






3.3.8 Investigating Protein Expression in Monolayer Cultures Compared to Spheroids 
Thereafter, the molecular differences in CRC cells cultured in 2D or 3D were examined using Western 
blot analysis (Figure 3.18a). The amount of protein was quantified by densitometric evaluation (Figure 
3.18b) of three biological replicates. MRP2 expression was similar in control 2D and 3D cells, however 
in both cultures increased expression of MRP2 was seen following drug treatment, with this being 
more evident in 3D cells. Similar to the data in Figure 3.17, UGT1A1 was not detected in the HCT116 
cell line and lower expression was observed in 3D CT26 cells. Additionally, expression of TOP I, CES1/2 
and γH2AX was seen to be considerably lower in 3D as compared to 2D cells. Following drug treatment, 
TOP I expression was suppressed to a greater degree in 2D cells compared to 3D. In summary, this 
data revealed a profound decrease in protein expression in cancer cells grown as spheroids, as 




Figure 3.18 Comparison of CRC cells cultured in 2D vs. 3D. CRC cells grown in 2D and 3D were treated with 
control (0.1% DMSO) or previously determined irinotecan and SN-38 IC50 concentrations for 72 hours. Where 
IC50 was not determined a nominal concentration of 100µM for irinotecan or 200nM for SN-38 was used. (a) 
Lysates were subjected to immunoblot analysis (b) The bands from three independent experiments were 






3.3.9 Differential Protein Expression in Human Tissues and Cell Cultures 
Cell lines traditionally have been used to study cancer biology and to build pre-clinical data guiding 
therapeutic strategies. Further analysis was performed to explore any similarities or differences in 
protein expression or expression patterns between human tissue and cells cultured in 2D and 3D. This 
would allow us to explore the relationship between tumour tissues and cancer cell lines and provide 
us with further knowledge as to how closely 2D or 3D cell cultures model the complex physiological 
behaviour (protein diversity and correlation) seen clinically in patient samples. Protein was extracted 
from patient-matched primary tumours, liver metastases and normal colonic mucosa. Histological 
staining (H&E) was performed, and this has been included in the appendix (Figure B.7). For proteins 
of interest concerning the uptake, activation and metabolism of irinotecan and SN-38, wide variation 
in protein expression between patients was observed. Proteins were generally highly expressed in 
tumour tissues, compared with non-tumour tissues. The data also showed that MRP2 and CES1 are 
expressed both in the tumour tissues and cancer cell lines. The CT26 cell line demonstrated similar 
levels of UGT1A1 expression, to that found within patient samples. However, TOP I levels were 
significantly higher in cells lines as compared to the tissue, wherein only two of the nine patient 
samples demonstrated any detectable levels of expression.  
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Figure 3.19 Comparison of human tissue vs. CRC cells cultured in vitro (a) Western blot analysis and 
quantification of proteins implicated in the uptake, metabolism and mechanism of irinotecan and SN-38. Patient 
tissue was provided by the LBIH biobank. Cells were cultured in vitro and processed without any treatment (b) 
The blots were quantified using densitometry and the average values of the independent experiments were 
plotted after normalization with actin. Data are shown as the average ± SD of three independent experiments. 
Statistical analysis was performed using a two-way ANOVA followed by Holm-Šídák multiple comparison post-







3.4 Discussion  
 
The overall survival rate of individuals with CRC undergoing systemic therapy has improved over the 
past 30 years. However, the five-year survival rate for metastatic CRC is still low at around 14% 
(Lichtenstern, Ngu, Shalapour, & Karin, 2020). Despite some success in targeted therapy, the attrition 
rates of anticancer drugs in clinical trials remains high. Evidently, there is an urgent need for more 
innovative pre-clinical in vitro models, to thoroughly test promising compounds before proceeding 
into clinical trials. Spheroid (3D) models could offer superior predictive power by more realistically 
recapitulating the response of tumours to anticancer compounds in vitro. This chapter focussed on 
the comparison of 2D monolayers with 3D spheroids. Spheroids were initially characterised and 
features such as morphology, protein expression and chemosensitivity were explored. In particular, 
the response of CRC cancer cell lines to irinotecan and SN-38 treatment was investigated. 
Spheroid diameter was optimised for uniformity and to reduce variability in the subsequent assays. 
Spheroids demonstrated a phase of exponential growth followed by a decline in growth rate (Figure 
3.3a and Figure 3.4a), which associated with the accumulation of non-proliferating (quiescent) and 
necrotic cells. A similar growth pattern is evident in tumours as, during the initial growth period, the 
volume of a tumour increases exponentially in the avascular growth phase, thereafter cellular growth 
is maintained in a dormant phase (Ward & King, 1997). The morphology of both the HCT116 and CT26 
spheroids according to the stage of development was consistent with previous reports (Riedl et al., 
2017; Valcarcel et al., 2008; Zoetemelk et al., 2019). Monolayer cell cultures displayed a flattened 
cellular morphology (see appendix Figure B.1) and cells here have a reduced cell-cell and cell-ECM 
interaction (Edmondson et al., 2014). These cultures are known to exhibit exponential cell 
proliferation, which is ultimately limited by surface availability. 
Histological H&E staining showed that once spheroids grew to 350-400µm in diameter (day 5 in 
culture), they were comprised of a highly compact, dense cellular network. Furthermore, H&E staining 
showed intense haematoxylin staining at the spheroid edge, suggesting a larger volume of nucleic 
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acids which is indicative of an outer proliferating rim (Mehta et al., 2012; Sutherland, 1988; Zanoni et 
al., 2016). Alcian blue staining in HCT116 spheroids was seen to a lower degree to what has been 
reported in the literature (Tchoryk et al., 2019). This could have been due to differences in culture 
conditions. Nevertheless, the detection of glycosaminoglycans within HCT116 spheroids signifies the 
presence of an ECM and suggests that spheroids offer a penetration barrier, as seen in vivo. Negligible 
levels of cleaved-caspase-3, further displayed that spheroids do not undergo apoptosis. To investigate 
proliferation, staining of Ki-67 staining was performed (Figure 3.5b and Figure 3.6b). Ki-67 is a nuclear 
protein involved in cell proliferation, it is present throughout the cell cycle (G1, S, G2, and mitosis) but 
is absent during cellular quiescence (G0) (Gerdes et al., 1984). With increasing spheroid size, quiescent 
cells accumulated in the centre, whilst proliferation was still ongoing at the outer rim, confirmed by 
the presence of Ki-67 positively stained cells (Figure 3.5b and Figure 3.6b). The higher rate of 
proliferation in the spheroid periphery is explained by their easier access to oxygen and nutrients 
(Tredan, Galmarini, Patel, & Tannock, 2007). This closely reflects the in vivo situation of actively 
proliferating tumour cells, which are in close proximity to the capillaries (Friedrich, Ebner, & Kunz-
Schughart, 2007). In contrast, cells within spheroids remain in a senescent or necrotic state due to the 
lack of oxygen (hypoxia) and nutrients (Minchinton & Tannock, 2006; Tredan et al., 2007). This also 
resembles tumours in vivo, as quiescent cells persist in regions distant from blood vessels, where 
glucose and oxygen are limited (Kyle, Baker, & Minchinton, 2012). Based on these observations, 
HCT116 and CT26 cells formed valid spheroids that displayed various in vivo like properties and they 
were subsequently investigated as pre-clinical test objects.  
Both irinotecan and SN-38 displayed enhanced efficacy in 2D cultures over their 3D counterpart’s i.e. 
elevated chemoresistance as seen by the higher IC50 values (see Table 3.5). The calculated IC50 values 
were consistent with literature findings (Friedrich et al., 2009; Kinoshita et al., 2018; Zoetemelk et al., 
2019). These results supported the notion that cytotoxic compounds, which target DNA replication 
and repair machinery, have limited activity in 3D models and that spheroid models are less sensitive 
to such therapy (Karlsson, Fryknas, Larsson, & Nygren, 2012; Nunes, Barros, Costa, Moreira, & Correia, 
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2019; Skardal, Devarasetty, Rodman, Atala, & Soker, 2015). It has been shown previously that relative 
sensitivities, correlates with the mechanism of action (Hartung, 2009; Kunz-Schughart et al., 2004; 
Vinci et al., 2012). For example, it has been reported that small-molecule kinase inhibitors are more 
sensitive in 3D cultures, while cell cycle inhibitors are more sensitive in 2D cultures. This is 
hypothesised to be a result of differences in the cultures, with respect to signalling pathways and 
genomic expression over time. Another suggestion for this differing sensitivity is that as 2D cells spend 
increased time in active cell cycle and DNA synthesis compared to 3D cultures (proliferate much 
slower), this provides a greater opportunity for such compounds to act (Gong et al., 2015; Luca et al., 
2013). Also, the growth media in 2D cultures is consistently distributed throughout all cells present, 
whereas a gradient-like distribution is present for 3D cultures, possibly leading to the unequal 
distribution of chemotherapeutics and lower activity (Kapalczynska et al., 2018). Other factors 
contributing to the reduced drug sensitivity in our study, could be due to the increased proportion of 
quiescent cells (i.e. spheroids have a lower percentage of actively dividing cells as compared to 
monolayers), hypoxia, ECM (intercellular interactions with high interstitial fluid pressure provide a 
physical barrier to limit drug diffusion) or altered gene expression including overexpression of efflux 
pumps, all hallmarks of in vivo tumours.  
IF studies from drug-treated spheroids confirmed that irinotecan and SN-38 rapidly stabilise TOPI-DNA 
covalent complexes (Figure 3.16). These TOPI-DNA covalent complexes act like other bulky DNA 
adducts, stalling replication forks, leading to replication fork collapse with accompanying DNA double-
strand breaks. Histological and IF results indicated that drug-induced apoptosis was primarily 
concentrated in cells located on the outer surface area of the spheroids. The simplest explanation is 
that cells on the inside of the spheroid are protected from drug penetration by the cells on the outside 
of the spheroid (Perche & Torchilin, 2012). However, the spheroid organisation (cell layers) is likely 
responsible for the impaired therapeutic efficacy of anticancer drugs. For instance, within the inner 
layer of the spheroid, i.e. the hypoxic region, cells proliferate much slower and these regions were 
mainly constituted of senescent and necrotic cells. Hence drugs that are most effective in targeting 
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rapidly dividing cells, would be expected to have an inferior therapeutic effect within the interior 
regions of the spheroid. Both irinotecan and SN-38 have mechanisms of action (formation of cleavable 
complexes during S-phase) that preferentially targets these actively dividing cells (Strumberg et al., 
2000; Ueno, Nonaka, Yamazaki, Deguchi, & Murai, 2002). Alternatively, as cells in hypoxia 
demonstrate resistance to apoptotic cell death, drugs that promote cell death through the formation 
of reactive oxygen species (e.g. doxorubicin and cisplatin) also have a lower therapeutic efficacy 
(Minchinton & Tannock, 2006; Tredan et al., 2007). These concepts could explain why HCT116 cells 
were much more sensitive than CT26 to both drugs i.e. they had a greater number of proliferating 
cells. Furthermore, the results also imply that cells in the central area may obtain a form of apoptotic 
resistance in 3D spheroids (see Figure 3.12 and Figure 3.13). It was only after repeated drug exposure 
studies, that spheroids displayed similar sensitivity to 2D cultures (see Table 3.6). However, after 
certain repeat exposures, spheroids displayed a limit of sensitivity. This is likely a result of 
dysregulation of apoptotic pathways, restricted drug transport and mechanisms of drug resistance 
associated with the spheroid microenvironment. Temporal processes such as drug metabolism and 
transport are known to be important factors implicated in resistance to chemotherapy and achieving 
optimal clinical therapy. 
The differential responses to irinotecan and SN-38 may additionally be explained by several 
mechanisms. Differential protein expression was observed in monolayer cell lines (Figure 3.17). For 
instance, the expression of UGT1A1 was greatest in the CT26 cell line and completely absent in the 
HCT116 cell line, which has previously been reported (Belanger, Tojcic, Harvey, & Guillemette, 2010; 
Gagnon, Bernard, Villeneuve, Tetu, & Guillemette, 2006). UGT1A1 is well known to be responsible for 
the inactivation of SN-38 (Gagne et al., 2002). Differences in the levels of UGT1A1 has the potential to 
modify the glucuronidation capacity at the target cell level and, hence, the biological effect of the drug 
i.e. lower rates of SN-38 glucuronidation would retain higher levels of the compound. This would 
support that UGT1A1 is associated with drug resistance and higher levels of UGT activity and 
expression was identified as a characteristic associated with a resistance phenotype to SN-38 in CRC 
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cells (Cummings et al., 2004). Similarly, differences in the expression of TOP I (formation of cleavable 
complexes), CES1 and CES2 (conversion of the prodrug to the active drug) could have contributed to 
the differential sensitivities of the cell lines. In addition, drug treatment elevated CES2 expression in 
all cell lines, apart from DLD-1, to differing degrees. These results are consistent with reports of CES2 
expression being regulated by the tumour suppressor gene p53, which is known to be activated by 
both drugs (Takeba et al., 2007; D. Xiao et al., 2013). Further work to investigate the role of CES1/CES2 
in the differential sensitivity, could incorporate knockdown and knockout experiments.   
Correspondingly, the immunoblotting data highlights the importance of employing a range of CRC 
subtypes for interpreting drug responses with respect to general biology, association with prognosis, 
changes of expression patterns of specific genes and target-proteins (Ahmed et al., 2013) (detailed 
differences between cell lines employed are outlined in the appendix Table B.1). Such information is 
of great value to understand in detail the molecular mechanisms by which therapeutic candidates act. 
However, a number of these biological differences, that contribute to how the cells are exposed and 
thus react to therapeutic agents, are more accurately imitated in 3D culture systems. In the present 
analysis, 3D cultures displayed a higher chemoresistance to anticancer drugs in comparison to cells 
grown in 2D. As a whole, protein expression was found to be lower in 3D, in comparison to 2D cultures. 
However, increased expression of MRP2 was observed following drug treatment in the spheroids, 
thereby suggesting enhanced drug efflux led to a lower intracellular accumulation of drug (Candeil et 
al., 2004; Gaedtke, Thoenes, Culmsee, Mayer, & Wagner, 2007). This corresponded to the decreased 
levels of DNA damage present and the restricted drug uptake and penetration detailed earlier. This is 
consistent with spheroid permeability data obtained in previous studies (Galateanu et al., 2016; Sensi 
et al., 2018; X. Wang et al., 2013). 
Besides, no clear relevance between the culture systems (2D and 3D) and patient tissue was seen. 
Large variation was present, which could have been caused by the heterogenic nature of the patient 
samples. Furthermore, a tumour can consist of different clones, which may have different protein 
composition and show varying degrees of central necrosis (Greaves & Maley, 2012). Some of the 
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differences observed between cancer tissues and cell lines may reflect cellular changes resulting from 
in vitro culture, inter-individual variation, or variation in treatment regimens (see γH2AX levels in 
Figure 3.19) the patients may have undertaken. Thus, conclusions from in vitro modelling systems 
cannot always be transferred to the clinical setting. Further investigations on differentially expressed 
proteins and their mechanisms, may be of scientific and clinical importance. Additional studies could 
be done to gather a deeper understanding of differences at the protein level between 2D and 3D 
cultures and could involve quantitative proteomic analysis. Analysis of spheroids once they have 
become more sensitive i.e. after repeated exposures would also help to clarify important distinctions 
between the cultures, in regards to understanding the response to anticancer drugs. To better 
simulate the microenvironment of tumours in vitro (closely resemble cellular heterogeneity in tumour 
tissues) and in turn make the spheroids more physiologically relevant, heterotypic spheroids or 
spheroid co-cultures (aggregates of cancer cells, endothelial cells and immune cells – 
macrophages/tissue-specific fibroblasts) could be employed (Costa, Gaspar, Coutinho, & Correia, 
2014; Courau et al., 2019; S. A. Kim, Lee, & Kuh, 2015). Moreover, embedding 3D tumour models into 
a microfluidic device that enables controlled media flow and mimics drugs pharmacokinetics could 
further improve the predictability of the model to the in vivo situation. Such models would allow 
access to monitoring drug penetration and measure changes in pharmacodynamic biomarkers in real-
time. Looking ahead, a combination of techniques for the generation of patient-derived tumour 
spheroids appears to be a promising solution to bridge the gap between the results from preclinical 
models and clinical trials (Arnadottir et al., 2018; Bregenzer et al., 2019; Kondo et al., 2019; Pyo, Hong, 
Lee, & Cho, 2020; Shuford et al., 2019; van der Waals et al., 2019). Organotypic multicellular spheroids 
are required for accurate reproduction of the tumour microenvironment. Tumour cells in these 
spheroids are surrounded by non-tumour cells and stromal components that are commonly found in 
the tumour microenvironment. There are several methods for obtaining organotypic tumour 
spheroids, including enzymatic dissociation of tissues to isolate spheroids with cellular heterogeneity, 
similar to the primary tumour (Kondo et al., 2011). In many cases, these cultures are generated using 
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mechanical dissociation of patient-derived tumour tissues. As a result, this model is capable of 
proliferation and can retain many of the histological features within the original tissues. Vlachogiannis 
et al. established a biobank of patient-derived organoids from metastatic colorectal and 
gastroesophageal cancer patients (Vlachogiannis et al., 2018). The authors demonstrated that 
phenotypic and molecular profiling of established organoids closely matched the original tumour. 
They compared ex vivo drug responses of the organoids with xenograft mouse models, as well as with 
clinical responses in patients and demonstrated that their methodology can predict clinical responses 
with 100% sensitivity and 93% specificity (Vlachogiannis et al., 2018). In vitro 2D and 3D cell culture 
models are most promising to be adopted for testing of patient-derived cells in clinics, due to their 
compatibility with high throughput, possibility to be performed within 2–3 days, and requirement of 
relatively low cell numbers. Performing such in vitro sensitivity tests as a routine in clinical practice 
will open a new era of precision medicine in oncology and will help to navigate the decision making 
toward successful therapy for each individual patient. 
In summary, the data implies that the manner in which cells are cultured (i.e. 2D or 3D) can 
substantially impact the effect of a drug. Also, this research highlights that it is a combination of the 
specific drug and the cellular environment that influences the cellular response. Reliable and robust 
screening systems are highly desired for the development and selection of antitumour drugs and 
functional delivery systems. 3D culture presents an attractive solution to the limitations of 2D culture. 
However, they have their limitations and challenges. As a result of the requirement for a large number 
of spheroids within a test sample, molecular biological assays including RT-PCR and Western blotting 
are costly and difficult to perform. Other techniques such as histology require tedious handling and 
protocols are generally low throughput. This often makes spheroid-based assays difficult to scale up. 
However, as spheroids can establish authentic pathophysiological features of interest, they are ideal 
as a supplement to monolayer-based assays for advanced drug testing and improved estimation of in 
vivo antitumour efficacy. In particular, spheroids would be valuable for the evaluation of 
101 
 
nanomedicine, as they have the potential to establish the penetration barriers seen in vivo, thereby 
allowing a more accurate study of the uptake, penetration, distribution and subsequent effect of 
differing drug delivery systems. 
 
3.5 Conclusion  
The results in this chapter have demonstrated that spheroid models, of both HCT116 and CT26 cells, 
represent a suitable model to form part of an in vitro cytotoxicity screening system. The formation of 
highly reproducible, uniform spheroids was presented, with simple standardised protocols utilised for 
cell viability assessment. These spheroids had appropriate growth kinetics, histological features and 
biological characteristics. The spheroids more closely mimicked the arrangement of cancer cells and 
the environment to which they are exposed in vivo. These features subsequently affect the cellular 
protein expression and the penetration, binding and bioactivity of therapeutic drugs. Hence, due to 
their intrinsic characteristics, spheroids represent a promising approach for the pre-clinical evaluation 
of newly developed anticancer therapies, in particular nanotherapeutics. The following chapter will 










Chapter 4:  Nanomedicines for Colorectal Cancer Therapy: In Vitro and In Vivo 
Assessment of SN-38 Encapsulated Nanoparticles 
 
Abstract 
The therapeutic effect and clinical utility of irinotecan has been extremely restricted by several factors 
such as the low conversion rate to its active metabolite SN-38, high inter-patient variability, and dose-
limiting toxicity. SN-38 displays 100-1000-fold more potent cytotoxicity in vitro compared to 
irinotecan, but the administration of SN-38 is unachievable due to its poor solubility and instability. 
The present chapter successfully synthesised polymer-based SN-38 encapsulated nanoparticles. 41 
different water-soluble formulations were iteratively screened initially to assess drug release. 
Thereafter, 10 select candidates were assessed for cytotoxicity and macrophage uptake, with 2 
formulations being chosen for pharmacokinetic analysis in vivo. Drug release was measured in PBS at 
pH 7.4 for 48 hours. No initial burst release was observed in the majority of the polymer 
nanomaterials. Moreover, CA formulations released SN-38 in a much slower and sustained manner in 
comparison to SB formulations. All nanoparticles displayed potent in vitro antitumour activity, similar 
to free SN-38, against colorectal cancer cell lines in both monolayer and spheroids. Macrophage 
uptake was also investigated, with only 8 of the 10 polymer nanomaterial’s displaying a lower cellular 
accumulation ratio (p ≤ 0.05 for 5 of these formulations). However, in a mouse model, the 
pharmacokinetic analysis revealed no benefit of the nanoparticles (SB1 or CA16) in terms of plasma 
exposure compared to irinotecan. Further preclinical testing of the material in regard to its 
biocompatibility, immunotoxicity, and a thorough analysis of its uptake by organs of the mononuclear 
phagocyte system is required. In summary, the data in this chapter demonstrated that the designed 
nanoparticles showed suitable characteristics in vitro, but these did not translate in vivo into the 






Chemotherapy is an important treatment option for patients, however, chemotherapeutic drugs such 
as irinotecan have various drawbacks such as nonspecific uptake by healthy tissue, inadequate 
circulation times, poor exposure to/suboptimal accumulation within tumour sites and a narrow 
therapeutic window. The efficient delivery of chemotherapeutic drugs to tumours remains an obstacle 
in the treatment of cancer and the continual development of drug delivery technologies, is 
fundamental to future advances. Nanoparticles (NPs) offer a promising approach in countering such 
limitations, because of their more favourable bio-distribution, improved biocompatibility, enhanced 
targeting, proficiency in protecting drug/cargo from hydrolytic or enzymatic inactivation and inherent 
ability to overcome multiple biological barriers e.g. avoidance of the mononuclear phagocytic system 
(MPS) (Arshad et al., 2020). Due to their submicron size range (10–1000nm), NPs can evade renal 
clearance (<20nm) and uptake by the liver and spleen (>150nm). Also, NPs can preferentially 
accumulate within tumours, via the enhanced permeation and retention (EPR) effect (Kobayashi, 
Watanabe, & Choyke, 2013; Maeda et al., 2000). The EPR effect is a consequence of the disorganised 
nature of the tumour vasculature, which results in increased permeability of polymer therapeutics 
and drug retention at the tumour site. Hence, NP-mediated delivery has the potential for improving 
the efficacy and safety of different classes of anticancer agents.  
Because of its potency, SN-38 represents an attractive molecule for anticancer drug development. Its 
hydrophobic nature prevents its administration clinically (poor water solubility 11–38μg/mL and high 
partition coefficient LogP: 2.65). Moreover, the instability of SN-38 in physiological circulation (pH 7.4) 
is an obstacle in its development, as the open carboxylate form of SN-38 has no therapeutic effect 
resulting in low anti-tumour activity. To overcome these limitations, various nanoscale pharmaceutical 
delivery systems are currently being developed and investigated. These include polymeric conjugates, 
dendrimers, liposomes, micelles, and polymer NPs (Carie et al., 2011; England et al., 2017; Koizumi et 
al., 2006; Roger, Lagarce, & Benoit, 2011; J. A. Zhang et al., 2004). Such delivery systems can improve 
solubility, efficacy, and circulation time, whilst reducing toxicity. Researchers have addressed the poor 
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solubility of SN-38 by covalently attaching SN-38 to a polymer or peptide i.e. a prodrug approach that 
is dependent upon enzymatic/chemical cleavage in order to release the active drug (Koizumi et al., 
2006; Meyer-Losic et al., 2008; Sapra et al., 2008). A formulation such as NK012, as well as a pegylated 
SN-38 formulation (EZN-2208), are currently in clinical trials (Hamaguchi et al., 2010; Sapra et al., 
2009). Similarly, a liposomal formulation encapsulating SN-38 was part of a Phase II trial for the 
treatment of metastatic CRC (NCT00311610). Various other carriers have been or are being 
investigated, as detailed in Table 4.1 below.  
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Table 4.1 SN-38 based nanoformulations currently in development 
Product Name 
(Owner Company) 
Phases Country/Region Route 
(Dosage form) 
Admin Regime Drug Delivery Category NME/Generic/OTC 
IT-141                                                                                       
(Intezyne, Inc.) 
Phase 1 - 
Infusion IV                                                 
(Injection Lyophilized 
Powder For Solution) 
Once for 2-
weeks NP, Micelle NME Not Marketed 








Infusion IV                                            
(Injection Lyophilized 






NME Not Marketed 
SP1063C                                                                         
(Supratek Pharma Inc.) 
Preclinical - Infusion IV - Cyclodextrins/Solubilizers New Formulation 
TRX-920                                                                                      
(TaiRx, Inc.) 
Preclinical USA Oral - Other Oral Delivery New Formulation 
IMMU-130                                                                                 
(Immunomedics Inc.) 
Phase 2
Preclinical - Injectable IV 
2-16 mg/kg once 
for 2-weeks 
Conjugates, Antibody-ADC 
Receptor/Carrier NME Not Marketed 
BEL-0222                                                                                 
(Belrose Pharma Inc.) 
Phase 2 
Phase 1 
Phase 2 Discontinued 
Phase 1 Discontinued 
Preclinical Discontinued 
China                                                         
USA 
Infusion IV                                              
(Injection Lyophilized 
Powder For Solution) 
9-16.5 mg/m2 
once a week 
Injectable Depot, Other 
Conjugates, PEG Polymer NME Not Marketed 







USA Infusion IV 
8-18 mg/kg once 
a week 
Conjugates, Antibody-ADC 
Receptor/Carrier NME Not Marketed 




Phase 1 Discontinued 
Asia                                                                    
USA 
Infusion IV Once for 2-4 
weeks 
Conjugates, PEG Polymer NME Not Marketed 
IMMU-132 + Imfinzi Co-
Therapy                                                  
(Immunomedics Inc.) 
Phase 2 - Injection - Injection, Other NME Not Marketed 
ATT-11T                                                                                          
(Aposense Ltd.) 
Preclinical USA Injectable IV                                                   (Injection Emulsion) - 
Conjugates, Small 
Molecule NME Not Marketed 
hPAM4/SN-38 Conjugate                                                                           
(Immunomedics Inc.) 
Preclinical - Injection - 
Conjugates, Antibody-ADC 
Receptor/Carrier NME Not Marketed 
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NK012                                                                                          




Phase 1 Discontinued 
Preclinical Discontinued 
USA 
Infusion IV                                                           
(Injection Lyophilized 
Powder For Solution) 
9-28 mg/m2 once 
for 21-28 days 
Conjugates, PEG Polymer 
NP, Micelle NME Not Marketed 
Epratuzumab/SN-
38/Veltuzumab Conjugate                                                                          
(Immunomedics Inc.) 
Preclinical - Injection - Injection, Other 
NME Not Marketed 
New Combination 




Preclinical Discontinued - Injection - Injection, Other NME Not Marketed 
IV – intravenous, NME - new molecular entity, OTC - over-the-counter  







A significant clinical advantage could be gained through the direct administration of the active 
metabolite, SN-38, using a drug delivery technology that is not reliant upon hepatic activation and 
metabolism. Also, the possibility to achieve greater site-specificity, whilst simultaneously protecting 
the drug within its active form would improve the therapeutic index. These features would allow for 
higher plasma and tissue levels of SN-38 with a consequential increase in anti-tumoral efficacy, whilst 
limiting toxicities and inter-patient variability. Sterically stabilised polymeric NPs can be generated via 
co-nanoprecipitation, which is a process that describes the precipitation of a polymer with a second 
polymer that can act as a stabilising species. This subsequently presents an opportunity for the 
potential encapsulation and delivery of therapeutic agents. Extensively branched, high molecular 
weight copolymers differing in composition were combined. A large library of polymeric materials was 
generated, in which the chemical compositions were varied through the incorporation of different 
monomer, copolymer and initiator chemistries. Based on this rationale, an encapsulated formulation 
of SN-38 was generated, using a hyperbranched polydendron NP system (Hatton, Chambon, 
McDonald, Owen, & Rannard, 2014). This resulted in the aqueous solubility of SN-38 without 
modification of the drug. These polymer NPs were iteratively screened in vitro to select the best 
candidates, before in vivo evaluation. For those materials termed CA formulations, the preparation 
involved the simultaneous nanoprecipitation of highly branched hydrophobic vinyl copolymers with 
amphiphilic PEG-based AB block copolymers and SN-38. Those materials termed SB formulations 
involved the preparation of polymers through the use of novel PEG-based caprolactone monomers. 
Factors taken into consideration included drug release, as it was crucial that the NPs still contain the 
drug once they reach the tumour to have any therapeutic effect. Thereafter, the cytotoxic activity of 
the NPs was measured to assess the ability of drug-containing NPs to kill cancer cells once they arrive 
at the tumour site. Macrophage uptake was assessed as they are a key clearance mechanism for NPs 
and evading uptake would increase the time NPs spend in systemic circulation. The plasma 
pharmacokinetic profile of the best candidates, compared to that of irinotecan and free SN-38, was 
examined in vivo, using BALB/c mice. 
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It was hypothesised that the encapsulation of SN-38 within these NPs would slow the release rate of 
the drug by augmenting drug retention. It was anticipated that this release behaviour would maintain 
SN-38’s cytotoxic effects in tumour cells, whilst being minimally cleared via the MPS. It was further 

























4.2 Materials and Methods  
4.2.1 Materials 
Irinotecan and SN-38 were purchased from Hangzhou J&H chemical company (J&H Chemical, 
Shanghai, China). Drug-free mouse plasma was purchased from BioIVT (West Sussex, UK). All other 
reagents and consumables were purchased from Sigma Aldrich (Dorset, UK) or Thermo Fisher 
Scientific (Loughborough, UK) unless otherwise stated, and were of LC-MS grade or the highest 
analytical grade commercially available.  
4.2.2 Animals 
All animal experiments were performed in accordance with criteria outlined in a Home Office UK 
approved project licence (PPL 70/8563/OWEN) granted under the Animals (Scientific Procedures) Act 
1986 and approved by the Animal Ethics Committee at the University of Liverpool. Male BALB/c mice 
weighing between 20-25g were purchased from Charles River Laboratories (Margate, UK) and housed 
in a licenced specified pathogen-free establishment. Mice were given free access to food and water 
and housed at a temperature between 19°C and 23°C under a 12-hour light-dark cycle. 
4.2.3 SN-38 Nanoparticles Preparation and Characterisation 
NPs were synthesised in the university’s chemistry department (Liverpool, UK). Briefly, following co-
nanoprecipitation of branched PEG polymers (NP formation and solvent evaporation), rapid formation 
of sterically stabilised SN-38 NPs in aqueous media was possible. All polymer co-nanoprecipitations 
were conducted from tetrahydrofuran (THF) into stirred water. SN-38 (1mg/ml in THF) was 
incorporated within the initial THF solution to target drug loadings as shown in Table 4.2 and Table 
4.3. The mixtures were left to stir for 24 hours at ambient temperature to allow for the complete 
evaporation of THF. Several NP formulations were synthesised, that differed in terms of percentage 
SN-38 loading and physical polymer properties i.e. monomer composition and polymer backbones.  
Dynamic light scattering (DLS) measurements (for a hydrodynamic diameter) and zeta potentials were 
performed using a Malvern Zetasizer Nano ZS instrument with a wavelength of 630nm. Measurements 
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were performed at 25°C at a NP concentration of 1 mg/ml. Dispersions were measured without 
additional filtration or centrifugation, in a polystyrene disposable fluorometric cuvette (size 
measurements) or a disposable capillary zeta flow cell (zeta measurements). Size measurements were 
obtained as an average of 3 individual measurements and were rounded to the nearest 5 nm. The DLS 
analyses revealed monomodal intensity-derived particle size distributions with an average 
hydrodynamic diameter of <200nm for all nanomaterials. 
 





SN-38 Loading (%) 
SB1 PEG5K-PCL40-BOD0.7 10 
SB2 PEG5K-PCL40-BOD0.7 50 
SB3 PEG5K-PCL40-BOD0.7 75 
SB4 
PEG5K-PMOP40-BOD0.7 
(12 week old) 
10 
SB5 PEG5K-PMOP40-BOD0.7 10 
SB6 PEG5K-PPOP40-BOD0.7 10 
SB7 PEG5K-PMOP40-BOD0.7 10 
SB8 PEG5K-PMOP40-BOD0.7 50 
SB9 PEG5K-PMOP40-BOD0.7 75 
SB10 PEG5K-PPOP40-BOD0.7 10 
SB11 PEG5K-PPOP40-BOD0.7 50 
SB12 PEG5K-PPOP40-BOD0.7 75 
SB13 PEG5K-PPHLOP40-BOD0.7 10 
SB14 PEG5K-PPHLOP40-BOD0.7 50 
SB15 PEG5K-PPHLOP40-BOD0.7 75 
SB16 PEG5K-PBOP40-BOD0.7 10 
SB17 PEG5K-PBOP40-BOD0.7 50 
SB18 PEG5K-PBOP40-BOD0.7 75 
SB19 PEG5K-PCL80-BOD0.8 10 
SB20 PEG5K-PCL80-BOD0.8 50 
SB21 PEG5K-PCL80-BOD0.8 75 
PEG, polyethylene glycol; PCL, polycaprolactone 
MOP, POP, BOP and PHLOP are all bespoke monomers 
Table 4.3 Nanoparticle formulations differing in the polymer composition 
Nanoparticle 
Formulation 
Polymer Composition SN-38 Loading (%) 




























CA5 EHMA100-co-Bisphenol : PEG5k-HPMA100  5 
CA6 EHMA20-co-Bisphenol : PEG5k-HPMA100  5 
CA7 EHMA20-co-EGDMA : PEG5k-HPMA100  5 
CA8 BuMA100-co-EGDMA : PEG5k-HPMA100  5 
CA9 EHMA100-co-EGDMAo.95: PEG5k-HPMA100  50 
CA10 EHMA100-co-GDMA : PEG5k-HPMA100  5 
CA11 EHMA20-co- GDMA : PEG5k-HPMA100  5 
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CA12 EHMA100-co-BpGDMA : PEG5k-HPMA100  5 
CA13 EHMA100-co-UDMA : PEG5k-HPMA100  5 
CA14 EHMA20-co-UDMA : PEG5k-HPMA100  5 
CA15 EHMA100-co-DSDMA0.75 : PEG5k-HPMA100  5 
CA16 EHMA20-co-DSDMA0.75 : PEG5k-HPMA100  5 
CA17 EHMA100-co-GDMA : PEG5k-HPMA100  10 
CA18 EHMA100-co-BPGDMA : PEG5k:HPMA100  10 
CA19 BuMA50-co-HPMA50-co-EGMA : PEG5k:HPMA100  5 
CA20 EHMA20-co-BPGDMA : PEG5k:HPMA100 5 
CA21  BuMa20- Bisphenol : PEG5k:HPMA100  5 
BPGDMA, bisphenol A glycerolate dimethacrylate; BUMA, butyl methacrylate; DSDMA, disulfide dimethacrylate; EHMA, ethyl α-
hydroxymethylacrylate; GDMA, glycerol dimethacrylate; HPMA, hydroxypropyl methacrylate; PEG, polyethylene glycol; UDMA, urethane 
dimethacrylate.  
4.2.4 Cell Culture 
4.2.4.1 Monolayer (2D) Culture 
DLD-1, HCT116, LoVo and CT26 cells were maintained and cultured in monolayer as described in 
section 3.2.3. 
4.2.4.2 Spheroid (3D) Culture 
HCT116 and CT26 spheroids, at 1000 and 1250 cells/well respectively, were cultured for 5 days as 
described in section 3.2.4. 
4.2.5 In vitro Assessment of SN-38 Release  
In vitro release studies were conducted using a previously published rapid equilibrium dialysis setup 
(Pierce RED Device), as shown in the schematic below (Bakshi et al., 2018). The inserts comprised of 
two compartments, separated by an O-ring-sealed dialysis membrane - 8kDa molecular-weight cut-
off. SN-38 NPs were diluted to 250ng/ml in PBS (pH 7.4). Free SN-38 was dissolved in DMSO before 
dilution with PBS, such that DMSO comprised <1% of the final volume. To assess release, 0.5mL of 
samples to be investigated were added to the donor compartment and 1mL of pre-warmed PBS was 
added to the acceptor compartment. Plates containing the inserts were placed on an orbital shaker 
(Heidolph Rotomax 120; 100rpm, 48hours, 37°C ± 1°C). Each insert represented a single time-point 
and at specified time intervals both acceptor (1mL) and donor fluid (0.5mL) were removed. Aliquots 
of each timed sample were then used to determine levels of SN-38 in each compartment, applying the 
validated LC-MS/MS method outlined in Chapter 2:. All experiments were performed ensuring sink 
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conditions. Data were expressed as the percentage of SN-38 released i.e. the amount which diffused 
across the membrane. 
Figure 4.1 An overview of the equilibrium dialysis method which was used for the measurement SN-38 release. 
Theoretically, the drug molecules diffuse across the dialysis membrane until the concentration gradient is zero. 
Hence, 50% release (equilibrium) represents the maximum release in this setup. 
4.2.6 In Vitro Cytotoxicity 
4.2.6.1 Monolayer (2D) Experiments  
After cells had adhered (24 hours), all media was aspirated and replaced with 100µL of each 
concentration of media containing SN-38 NPs (wells were 0.1% H2O by volume). The concentrations 
used, varied between 0.5-200nM. Blank NP and solvent only controls (0.1% H2O) were also included 
within the plate setup. Time points of 24, 48, 72 and 96 hours post-treatment, were used to assess 
the cytotoxicity of the NPs. The data were also compared to results obtained following exposure to 
irinotecan and free SN-38 solution in 0.1% DMSO, using the same time points. 
4.2.6.2 Spheroid (3D) Experiments  
Following 5 days in culture, 50µl of growth media was removed from HCT116 and CT26 spheroids. It 
was replaced with 50µL of each concentration of media containing SN-38 NPs (wells were 0.1% H2O 
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by volume). The concentrations used, ranged between 0.5-200nM for HCT116 spheroids and 2.5-
400nM for CT26 spheroids. Blank NP and solvent only controls (0.1% H2O) were also included within 
the plate setup. Time points of 72- and 144-hours post-treatment, were used to assess the cytotoxicity 
of the NPs. The data were also compared to results obtained following exposure to irinotecan and free 
SN-38 solution in 0.1% DMSO, using the same time points. 
4.2.6.3 Determination of Cell Viability Following Treatment 
Cell viability was measured using the CellTiter-Glo luminescent cell viability assay (Promega, 
Hampshire) as described in section 3.2.7.4. Cell viability was calculated as a percentage of untreated 
vehicle control (blank NP samples or 0.1% DMSO). A concentration-response curve was plotted and 
used to determine an IC50 value (average ± SD, n=3). 
4.2.7 Macrophage Uptake 
Monocytes were isolated by ficoll plaque separation of anonymised healthy volunteer buffy coats, 
purchased from the NHS Blood and Transfusion Service. Freshly isolated CD14+ monocytes were 
differentiated into classically activated M1 macrophages using macrophage generation media DXF 
(PromoCell, Heidelberg, Germany). Macrophages were detached using macrophage detachment 
solution DXF (PromoCell, Heidelberg, Germany) and subsequently, 1x106 macrophages were plated 
onto 24 well plates. They were left to adhere for 3 hours. Following this, they were treated at a fixed 
concentration of 50µM for 24 hours with selected nano-formulations. Both extracellular and 
intracellular (following lysis with H2O) levels of SN-38 were quantified using the developed LC-MS/MS 
method, see Chapter 2:. Data were presented as a cellular accumulation ratio (CAR) (average ± SD, 
n=3).  
 
4.2.8 In Vivo: Pharmacokinetic Evaluation 
To characterise the plasma pharmacokinetics, mice (n=3) were intravenously injected (tail vein) with 
freshly prepared SB1 at 2mg/kg, CA16 at 2mg/kg, free SN-38 at 2mg/kg or irinotecan at 40mg/kg. Free 
114 
 
SN-38 and irinotecan were made up in 10% and 2.5% DMSO containing saline, respectively. Where 
possible, blood was collected in heparinised tubes following cardiac puncture at 0.083-, 0.25-, 0.5-, 2-
, 2.5-, 3-, 4- and 5-hours following dose administration. Samples were centrifuged at 10,000 rpm for 
10 minutes to separate plasma and stored at −40°C un l analysis. The previously developed LC-MS/MS 
method detailed in Chapter 2: was used for determining concentrations of irinotecan, SN-38 and SN-
38G. Pharmacokinetic parameters were calculated using the PK Solver add-in (Y. Zhang, Huo, Zhou, & 
Xie, 2010). 
4.2.9 Statistical Analysis 
Unless otherwise stated, all reported values are the average with their respective standard deviation 
(SD). The number of replicates is always indicated in the figure legends. Experiments were conducted 
at least in biological triplicates and datasets were analysed with SigmaPlot version 14.0 (Systat 
Software, Inc., San Jose California USA). A two-way analysis of variance (ANOVA) with Holm-Šídák 














4.3.1 Characterisation and Selection of NPs 
4.3.1.1 Drug Release  
A total of 41 different NPs were screened in an iterative manner using the dialysis method. The in vitro 
release behaviour of the SN-38 loaded NPs is summarised, with the percentage release over 48 hours 
shown in Figure 4.2 and Figure 4.4 and percentage release over 8 hours shown in Figure 4.3 and Figure 
4.5. Most of the free SN-38 quickly diffused across the dialysis membrane and the process was 
essentially complete (approaching equilibrium) following 8 hours (see black markers on all graphs for 
free SN-38). For several of the SB NPs, an initial burst release was present, similar to that seen with 
free SN-38. This was followed by a gradual sustained release up to 48 hours (Figure 4.2 and Figure 
4.3). Only polycaprolactone (SB1 and SB2) and PBOP (SB17 and SB18) based NPs showed a slower 
release than free SN-38 over the first two hours.   
However, this behaviour was not observed in CA NPs, which showed a clear reduction in drug release 
in comparison to the free drug (Figure 4.4 and Figure 4.5). No burst release was present and CA NPs 
displayed a typical slower sustained drug release profile. Release of SN-38 from CA NPs was 
consistently lower than free SN-38 up to 24 hours. In particular, a lower DPn value (number-average 
degree of polymerisation) of 20 monomer units (Figure 4.5a) in comparison to 100 monomer units 
(Figure 4.5b) lead to a reduction in SN-38 release (See CA6 vs. CA3 and CA20 vs. CA12). Changes to the 
DPn value within the other polymeric systems had little effect on SN-38 release. In both sets of NPs, 
increasing drug loading did not seem to impact the release rate. For select candidates, additional 
release studies were completed in PBS at a lower pH (5.5). These experiments displayed a faster 
release profile for the NPs in a more acidic environment (see appendix Figure B.8). 
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Figure 4.2 Drug release profiles of free SN-38 and SN-38 loaded SB polymer nanoparticles, in phosphate-buffered 
saline at pH 7.4, over 48 hours. Increasingly loaded nanoparticles with polycaprolactone monomer compositions 
are shown in (a), PMOP monomer compositions in (b), PPOP monomer compositions in (c), PPHLOP monomer 
compositions in (d) and PBOP monomer compositions in (e). The dotted line at 50% represents the maximum 
release achievable in this setup. Where error bars are present, each point is shown as the average ± SD (n = 3). 
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Figure 4.3 Drug release profiles of free SN-38 and SN-38 loaded SB polymer nanoparticles, in phosphate-buffered 
saline at pH 7.4, for the first 8 hours. Increasingly loaded nanoparticles with polycaprolactone monomer 
compositions are shown in (a), PMOP monomer compositions in (b), PPOP monomer compositions in (c), 
PPHLOP monomer compositions in (d) and PBOP monomer compositions in (e). The dotted line at 50% 
represents the maximum release achievable in this setup. Where error bars are present, each point is shown as 
the average ± SD (n = 3). 
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Figure 4.4 Drug release profiles of free SN-38 and SN-38 loaded CA polymer nanoparticles, in phosphate-
buffered saline at pH 7.4, over 48 hours. Nanoparticles with an EHMA20 monomer composition are shown in (a), 
EHMA100 monomer compositions in (b), BUMA monomer compositions in (c) and differently loaded EHMA 
monomer compositions in (d). The dotted line at 50% represents the maximum release achievable in this setup. 
Where error bars are present, each point is shown as the average ± SD (n = 3). 
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Figure 4.5 Drug release profiles of free SN-38 and SN-38 loaded CA polymer nanoparticles, in phosphate-
buffered saline at pH 7.4, for the first 8 hours. Nanoparticles with an EHMA20 monomer composition are shown 
in (a), EHMA100 monomer compositions in (b), BUMA monomer compositions in (c) and differently loaded EHMA 
monomer compositions in (d). The dotted line at 50% represents the maximum release achievable in this setup. 
Where error bars are present, each point is shown as the average ± SD (n = 3). 
 
The SN-38 release profiles of the best candidates, from each set of NPs in PBS (pH 7.4), is shown in the 
figure below (Figure 4.6). Candidate formulations were selected based on their ability to release SN-
38 in a slower, sustained manner over time. These included SB1, SB2, SB3, SB7, SB8, CA1, CA14, CA16, 




Figure 4.6 The ten best nanoparticles identified from the in vitro drug release screen. The release profiles for 
free SN-38 and selected candidates are listed in (a). The data for the first 8 hours is depicted in a graphical format 
as shown in (b) and (c). The dotted line at 50% represents the maximum release achievable in this setup. Where 
error bars are present, each point is shown as the average ± SD (n=3). 
4.3.1.2 Cytotoxicity Studies  
The sensitivity of a panel of CRC cell lines to free SN-38, the 10 selected NPs and irinotecan was 
compared using an ATP assay. The cell viability was quantified at 24-, 48-, 72- and 96-hours post-
incubation in monolayer culture, or 72- and 144-hours post-incubation in spheroid culture. As shown 
in Figure 4.7, both free SN-38 and all NPs were potent to differing degrees and the sensitivity of the 
cells to NPs after 96 hours, was similar to free SN-38 across the cell lines. Overall, a trend showing that 
slower releasing CA NPs were slightly less potent (higher IC50 values), than the faster releasing SB NPs 
was seen. However, irinotecan was several orders of magnitude less toxic than either free SN-38 or 
any of the NPs at all time points. Data for 24 hours cytotoxicity is not included here, as IC50 
concentrations were not achieved. All individual graphs for monolayer studies have been included in 




Figure 4.7 Potency of SN-38 encapsulated nanoparticles compared to free SN-38 and irinotecan in monolayer colorectal cancer cell lines. IC50 values (nM) were determined 
at 48 hours (a and d), 72 hours (b and e) and 96 hours (c and f). Dashed lines are indicative of the IC50 for free SN-38 within each cell line. Data are presented as average ± 
SD. (N.D - IC50 not determined)
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Like the data seen in monolayer cells, spheroids treated with NPs showed varying degrees of 
cytotoxicity (Figure 4.8), with the faster releasing SB NPs being more potent than the slower releasing 
CA NPs. Moreover, as seen in Figure 4.9 and Figure 4.10, following NP treatment a clear reduction in 
spheroid size was present, similar to that seen with free SN-38 or irinotecan treatment in the previous 
chapter. Also, blank NPs did not impact the viability of the spheroids. Individual graphs for all spheroid 
studies have been included in the appendix, see Figure B.10. As all formulations were still significantly 
more potent than the parent drug, irinotecan, the cytotoxicity data was therefore not able to exclude 
any further candidates. 
 
Figure 4.8 Potency of SN-38 encapsulated nanoparticles compared to free SN-38 and irinotecan in spheroid 
colorectal cancer cell lines. IC50 values (nM) were determined at, 72 hours (b) and 144 hours (a) and (c). Dashed 





Figure 4.9 Cytotoxicity of SB1 NPs in spheroids. ATP levels were measured in HCT116 and CT26 spheroids treated with SN-38 or SB1 NPs, for 72 (a) and (c) or 144 hours (b) 
and (d). Cell viability was calculated as a percentage of untreated vehicle control (DMSO – 0.1% or blank NP samples). Representative phase-contrast images (10x objective) 
are documented to capture spheroid integrity following treatment with SB1. Data points are average ± SD, with n=6 individual spheroids per condition. Comparison between 




Figure 4.10 Cytotoxicity of CA16 NPs in spheroids. ATP levels were measured in HCT116 and CT26 spheroids treated with SN-38 or CA16 NPs, for 72 (a) and (c) or 144 hours 
(b) and (d). Cell viability was calculated as a percentage of untreated vehicle control (DMSO – 0.1% or blank NP samples). Representative phase-contrast images (10x objective) 
are documented to capture spheroid integrity following treatment with SB1. Data points are average ± SD, with n=6 individual spheroids per condition. Comparison between 
treatments with a two-way ANOVA and a Holm-Šídák post-hoc analysis showed statistically significant differences denoted with *p < 0.05 and **p < 0.001. 
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4.3.1.3 Macrophage Uptake  
For the final phase of the in vitro screen and to gain an understanding of the fate of NPs in vivo, the 
10 NP candidates were further investigated using an in vitro cellular uptake assay. NPs were incubated 
with M1 macrophages for 24 hours at 37°C. A CAR was calculated, with a higher CAR indicating higher 
NP uptake. Figure 4.11 shows a significantly decreased uptake (lower CAR) of SB NPs when compared 
to free SN-38 (SB1<SB7<SB8<SB2<SB3, ranking order concerning CAR). CA1, CA14 and CA16 also 
demonstrated a lower macrophage uptake, however, these differences did not reach levels of 
significance. CA18 and CA19 were the only NPs to exhibit a higher average uptake when compared to 
free SN-38. Furthermore, when comparing both types of formulations SB NPs accumulated less in the 
macrophages than CA NPs. 
Figure 4.11 Uptake of nanoparticles by macrophages. M1 macrophages (1x106) were plated out and treated 
(50µM) for 24 hours with the above polymer nanomaterials or free SN-38. Both extracellular and intracellular 
levels of SN-38 were quantified and a cellular accumulation ratio was calculated. Data shown as average ± SD 
(n=3) was assessed using a one way ANOVA with Holm-Šídák post hoc analysis. Levels of significance are denoted 
as * for p ≤ 0.05 and ** for p ≤ 0.01. 
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4.3.2 Candidate Selection 
In order to select the best candidates, for each formulation, to proceed for in vivo analysis, all three 
parameters, drug release, cytotoxicity and macrophage uptake were taken into consideration. For the 
SB formulations, SB7 and SB8 were excluded as their release profile was similar to that of free SN-38 
(see Figure 4.3). SB1, SB2 and SB3 all had similar cytotoxic effects (Figure 4.7 and Figure 4.8) and as 
SB1 had the lowest macrophage uptake profile (Figure 4.11) it was therefore chosen. Similarly, all CA 
formulations showed slower sustained release profiles and demonstrated adequate cytotoxicity, in 
comparison to the parent drug. As CA16 had on average the lowest macrophage uptake, it was given 
preference. A summary is shown in Figure 4.12. 
Figure 4.12 Summary of candidates from the in vitro tiered screen.  






4.3.3 In Vivo Plasma Pharmacokinetics 
The pharmacokinetics of SB1 and CA16 NPs, following a single intravenous (tail vein) administration, 
was assessed by measuring SN-38 concentrations in blood using LC-MS/MS. These values were 
compared with concentrations measured in mice, following dosing with irinotecan and free SN-38. 
The plasma concentration-time profiles are presented in Figure 4.13 and the respective 
pharmacokinetic parameters are summarised in Table 4.4. A full overview of the pharmacokinetic 
parameters is detailed in the appendix (see Table B.2, Table B.3, Table B.4 and Table B.5). 
After injection of irinotecan (40mg/kg), the concentrations of SN-38 in plasma declined rapidly with 
time, in a log-linear fashion. However, the clearance of SN-38 from both SB1 (2mg/kg) and CA16 
(2mg/kg) was considerably faster and the maximum concentration of SN-38 observed was 3- and 23- 
fold lower when compared to irinotecan administration, for SB1 and CA16 respectively. Data points 
for both SB1 (all time-points apart from 0.083 hours) and CA16 (at all time-points) were significantly 
lower (P ≤ 0.001) than the concentrations observed following irinotecan administration. Similarly, a 
lower AUC was observed following NP administration, compared with irinotecan. Following 
administration of free SN-38 (2mg/kg), SN-38 levels were significantly reduced at 5 minutes after 




Figure 4.13 Plasma concentration-time profiles of SN-38 following intravenous administration of (i) irinotecan, 
(ii) free SN-38, (iii) SB1 and (iv) CA16 in BALB/c mice. Data are shown as average ±SD (n=3). Statistical analysis 
was performed using a two-way ANOVA followed by Holm-Šídák multiple comparison post-hoc test. A P-value 
of P < 0.05 was considered significant and where indicated * represent P ≤ 0.001. 
Table 4.4 Pharmacokinetic parameters of irinotecan, free SN-38, SB1 and CA16 after intravenous administration 
in BALB/c mice 
Parameter Irinotecan Free SN-38 SB1 CA16 
AUC0-t 
(ng/ml hrs) 2478.13 12.51 170.62 37.00 
AUC0-∞ 
(ng/ml hrs) 2530.88 16.49 194.72 50.72 
Cmax  
(ng/ml) 1189.41 7.41 388.69 47.98 
Tmax 
(hrs) 0.5 0.083 0.25 0.083 
T1/2 
(hrs) 0.96 2.00 3.74 2.95 
AUC, area under the curve; t½, half-life; Cmax, maximum concentration and Tmax, time of maximum concentration observed 
Data are shown as average ±SD (n=3) 
 
The plasma concentrations of SN-38G were also determined (Figure 4.14). Maximum levels of SN-38G 
were found at 30 minutes after administration for irinotecan and CA16. For SB1, Tmax was at 15 
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minutes. Both SB1 and CA16 had a greater glucuronidation ratio, in comparison to irinotecan (SN-38G 
AUC/SN-38 AUC; 0.21, 1.56 and 1.01 for irinotecan, SB1 and CA16 respectively). SN-38G levels, 
following SN-38 administration, could not be determined. A full list of pharmacokinetic parameters 




Figure 4.14 Plasma concentration-time profiles of SN-38 glucuronide following intravenous administration of 
irinotecan, SB1 and CA16 in BALB/c mice. An overview is provided in (a) with each plot indicated in (b). Data are 




SN-38, the active metabolite of irinotecan, is a 100–1000 times more potent at inhibiting TOP I 
(Kawato, Aonuma, Hirota, Kuga, & Sato, 1991; Rothenberg et al., 1993). Even though irinotecan is 
applied clinically as a prodrug its efficacy is related to maintaining inhibition of TOP I for prolonged 
periods and dependent upon CES enzymes for conversion to the active metabolite. Irinotecan 
treatment is frequently followed by late-stage diarrhoea (24% grade 4 incidence) and this limits the 
dose of irinotecan that can be administered safely in subsequent administrations, thereby reducing 
response rates in patients (Rothenberg, 2001; Saigi et al., 2004; Ychou et al., 2002). However, the 
clinical application of SN-38 itself has been hampered by its poor solubility, dose-limiting toxicities, 
and instability at physiological pH. In this chapter, polymeric NPs encapsulating SN-38 were 
formulated, providing better solubility by efficiently encapsulating the hydrophobic SN-38 drug 
molecules. 
To demonstrate controlled and sustained SN-38 release, the drug release kinetics were initially 
assessed. The rate of drug release is a key parameter affecting the bioavailability and therefore 
efficacy and toxicity of a drug formulation. A burst release was avoided as it would lead to the drug 
being cleared rapidly, whilst also causing increased toxicity (Jeong, Bae, & Kim, 2000; Liechty, Kryscio, 
Slaughter, & Peppas, 2010). Similarly, NPs releasing SN-38 too slowly would lead to insufficient levels 
of the drug at the target site, producing no therapeutic benefit. A suitable release profile (steady-state 
concentration of SN-38) was subsequently required as it would give rise to sustained therapeutic drug 
concentrations at target cells, whilst also allowing for better internalisation. Moreover, previous 
reports have shown that with a suitable release profile, SN-38 glucuronidation is less efficient (Patnaik 
et al., 2009). Based on the release data, free SN-38 showed an initial rapid release. The early burst 
release phase of SN-38 could be due to the low interaction between SN-38 and the vehicle (polymer 
NP) itself. Moreover, passive diffusion determined by the concentration gradient was the major 
driving force (Fu & Kao, 2010). As seen in Figure 4.3 and Figure 4.5, certain SB formulations and to a 
greater extent CA formulations did not display an initial burst release, in comparison to free SN-38. 
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This slower release initially, was thought to be due to the entrapment of SN-38 drug molecules in the 
polymer matrix, which prevented its rapid release (Kamaly, Yameen, Wu, & Farokhzad, 2016). The 
slow-release rate was also expected due to the hydrophobic nature of SN-38. However, all SB 
formulations released SN-38 faster than CA formulations, with similar release profiles to free drug. A 
possible explanation for this could be the faster migration of the weakly adsorbed drug molecules, 
within or on the surface of the NP (Kamaly et al., 2016; Moreno Raja et al., 2019). On the other hand, 
CA NPs had a slower release profile. This could be due to the slower drug diffusion through the 
polymer matrix or existing pores present within the inner regions of these formulations (Fredenberg, 
Wahlgren, Reslow, & Axelsson, 2011). The release profiles were of a typical shape commonly obtained 
by other polymeric-based nano- or micro-particle delivery systems (M. Chen et al., 2017; England et 
al., 2017; Fang, Chuang, Wu, Lin, & Lu, 2018; H. C. Lin, Chuang, Cheng, Lin, & Fang, 2019). As a 
reduction in the release was seen in CA formulations by decreasing the DPn value and since the 
monomer and divinyl chemistry were consistent throughout, differences, therefore, were within the 
polymer primary chain length and the subsequent mass of the divinyl monomer. The reduction in SN-
38 release in these formulations could be due to several factors influencing SN-38 interactions with 
the polymeric core of the NP. This could include the increased relative mass of monomer, the increase 
in chain-end concentration, or the variation in the glass transition temperature that would be present 
as the primary chain length decreases. Overall the in vitro release data highlighted the polymer 
nanomaterial’s that were capable of sustaining SN-38 drug release and this was thought to be 
beneficial to prolong the time in circulation and reinforce the EPR effect in vivo. 
Thereafter, to verify whether the released SN-38 was still pharmacologically active, in vitro cytotoxicity 
testing against a panel of CRC cell lines was performed. In vitro, the NPs were found to possess potent 
cytotoxic activity, which was similar to that of free SN-38, but several-fold more potent than irinotecan 
(Figure 4.7 and Figure 4.8). As an adjunct to monolayer, 3D spheroids were utilised to confirm the 
cytotoxicity mediated by the selected NPs. As previously shown in Chapter 3:, a similar trend in 
sensitivity (increased sensitivity) was observed with spheroids treated with SN-38 NPs. The 
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cytotoxicity data, therefore, indicated that both SB and CA polymer nanomaterial’s could undergo 
efficient cellular uptake and subsequently release therapeutically active SN-38 into the intracellular 
environment. Before the in vivo animal study, an in vitro macrophage uptake assay was carried out to 
evaluate the phagocytosis of NPs by the M1 macrophages of MPS. The data revealed the 8 of the 10 
NPs were less readily uptaken than free SN-38. Avoiding or minimising clearance via the MPS would 
allow for a prolonged time within the systemic circulation, improving the accumulation of the NPs at 
the tumour site through the EPR effect i.e. taking advantage of the leaky vasculature and poor 
lymphatic drainage could lead to the delivery of sufficient levels of drug payload. Additionally, all NPs 
demonstrated surface modification with PEG, which has also been reported to be an effective strategy 
against opsonisation and phagocytosis (Suk, Xu, Kim, Hanes, & Ensign, 2016). Based on the screening 
criteria, SB1 and CA16 were chosen for in vivo pharmacokinetic analysis.  
Plasma SN-38 pharmacokinetic studies were performed in mice, to confirm whether there would be 
prolonged therapeutic levels of SN-38 in circulation (Figure 4.13). Compared to SN-38 derived from 
irinotecan, neither SB1 nor CA16 achieved the desired sustained exposure of SN-38 in vivo (both NPs 
produced significantly lower concentrations of SN-38, P ≤ 0.001), similar to previous studies (M. Chen 
et al., 2017; Fang et al., 2018; H. C. Lin et al., 2019; Zhou et al., 2014). This was demonstrated as the 
plasma AUC from SN-38 exposure from irinotecan exposure was 14- and 66-fold higher than the SN-
38 exposure from SB1 and CA16 respectively. Consistent with previous reports, SN-38 generated after 
administration of irinotecan was rapidly cleared into SN-38G (Adkins et al., 2015; Koizumi et al., 2006). 
Moreover, results were not obtained from free SN-38, most likely due to solubility issues. Interestingly 
both SB1 and CA16 displayed lower plasma levels of SN-38, as well as the inactive metabolite SN-38G 
(Figure 4.14). Hence, the data also suggested that the ability of the NPs to escape MPS was limited, 
meaning that the NPs were possibly accumulating within well-perfused organs (heart, liver, spleen, 
lung and kidney). This would corroborate with what was observed during the PK study as both SB1 
and CA16 treated mice showed signs of slow and laboured breathing (SB1 time-points were shorter 
due to this reason). These findings are In agreement with the data in several recent publications, which 
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has shown SN-38 or irinotecan-based NPs to accumulate in organs such as the lungs, subsequently 
leading to acute respiratory distress syndrome or interstitial pulmonary disease (Fang et al., 2018; 
Maitani et al., 2013; Passero, Grapsa, Syrigos, & Saif, 2016; Sepehri et al., 2014; Sumitomo et al., 2008; 
Zhou et al., 2014). To summarise the pharmacokinetic behaviour of SN-38 loaded NPs demonstrated 
a decreased retention time and exposure of SN-38 in comparison to irinotecan. 
However, there were some important limitations to our methodology, which could be improved to 
better interpret data on NP characteristics, biodistribution and pharmacokinetics. Given that 
equilibrium dialysis is predominantly a diffusion-controlled process, the appearance of free drug 
molecules in the acceptor chamber is dependent on the rate of diffusion of free drug molecules across 
the membrane (Wallace, Li, Nation, & Boyd, 2012). This may lead to an inaccurate representation of 
drug release, which has also been demonstrated in a study investigating the release of diazepam 
(Benita & Levy, 1993). Moreover, the methodology was not able to account for any unencapsulated 
drug present on the surface or within the NP solution and percentage encapsulation within most of 
the formulations was not confirmed. Hence any differences present could have been due to variations 
in drug loading. Improvements could have been implemented in our study by, making using of an 
ultracentrifugation method to separate the free drug from encapsulated fractions, further ensuring 
sink conditions through the addition of surfactants and measuring drug release in plasma to mimic the 
in vivo situation more closely, whilst also acquiring an understanding of the stability of the NPs within 
plasma. To further explore and understand the pharmacokinetic profiles of SB1 and CA16 and their 
bio-distribution, in vitro uptake studies using macrophages present in specific organs (liver, spleen, 
lung and kidney) could have been performed during the screening process. Similarly, specifically 
understanding the differences in M1 and M2 macrophage uptake would also have been valuable. 
Moreover, the formation of a protein corona on the NP surface and how this affects its interaction 
with cells (distribution and clearance) needed to be considered. Lastly, the biocompatibility was 
another important design feature that required investigation preclinically. This would have allowed 
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confirmation that in the absence of SN-38 loading, the polymer NPs were well tolerated and elicited 
no observable side effects (endotoxemia) or immune responses. 
 
4.5 Conclusion 
In conclusion, a panel of polymeric NPs encapsulating SN-38 were developed and characterised to 
enable the solubilisation and delivery of SN-38. Following an initial screen involving drug release, 
cytotoxicity and macrophage uptake, SB1 and CA16 were selected. Despite promising results in vitro, 
no benefit for the pharmacokinetic parameters was observed in vivo. Further research is required to 
fine-tune the NPs to achieve appropriate features in preclinical studies and to ultimately translate 












Chapter 5: General discussion 
5.1 Introduction 
The neoadjuvant and adjuvant treatment of CRC with chemotherapy is currently reliant upon 
standardised regimens. Responses to standard therapy can vary considerably, with several patients 
experiencing toxic side effects and life-threatening complications. Bringing novel medications to 
patients remains a considerable challenge. Attrition rates within the pharmaceutical industry are high 
and many of the easily “druggable” targets have been already been addressed, leaving key targets 
that are considered “undruggable” by traditional small molecule medicinal chemistry or antibodies. 
One of the challenges to innovative medicines remains a lack of therapeutic index. Nanomedicines 
can enable new drug products by altering a candidate drug’s distribution and enhancing drug 
concentrations at tumour sites relative to healthy tissue. This change in biodistribution together with 
careful selection of drug release rate from a NP has the potential to improve both efficacy and safety, 
therefore enabling promising treatments otherwise limited by a narrow therapeutic index. Commonly 
designed for intravenous injection, in vivo studies of NPs have been shown to deliver anticancer drugs 
more effectively to tumour cells (Carie et al., 2011; M. Chen et al., 2017; England et al., 2017). Of the 
numerous strategies being investigated, drug-loaded NPs show particular promise.  
Irinotecan is a prodrug converted into the activate metabolite SN-38, which acts as a TOP I inhibitor, 
preventing cell division and replication. Its metabolism is complex, relying on the CES’s, predominantly 
located within the liver and tumour site, for conversion to SN-38, UGT1A1 for glucuronidation to its 
inactive form SN-38G and the ABC transporters for excretion into bile. While irinotecan has clinical 
utility, its various limitations suggest further improvement may be possible. One key limitation is that 
only 2−10% of an injected dose of irinotecan is converted to SN-38 in humans (G. G. Chabot, 1997; 
Senter et al., 2001; J. G. Slatter et al., 2000). Also, the lactone E-ring of SN-38 can be readily converted 
to an open carboxylate form that is inactive against TOP I and excessively binds to human serum 
albumin (Mathijssen et al., 2001; J. G. Slatter et al., 2000; N. F. Smith, Figg, & Sparreboom, 2006). 
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Particularly, it was shown in humans that 24 hours after irinotecan infusion, approximately 25% and 
55% of irinotecan and SN-38, respectively, were in the closed lactone form (G. G. Chabot, 1997). 
Preventing the conversion to the inactive open carboxylate form of the molecule may have 
therapeutic benefit. Finally, while SN-38 has 100- to 1000-fold more potent in vitro cytotoxic activity 
compared with irinotecan (G. G. Chabot, 1997), it has poor solubility in any pharmaceutically 
acceptable excipient and cannot be used for systemic applications.  
The overriding aim of this thesis was to develop and characterise a panel of water-soluble SN-38 drug-
loaded NPs. An in vitro tiered screening system was developed and the best candidates were selected 
for in vivo analysis. As we wanted to target CRC liver metastases, the approach involved developing 
NPs with long circulation times to enable better tumour uptake and to limit the release of SN-38 in 
systemic circulation, so to minimise non-target organ accumulation. To prolong systemic retention, 
the NPs needed to circumvent and minimise the liver, lung and spleen accumulation by possessing 
features to decrease scavenger cell uptake and subsequent off-target toxicity. This is typically 
controlled by the addition of polymers and depends on the size, surface charge, hydrophilicity, 
polymer type and protein binding. A schematic of what we were attempting to achieve is shown in 
Figure 5.1. 
5.2 LC-MS/MS Method Development 
Chapter 2: describes the development of an LC-MS/MS assay for the quantitative detection of 
irinotecan, SN-38 and SN-38G in a variety of biological matrices. The assay was fully validated to FDA 
standards. The assay was sensitive, specific, accurate, and reproducible, and was successfully used 
throughout various parts of the thesis. As demonstrated in Chapter 4:, the method was able to 
characterise the pharmacokinetic attributes and verify the appropriateness of the NP formulations to 
achieve the intended systemic exposure level. The assay could be additionally adapted to determine 
the concentrations of both the carboxylate and lactone forms of SN-38 (L. P. Rivory et al., 1994; X. 
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Yang et al., 2005). Given that only the lactone form is active, such measurements would provide 
greater insight into the pharmacokinetics and underlying mechanisms of SN-38 NPs. 
5.3 The Establishment and Characterisation of Colorectal Cancer Spheroids 
Traditional drug studies have been performed in 2D cultures, where cells are seeded to form a 
monolayer. This method has been extensively used by researchers and pharmaceutical companies 
because of its simplicity. However, the translation of the results obtained from cancer cell monolayers 
to a tumour is not promising, because 2D models are unable to replicate the cell-cell and cell-ECM 
signalling of complex 3D tissues (Pampaloni, Reynaud, & Stelzer, 2007). As a result, great effort has 
been made during the past few years to develop more reliable in vitro models, particularly by utilising 
3D cell cultures (J. B. Kim, 2005). Therefore in Chapter 3: the applicability of an easy-to-use 3D cell 
culture platform based on CRC cell line spheroids was demonstrated. Using HCT116 and CT26 cells, 
methods were developed to (1) assess the histology and structure of spheroids, (2) analyse SN-38 and 
irinotecan cytotoxicity, (3) follow growth inhibitory effects over time (repeated exposures) similar to 
in vivo efficacy studies and (4) evaluate drug uptake. These methods were used to investigate the main 
hypothesis that 3D spheroids provide a more relevant in vitro model than monolayer cells for the 
testing of therapeutic agents. To investigate this, responses of cells to irinotecan and SN-38 in 2D and 
3D were compared. 
Spheroids grew according to sigmoidal growth patterns reflective of tumour growth in vivo (Figure 3.3 
and Figure 3.4) and possessed histological features similar to those of the native tumour 
microenvironment including gradients in cell proliferation and regions of necrosis (Figure 3.5 and 
Figure 3.6). As shown in Figure 3.8 and Figure 3.9 spheroids demonstrated considerably greater 
resistance to treatment with irinotecan or SN-38, relative to cells grown in monolayer cultures. This 
may be a result of the limited exposure of cells within spheroids to treatment due to poor drug 
penetration, a reduction in cellular proliferation and/or resistance associated with 3-D cell adhesion. 
As a result, most of the cytotoxic effects of the drugs would, therefore, be observed in the outer layers 
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of the cells in the spheroids. Moreover, the quiescent zone in the tumour spheroid can alter the 
cytotoxic effect of drugs. As both irinotecan and SN-38 are DNA damaging agents, these drugs are 
effective in rapidly proliferating cancer cells. However, due to the non-proliferating nature of cells in 
the quiescent zone, which is located between the core and outer layer, cells in the dormant stage 
remain protected (Jo et al., 2018). For this reason, tumour spheroids may reduce in size, as observed 
in Figure 3.10C and Figure 3.11C but are not completely killed. Therefore, the tumour can resume 
proliferation once the cells in the outer layer are dead (Aljitawi et al., 2014; Chitcholtan, Asselin, 
Parent, Sykes, & Evans, 2013). However, following repeated exposures, spheroids became more 
sensitive with each subsequent treatment. However direct comparison to monolayers could not be 
made, as 2D cultures are not suited for long term culture. The cytotoxicity data was in agreement with 
the literature whereby many anticancer drugs with similar mechanisms of action (i.e. targeting actively 
proliferating cells) were more resistant than cells cultured in monolayer (Horning et al., 2008). 
Differential drug responses of cells grown in 3D versus 2D are not solely related to the differential 
zones of proliferation. Multiple studies report differences in gene and protein expression between 3D 
spheroids and 2D cultures that impact drug efficacy, metabolism, and cell communication (Aljitawi et 
al., 2014; Edmondson et al., 2014; O. Jeon, Marks, Wolfson, & Alsberg, 2016; Ravi, Paramesh, Kaviya, 
Anuradha, & Solomon, 2015; Sakai, Ito, & Kawakami, 2010; Sato et al., 2016). Our data revealed a 
profound decrease in protein expression in cancer cells grown as spheroids, as compared to those 
cultured in the respective conventional 2D system. However, MRP2 was induced to a greater degree 
in spheroids as compared to monolayer cells. Increased levels of this multidrug resistance protein have 
been previously associated with increased resistance to drug treatment (Hinoshita et al., 2000; 
Knuchel, Hofstadter, Jenkins, & Masters, 1989; Oloumi, MacPhail, Johnston, Banath, & Olive, 2000). 
This could have been another contributing factor to the reduced chemotherapeutic efficacy seen in 
our spheroids (Table 3.5). Further studies are required to investigate whether expression patterns 
observed in spheroids more closely resemble those found in vivo. In particular, understanding changes 
in protein expression in the repeated exposure studies, would further aid our understanding of the 
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mechanisms underlying the changes in sensitivity seen. Additionally, using proteomic approaches 
would be useful in determining the supposedly wide spectrum of changes between 2D and 3D cultured 
cells, both in terms of pathways involved and protein patterns. These could include studies on other 
cell lines, including primary tumour tissues, as well as other drugs and related proteins which would 
help further study the correlation and to understand the role of cell culture type in protein expression 
levels which may, in turn, impact the cellular responses to anti-cancer therapeutics. To better 
recapitulate the in vivo multicellular complexity and microenvironment of tumours, 3D co-cultures 
have been developed. Co-cultures usually combine tumour cells with stromal cell types such as 
endothelial cells, immune cells or cancer-associated fibroblasts. For example, co-culture of hepatic 
stellate cells (HSC) with tumour cells in vitro significantly increased the invasion and proliferation of 
tumour cells (Okabe et al., 2009). Implementing a vascular component in 3D cell culture models is 
important since blood vessels can create oxygen gradients that in turn can lead to endothelial 
sprouting and promote cell migration via chemotaxis (Mosadegh, Xiong, Dunham, & Min, 2015; 
Verbridge et al., 2013). Recently, microfabricated devices with capillary-like channels and spheroid-
on-a-chip systems have become attractive platforms in mimicking the fluidic in vivo 
microenvironment. It is anticipated that such organotypic in vitro models will increase our 
understanding of human bodily functions, are of value for disease modelling and screening of novel 
therapeutic interventions. 
Collectively, the results obtained in this chapter highlight the importance of incorporating complexity 
into in vitro tumour models used for studying cancer and for preclinical phases of the drug discovery 
process. Further enhancement of the spheroid model could help uncover the role of biochemical and 




5.4 Preclinical Assessment of SN-38 Loaded Nanoparticles 
Despite improvements in chemotherapeutic drugs, the efficacy of conventional delivery systems for 
CRC is limited by non-specific toxic effects. Hence, there is a need to develop delivery systems capable 
of delivering high drug concentrations to the tumour site, while minimising damage to surrounding 
normal tissue. As discussed previously, NP mediated drug delivery is a promising technology that 
offers a degree of controlled release and the ability to limit the off-target effects in a way that the bulk 
material or the free drug is unable to. The overarching goal of Chapter 4: was to develop, characterise 
and evaluate a panel of SN-38 NP formulations, before systemic administration in mice in vivo, with 
an overall focus on delivery to CRC liver metastases. A tiered in vitro screen was used which consisted 
of assays involving drug release, cytotoxicity and macrophage uptake. It made use of the LC-MS/MS 
method and CRC spheroids which were developed and characterised in Chapter 2: and Chapter 3:, 
respectively. Candidates to take forward in vivo were selected on their capability of protecting SN-38 
from premature burst release, maintaining the cytotoxicity of SN-38 in CRC cells and evading 
macrophage uptake. Ten NPs were selected on the basis that they did not show an initial burst release 
and had an overall slower sustained release profile in comparison to free SN-38 (Figure 4.6). 
Cytotoxicity was comparable to that obtained for free SN-38 and significantly increased in comparison 
to the parent drug, irinotecan (Figure 4.7 and Figure 4.8). An uptake assay was also used to 
differentiate between how NPs interact with M1 macrophages (Figure 4.11). As a result, SB1 and CA16 
were taken forward for the proof-of-concept in vivo study. However, neither formulation showed any 
beneficial effects in vivo i.e. they did not prolong or enhance the levels of SN-38 in circulation (plasma 
half-life). As discussed in Chapter 4:, the non-specific uptake of NPs by the MPS in liver, spleen and 
lung may have contributed to the lower plasma levels of SN-38. This corroborated with the physical 
signs of toxicity in mice treated with either of the polymer nanomaterial’s and also with previous 
studies utilising SN-38 NPs (Fang et al., 2018; H. Liu et al., 2015; Palakurthi, 2015). 
It is important to consider the implications of these results for future studies, as certain limitations 
could be addressed. In comparison to SN-38 release data from the literature, not taking into account 
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the methodology used, the NPs developed within this thesis displayed faster release profiles (Al-
Kasspooles et al., 2013; Carie et al., 2011; M. Chen et al., 2017; England et al., 2017; Fang et al., 2018; 
H. Zhang et al., 2013). This could indicate the need for developing NPs that release at an even slower 
rate than what has been presented in the thesis. Ideally, an in vitro release method should simulate 
in vivo conditions and release mechanisms. One disadvantage of the rapid equilibrium dialysis method 
employed is that it can occasionally restrict the diffusion and/or interact with drug molecules (D’Souza, 
2014). Employing a beaker dialysis setup (larger volume) would ensure that sink conditions were 
maintained throughout and radiolabelling of the NPs would give important insights to address the 
above-mentioned issues. As demonstrated the macrophage uptake did not correlate to NP in vivo 
performance. More sophisticated testing of the polymer material and drug-loaded NPs involving the 
MPS within the different organ systems is required, to ensure that relevant correlative in vivo 
information is derived. This would help to elucidate how the NPs are cleared or elicit toxicity 
(leukocyte proliferation in vitro, release in vitro of TNF-α, IL-1β and IL-8), thereby providing guidelines 
for direct manipulation of the NPs physicochemical characteristics to minimise uptake and reduce 
potential inflammatory-mediated events. A further study that could be performed in vivo was to 
measure levels of the drug in the different organ compartments. Hence additional information 
regarding the biodistribution of the NPs would be generated, thereby allowing further fine-tuning of 
the NP physicochemical properties. In this regard, subsequent experiments with appropriately 
characterised and redeveloped NPs could be carried out using CRC liver metastases tumour models to 
investigate if NP administration leads to the improvement of in vivo therapeutic index and the 
performance of the therapeutic agent. 
An alternative approach to reduce the non-specific uptake and enhance the selectivity of the NPs 
would be to introduce an active targeting component on the NP surface. Relevant tumour-specific 
targets could be identified through proteomic comparison of the liver metastases, primary tumour 
tissue and normal mucosa. Identified upregulated proteins that represent attractive targets could then 
be investigated for their suitability. Previous studies at the University of Liverpool (unpublished) have 
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uncovered the following tumour membrane proteins; Filamin-A, Neuroblast differentiation-
associated protein AHNAK, Talin-1, Fibronectin, Complement C3, Ig gamma-1 chain C region, Alpha-
enolase, Alpha-actinin-1, Clathrin heavy chain 1 and Vinculin. Another factor that needs consideration 
is drug loading (≥20% or greater is generally the accepted minimum level). Low drug loading may 
significantly limit the clinical application because repeated administration of a large number of 
inactive carriers into patients may induce systemic toxicity (Palakurthi, 2015). However, these NPs 
have the potential for patient stratification, as irinotecan treated mCRC patients were associated with 
lower response rates in individuals who displayed low expression of CES2 and high expression of TOP 
I (Shaojun, Li, Haixin, & Guisheng, 2018). This would suggest that irinotecan treatment is ineffective, 
due to the low generation of the active drug. Hence, directly delivering SN-38 via NPs would offer a 
potential solution to patients expressing such profiles (bypassing CES2 metabolism). In summary, the 
data presented in Chapter 4: showed the successful encapsulation of SN-38 in a water-soluble form. 










Figure 5.1 Following intravenous injection, nanoparticles are distributed systemically through the bloodstream. Nanoparticles can enter the liver via the portal vein after 
which, they have to evade tissue-resident macrophages (Kupffer cells and liver sinusoidal endothelial cells). If successful they can accumulate at the tumour site, by taking 
advantage of the enhanced permeation and retention effect. However, a fundamental understanding of tumour biology and its physiological features is necessary for the 
design and development of effective nanomedicines. 
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5.5 Future Considerations 
Despite technological improvements in nanotechnology, the complexity of biological systems hinders 
the prospect of nanomedicines being applied in cancer therapy. When designing novel polymer-based 
drug-delivery systems for translation into the clinic, there are many considerations to take into 
account before and during development. Several biological barriers, aspects of the tumour biology, 
together with the physicochemical features of the nanocarrier need to be considered to develop 
effective nanotherapeutics for CRC patients with liver metastases. From a platform perspective, 
important features for polymer carriers include synthetic reproducibility, low 
toxicity/immunogenicity, a suitable clearance mechanism/biodegradability and capacity for high drug 
loading. Other considerations should include ease of manufacture, formulation, analytical 
characterisation and low cost of goods. Based on the data presented in this thesis, it is clear that 
incorporating an interdisciplinary approach when developing nanomedicines should assure the 
appropriate disease-driven design and that this will form a critical step in improving their clinical 
translation. 
5.5.1 Improving Translation 
The application of nanotechnology in drug delivery is increasing rapidly. However, despite significant 
advances in materials understanding, clinical translation is still limited. Research is now shifting away 
from traditional methods that prioritise the drug delivery system, to disease-based design approaches; 
a concept where the underlying biology and the material’s physicochemical properties are given 
precedence (Hare et al., 2017). As in the case of CRC liver metastases, a better understanding of the 
disease pathophysiology and how this can influence accumulation, distribution, retention and efficacy 
requires further consideration. However, these tumours can be highly heterogeneous and throughout 
the progression of the disease, intra- and inter-patient variability is apparent (Moro, Bozoky, & 
Gerling, 2018; Sveen et al., 2016; Vermaat et al., 2012). Consequently, certain tumours may be more 
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amenable to NP drug delivery than others, as fewer barriers may impede the disease-specific 
localisation of NPs. 
A major issue with the clinical translation of NPs is the gap between preclinical and clinical studies. 
Currently, preclinical models of CRC liver metastases do not completely recapitulate the different 
aspects of these tumours nor the heterogeneity. The majority of animal models are syngeneic or 
xenografts and use ex vivo manipulated tumours. Therefore, their ability to mimic CRC liver 
metastases is limited. Differences in features such as the size/pattern of the tumour, vascularity, levels 
of IFP and presence of hypoxia highlight some of the challenges of using such models for estimating 
clinical NP performance. To offset this, various sophisticated in vitro platforms that act as predictive 
human tissue models are being developed to profile NPs. Examples include 3D tumour models 
(spheroids and organoids) consisting of several cell types as well as components of the ECM, which 
display improved predictive power of in vivo pharmacological efficacy as compared to traditional 
monolayer cell culture (Durymanov et al., 2019; Fong, Toh, Yu, & Chow, 2017; Langhans, 2018). More 
recently it was demonstrated that organoids derived from human CRC liver metastases were able to 
recapitulate additional aspects of the disease (Buzzelli, Ouaret, Brown, Allen, & Muschel, 2018). When 
applied in vivo, metastatic CRC organoids were competent and colonised within the liver, displaying 
their potential for translation from in vitro to in vivo preclinical models (Cristobal et al., 2017; Fujii et 
al., 2016). As CRC metastasis is a multifaceted and heterogeneous disease, merging different organoid 
models offers the opportunity to study the effect of intratumoural heterogeneity on CRC phenotypes. 
Furthermore, patient-derived xenograft animal models which display metastasis are the ‘go-to’ 
models being used to characterise in vivo endpoints. They can mimic tumour cell interactions and 
generate a relevant tumour microenvironment (T. Jiang, Jin, Liu, & Pang, 2017). A shortcoming of 
patient-derived xenograft models is that the immune system is impaired, which impacts cancer 
progression (Jung et al., 2017). An alternative ‘go to’ approach for developing liver metastasis is the 
use of genetically engineered mouse models, which have intact immune systems. This method poses 
challenges in evaluating therapeutic responses, as the metastases have long latency (Young, Hong, 
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Lee, & Cho, 2017). At present, there is no ideal animal model for entirely recapitulating the 
mechanisms and processes found in human CRC liver metastasis. Consequently, multiple models are 
frequently needed to address specific clinically relevant experimental questions.  
More advanced models termed ‘organ-on-a-chip’ systems may be key to accurately assessing the 
toxicity, pharmacokinetics and pharmacodynamics of NPs. These microfluidic devices can integrate 
vascular networks, reproduce the tumour microenvironment and have the potential for 
personalisation (Millard et al., 2017). However, the use of these devices for evaluating NPs has not 
been extensively implemented, meaning that there is not yet enough data to show their predictive 
power clinically. Nevertheless, the application of more relevant preclinical models in NP testing will 
likely translate to clinically beneficial outcomes in the medium- to long term.  
Furthermore, features of the tumour as well as the various facets that compose the tumour 
vasculature and microenvironment may diminish the effects of NPs and need to be considered. These 
have been outlined below in Figure 5.2. 
 
Figure 5.2 Overview of several key interactions involving NPs within the tumour 
5.5.2 Vascularisation and Perfusion 
As mentioned previously in 0, the tumour vasculature is tortuous and irregular leading to 
compromised blood flow. This may further influence the site-specific accumulation of NPs. Although 
the permeability of the tumour vasculature forms the basis of the EPR effect, it also allows excessive 
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extravasation of blood constituents such as fluid and plasma macromolecules. Elevated fluid viscosity 
inside the tumour mass is therefore apparent, hindering the movement of NPs. Vascular perfusion 
inside tumours is heterogeneous and certain intratumoural regions can be hypoperfused due to a 
decreased blood flow caused by plasma leakage, in conjunction with blood vessel compression 
(Stylianopoulos et al., 2018). Recent findings have revealed that the levels of type IV collagen are 
significantly higher inside liver metastases when compared to their primary tumours (Kai et al., 2019). 
In general, it is thought that liver metastases are poorly perfused in comparison to their primary 
tumour and their vascular permeability is limited (Tanei et al., 2016). Accordingly, NP delivery is limited 
as tumour cells are too distant from normal functioning vessels, ultimately restricting the distribution 
of therapeutic agents.  
Previous research has shown that the hepatic artery supplies large metastatic tumours, whilst 
micrometastases (<2mm) have been reported to be predominantly supplied by the portal venous 
system (Casillas et al., 1997). More recent observations have shown that vascularisation also differs 
depending on the type of liver metastases. Due to vessel co-option, replacement liver metastases are 
often in continuum with the sinusoidal blood vessels, whereas in desmoplastic liver metastases the 
capillaries connect to blood vessels of the arteriole (Lazaris et al., 2018; Van den Eynden et al., 2012). 
Further evidence revealing that replacement liver metastases co-opt the pre-existing vasculature is 
indicated in reports, as co-opted vessels maintain expression of lymphatic vessel endothelial 
hyaluronan receptor (LYVE)-1 (Stessels et al., 2004). On the other hand, desmoplastic liver metastases 
contained very few LYVE-1-expressing vessels, indicative of angiogenesis. This angiogenesis seen in 
desmoplastic liver metastases is distinguished by regions of high vessel density termed vascular 
hotspots. These newly formed blood vessels appear leaky and functionally impaired due to the 
presence of fibrin deposits. In contrast, replacement liver metastases display a small amount of 
proliferating endothelial cells, with no apparent signs of fibrin deposition (Stessels et al., 2004). The 
appearance of vessel co-option could have important implications in the context of NP delivery. In this 
manner, liver metastases may incorporate ‘normal-looking’ vasculature i.e. less permeable and 
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unlikely to display the EPR effect. Hence, NPs whose actions solely rely on the abnormal vasculature 
may be impaired and any strategies to normalise the tumour vasculature through antiangiogenic 
therapies may be hindered by drug resistance, as seen from previous studies (Emblem & Jain, 2016; 
Frentzas et al., 2016; Qian, 2013). More recently, it was highlighted that approximately two-thirds of 
patients presented with mixed growth patterns (mixed phenotype of co-opted vessels and 
angiogenesis) (van Dam et al., 2017). Therapeutic approaches that can suppress both angiogenesis 
and vessel co-option may, therefore, be justified. In particular, specifically targeting the co-opted 
vasculature by capitalising on their altered protein expression via active targeting strategies, may be 
a possibility (Roodink et al., 2010). 
Drug delivery strategies need to ensure sufficient drug penetration/distribution is achieved, such that 
both the peripheral and central regions of the tumour are accessed. Some researchers have sought to 
manipulate the tumour vasculature through utilising hyperthermia and growth factors, with the intent 
being to facilitate extravasation of NPs into the tumour microenvironment (Chatterjee, Diagaradjane, 
& Krishnan, 2011; W. Jiang, Huang, An, & Kim, 2015). This is exemplified by local hyperthermia (41°C) 
eliciting an increase in vascular permeability up to 10µm in a variety of tumour models, allowing 
greater penetration into the tumour microenvironment (L. Li et al., 2013). For instance, ThermoDox® 
(lyso-thermosensitive liposomal doxorubicin technology) was combined with image-guided 
radiofrequency ablation in a porcine model (Swenson et al., 2015). In the presence of heat, the amount 
of doxorubicin deposited increased and the treatment zone was enlarged. Despite this, no clinically 
meaningful benefit was found in patients with hepatocellular carcinoma in the phase III HEAT study 
(Lencioni & Cioni, 2016). Similarly, a phase 1 trial examined the combined treatment of 
thermosensitive liposomal doxorubicin and non-invasive focused ultrasound hyperthermia (39.5–
43°C), with the latter being used to trigger drug release (Lyon et al., 2018). The study displayed 
enhanced intratumoural delivery in human liver tumours (patients investigated had solid primary or 
metastatic tumours), whilst also posing no additional safety concerns in comparison to standard 
chemotherapy alone. Hyperthermia itself is able to exert a cytotoxic effect and following combination 
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with certain cytotoxic agents, synergistic effects are present (Jacquet, Averbach, Stuart, Chang, & 
Sugarbaker, 1998; Kusamura, Dominique, Baratti, Younan, & Deraco, 2008). Other reports have also 
shown hyperthermia to modify membrane permeability, drug uptake and drug penetration (Di Miceli 
et al., 2012; Hompes et al., 2012). A recent meta-analysis displayed that patients with mCRC show a 
tendency towards increased median overall survival after cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy combined with resection of liver metastases, when compared to 
treatment with systemic chemotherapy (de Cuba et al., 2013). However, there are several challenges 
still facing the mentioned approaches, which include tumour heterogeneity and regional variation. 
The tumour vascular network remains a major obstacle in the vascular transportation of NPs. 
5.5.3 The Tumour Microenvironment 
The mCRC tumour microenvironment is a multifaceted dynamic system. Its regulation depends on the 
interactions between cellular (tumour cells and resident cells of the liver) and non-cellular 
components (hypoxia, pH, signalling molecules and ECM). Compared to normal tissue, the tumour 
microenvironment possesses numerous unique characteristics. It presents an acidic pH due to the 
Warburg effect and hypoxia is generated as cells residing deep in the tumour mass are deprived of 
oxygen because of inadequate vasculature, lack of nutrients and uncontrolled proliferation. In 
particular, hypoxia within CRC liver metastases has been observed at an average distance of 80μm 
from the vasculature and it is postulated that large oxygen consumption is the principal contributing 
factor (van Laarhoven et al., 2006). Taking into consideration such features of the tumour 
microenvironment when designing NPs, may aid their delivery into tumours. Various NPs have been 
designed to utilise the acidic pH microenvironment to selectively trigger release. For instance, 
polymeric micelles with a pH-sensitive component containing cell-penetrating peptides were designed 
for the treatment of CRC (Bao et al., 2016). Following intravenous administration, findings revealed 
the destabilisation of the polymer at lower pH (pH 6.8) allowed for enhanced action, both in vitro and 
in vivo, owing to improved targeting and cellular uptake. The hypoxia in tumours can also be employed 
to control drug release or activate prodrugs. Kulkarni et al. constructed lipid NPs containing a hypoxia-
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sensitive component, which displayed a better penetration depth and cytotoxicity under hypoxic 
conditions (Kulkarni et al., 2016). Similarly, hypoxia-responsive doxorubicin NPs have been reported 
to selectively release drug under hypoxic conditions (Thambi et al., 2014). These NPs exhibited 
enhanced anti-tumour efficacy, higher toxicity to hypoxic cells and in vivo imaging showed them to 
successfully accumulate at the tumour site. The presence of improved penetration demonstrated the 
advantages offered by hypoxia-activated chemotherapeutic delivery. Even with recent advances in 
the development of hypoxia-responsive NPs, accessing hypoxic regions located deep inside the 
tumour remains an unmet challenge.  
Another hurdle compromising the transport of NPs is the high interstitial fluid pressure (IFP). IFP is 
elevated as a result of the abnormal vasculature, intratumoural lymphatic vessels that do not 
effectively drain interstitial fluid and a dense ECM. Moreover, it has been demonstrated in the 
literature that patients with CRC liver metastases, had a mean IFP ten times above the IFP of normal 
liver tissues (Less et al., 1992). The IFP at regions close to the tumour margin is often normal, meaning 
that there is an outward pressure gradient (Jain, Tong, & Munn, 2007). Consequently, it can limit the 
ability of NPs to diffuse into the tumour interstitium, slow down their biodistribution, and hinder NP 
transport within the vasculature. In the worst-case scenario, the IFP can cause the intravasation of 
NPs back into the blood supply. To try and counteract this, researchers utilised gelatin-modified 
cationic lipid NPs intending to reduce tumour IFP and subsequently improve drug delivery. It was 
demonstrated that delivery of imatinib caused a significant reduction in tumour IFP when combined 
with docetaxel and quercetin in NPs (Gao et al., 2017). Likewise, the reduction of tumour IFP by 
eradicating fibroblasts promoted deeper chemotherapeutic penetration in HepG2 spheroids, thereby 
demonstrating that reducing tumour IFP could be beneficial for improving NP delivery (B. L. Chen et 
al., 2016). PEGPH20 is a therapeutic candidate currently being explored for improving local 
permeation, through the degradation of hyaluronan in the tumour microenvironment. This reduces 
tumour IFP, and PEGPH20 is thought to enable increased access to anti-cancer therapeutics and 
immune cells (Halozyme, 2019). Its use in advanced pancreatic adenocarcinoma and metastatic breast 
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cancer have shown encouraging results in terms of safety, overall survival and response rate, thereby 
prompting further studies (Gourd, 2018).  
The ECM consists mainly of a cross-linked network of collagen, elastin fibres, proteoglycans and 
hyaluronic acid. ECM proteins can interact with growth factors promoting cell migration and 
metastatic progression. The ECM is often denser and highly cross-linked within tumours. Patients with 
CRC liver metastases have shown to display abnormal ECM protein synthesis and degradation, with 
collagen turnover related proteins being up-regulated (Van Huizen et al., 2019; Williamson, 
Sultanpuram, & Sendi, 2019). This may pose a significant barrier to the diffusion of NPs through the 
interstitium, causing drug release distant from the tumour cells. Within the tumour microenvironment 
transdifferentiated HSCs, tumour associated macrophages and the KCs create a reactive tumour 
stroma by producing a plethora of remodelling factors, including the proteolytic matrix 
metalloproteinase enzymes involved in ECM turnover (Kang, Gores, & Shah, 2011). This further 
impacts the composition, structure and elasticity of the ECM. These factors have to be accounted for, 
in order to obtain appropriate interstitial penetration and homogeneous drug distribution. In 
conjunction with this, combining locoregional therapy such as hepatic arterial infusion or transarterial 
chemoembolisation with nanotechnology and the use of intratumoural depots/implants for sustained 
release may overcome the limitations of tumour biology. In a rat model of CRC liver metastases, 
Kauffels et al. were able to show that delivery of drug-loaded into embolisation particles (Irinotecan 
with EmboCept® S) using hepatic arterial infusion led to significantly higher concentrations within the 
tumour when compared with systemic administration (Kauffels et al., 2019). The application and 
toxicity of such delivery strategies require further investigation.  
It is still unknown to what extent the tumour microenvironment, influences the different metastatic 
growth patterns and directs whether blood vessels are pre-existing or newly formed. Such attributes 
of CRC liver metastases are not fully understood in humans, with research being primarily conducted 
in animal models. Experiments have suggested that the adopted growth pattern is strongly associated 
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with the route of dissemination into the liver (Bugyik et al., 2016; Paku, Kopper, & Nagy, 2005; Paku 
& Lapis, 1993). In a mouse model of liver metastases, once tumour cells were delivered into the liver 
via the arterial system they displayed signs of angiogenesis, as seen by the presence of numerous 
small vessels. Whereas, entry into the liver via the portal vein corresponded with co-option of 
sinusoidal vessels (Paku & Lapis, 1993). Mechanistic features of vascularisation at early stages of CRC 
liver metastases in humans have not been completely described. It is believed that many elements 
such as the tumour cells, angiogenic factors (VEGF, HIF-1α, E-selectin and endothelin) and the host 
microenvironment influence this process. Published reports have pointed out that activated HSCs play 
a central role in the development of the vasculature (Paku et al., 2005; B. Xu, Shen, Cao, & Jia, 2013). 
They are thought to create a proangiogenic microenvironment and to be responsible for the 
recruitment and survival of endothelial cells. Researchers investigated changes that occur in 
intratumoural microvessels and microcirculation during the establishment of liver metastases in mice. 
Findings showed that liver metastases smaller than 500µm were hypovascular, whilst those larger 
than 2000µm showed an exclusively arterial blood supply. Increased alpha-smooth muscle actin 
positive arterioles and levels of CD34 (a marker of tumour neovascularization) were also seen (Archer 
& Gray, 1989; Joo et al., 2011; Y. Liu & Matsui, 2007). Such features could have significant implications 
for the delivery of NPs, as accessing hypovascular tumours would be challenging and the differences 
in vascularisation will likely influence NP tumour accumulation. 
5.5.4 Active Targeting 
As mentioned in 0, the active targeting of NPs is also a promising approach to facilitate their 
internalisation. Active targeting approaches have been documented to provide clinical benefits in 
cancer therapy, in large part due to their ability to target molecular markers overexpressed on the 
membranes of cancerous cells in comparison with normal cells (Yu, Tai, Xue, Lee, & Lee, 2010). Many 
colon-targeted approaches employ targeting ligands such as folic acid, hyaluronic acid, lectin, 
mannose, EGFR and antibodies by surface functionalization of nano-drug delivery systems for the 
active targeting of a disease site (Byrne, Betancourt, & Brannon-Peppas, 2008). To meet the actual 
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need, these advanced medicines can be developed based on tumour genetic profiles allowing tailoring 
of targeting approaches and pre-selection of patients, so-called personalised nanomedicine 
(Fornaguera & Garcia-Celma, 2017; Lammers, Rizzo, Storm, & Kiessling, 2012; Patel, Pattni, Abouzeid, 
& Torchilin, 2013). 
Additionally, the interactions between targeting ligands decorated on nano-drug delivery systems and 
particular receptors overexpressed at the diseased site or specific cells are expected to enhance the 
adhesion and internalisation of NPs. These effects will lead to selective drug accumulation at the target 
site that may increase therapeutic efficacy and reduce side effects. Endocytic pathways may result in 
trafficking, to either the acidic environment of lysosomes where the NP is subsequently degraded or 
a non-target organelle site. In light of this, recent research has focused on strategies to promote 
endosomal escape or avoid lysosomes. The incorporation of cationic polymers, such as 
polyethylenimine and poly-L-lysine, in NP design, represents a viable strategy for inducing release 
from endosomal compartments. The cationic charge of the NP interacts with the outer negatively 
charged surface of the endosomal membrane, leading to membrane flipping and subsequent 
destabilisation, also known as the flip-flop mechanism (Varkouhi, Scholte, Storm, & Haisma, 2011). 
Furthermore, pH-sensitive material can induce endosomal escape via the proton sponge effect. 
Buffering polymers absorb protons thereby preventing acidification of endosomal vesicles. This 
ultimately leads to osmotic swelling inside the endosome, membrane rupture and eventual leakage 
of NPs into the cytosol. Some drugs may take effect instantly, whilst those that act upon DNA must 






5.6 Perspectives and Conclusion 
Current therapeutic options to target CRC liver metastases are limited and the clinical need to deliver 
tolerable and effective therapeutics to such regions is clear. It is hoped that designing agents to 
efficiently access the liver and eradicate metastases, will provide a larger survival benefit in 
comparison to current chemotherapy, which is only of modest efficacy. In addition to CRC, the liver is 
a common site of metastasis for various types of solid tumours including sarcoma, breast, kidney, 
pancreatic, ovarian, prostate and lung cancers (Brodt, 2011; Fan & Gao, 2017; Hess et al., 2006). As a 
metastatic site, the liver poses significant challenges, which impairs drug distribution and subsequent 
efficacy. An anti-metastatic nanotechnology-based approach may therefore present a promising route 
for tackling such issues. 
Evidently, successful drug delivery is hampered by the presence of several biological and 
physicochemical barriers mentioned above, which in turn impairs the ability to effectively treat 
cancers. Rather than designing nanomedicines that take a holistic approach i.e. addressing each and 
every stumbling block, the focus should remain on the development of a safe and efficacious drug 
delivery system. In relation to CRC liver metastases this involves selectively targeting the tumour cells, 
whilst simultaneously minimising non-specific interactions, be it binding with or uptake into other cell 
types located within the hepatic sinusoids (B cells, hepatocytes, KCs and LSECs). This may be central 
to additionally targeting micrometastases which often go undetected and are associated with poor 
prognosis. Efforts also need to be made to improve extravasation and intratumoural accumulation, 
both of which may benefit the efficacy of the treatment. Coincidentally, ensuring that the drug is 
either released so that it diffuses throughout the tumour region, or that the drug is delivered intact to 
its site of action, are critical factors in assuring efficacy. Although the physicochemical properties of 
nanomedicines may not be directly involved in the above processes, collectively with the tumour 
biology they play a key role in determining the interactions and pharmacokinetics of nanomedicines. 
In view of this, the physicochemical properties of the NP need to be optimised (size, charge, shape 
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and surface chemistry), making sure to integrate these biological factors into the design of 
nanomedicines so that they don’t impede efficacy.   
Other factors such as tumour heterogeneity concerning the EPR effect and enhanced circulation times 
are important features to consider, but they do not guarantee that nanomedicines will reach or access 
the tumour site. Simply relying on the EPR effect is not sufficient for delivery, especially into poorly 
perfused tumours e.g. replacement liver metastases. Added to this, some studies have indicated that 
extending circulation time beyond a certain point does not lead to improved efficacy (Nichols & Bae, 
2013). Moreover, overexpression and specificity should not be conflated when considering targeting 
strategies. In particular, precautions should be taken for strategies that aim to reshape the tumour 
microenvironment. Such methods may promote tumour cell migration and increase drug resistance. 
For many a target, the intratumoural expression varies both spatially and temporally according to the 
microenvironmental conditions (Bae & Park, 2011). Hence, better characterisation of molecular 
targets that are specific to CRC liver metastases is essential, with serious consideration being given to 
whether a targeting strategy will convey an actual benefit.  
During preclinical development, it is vital to understand the well-described interactions with 
components of the immunological and haematological systems (Halamoda-Kenzaoui et al., 2019; 
Rosslein et al., 2017; Urban, Liptrott, & Bremer, 2019) to de-risk translation (Halamoda-Kenzaoui et 
al., 2019). NPs carrying a cationic charge interact with biological membranes electrostatically, and 
trigger haemolysis, platelet activation and induction of leukocyte procoagulant activity 
(Dobrovolskaia, Shurin, & Shvedova, 2016). As well as surface charge, NPs with high aspect ratios have 
been shown to activate intracellular sensors such as the NLRP3 inflammasome (Baron et al., 2015). 
The use of surface coatings such as PEG may reduce interactions with immunological systems by 
preventing opsonisation by proteins such as immunoglobulins and components of the complement 
system. However, it has also been demonstrated that many people produce anti-PEG antibodies as a 
consequence of pre-exposure to PEG-containing products (B. M. Chen et al., 2016; Richter & 
157 
 
Akerblom, 1984). The presence of anti-PEG antibodies has been correlated with immediate-type 
hypersensitivity reactions to a PEGylated aptamer (Pegnivacogin) in a clinical trial (Povsic et al., 2016). 
Infusion reactions are immune-mediated toxicities that occur within the first minutes to hours of the 
systemic administration of various drug products, at their relevant therapeutic doses. Activation of 
complement and the resultant complement activation-related pseudoallergy is one mechanism 
underlying such infusion reactions to NPs (Neun, Barenholz, Szebeni, & Dobrovolskaia, 2018). A robust 
understanding of interactions with immunological and haematological systems is critically important 
to the translation of NPs for CRC. 
Even though there has been a myriad of advances in nanomedicine and drug delivery, there are 
various concepts and mechanisms that are still not fully understood due to a lack of experimental 
data. Some questions that still need to be answered include; the dynamics underlying the EPR effect 
clinically within the different liver metastases growth patterns, the importance of biodegradability and 
clearance of the nanocarrier within the liver metastases from a toxicity perspective, the consequences 
of long term exposure to the NP, and the significance of modulating the different immune cells located 
in the sinusoids. It may be that patient or cancer-specific stratification is required to ultimately lead 
to an enhanced understanding and subsequent improved clinical success. It is apparent that greater 
insight into the opportunities and challenges presented by cancer nanomedicines is required. To 
support the successful development and clinical translation of nanomedicines, converging ideas from 
both nanotechnology and tumour biology is critical. If these challenges can be met, nanotechnology 
holds great promise for improving patient survival by transforming the paradigm of cancer treatment.  
From a wider perspective, NPs hold great potential for antiviral repurposing, as they can be applied 
much more rapidly than new drug development. These advanced drug delivery technologies can be 
designed to act directly towards an infection, increase the effectiveness of conventional antiviral 
drugs/combinations, or even trigger the immune response of a patient. However, it is to be noted that 
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changes in formulation, dosing schedule, or route of administration for pre-existing drugs are not 
without significant challenges. 
In conclusion, the work presented in this thesis demonstrated the development and characterisation 
of SN-38 NP formulations. They offer an alternative to solve issues surrounding the solubility of SN-38 
and its delivery to tumour sites. Despite the promising in vitro data, the results of the pharmacokinetic 
studies did not reveal any benefit of the SN38-loaded NPs, compared to the prodrug irinotecan. NPs 
represent a potentially feasible and favourable choice for SN-38 in antitumour research and it is 
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Appendix A Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities 




As the first lockdown was announced and COVID-19 became a bigger issue in the UK, it led to the 
shutdown of universities and other research institutions. This prompted a change in research direction 
and we decided to pivot our focus onto COVID-19 research, with a specific focus on identifying 
potential therapeutic interventions. There is a rapidly expanding literature on the in vitro antiviral 
activity of drugs that may be repurposed for therapy or chemoprophylaxis against SARS-CoV-2. 
However, this has not been accompanied by a comprehensive evaluation of the target plasma and 
lung concentrations of these drugs following approved dosing in humans. Accordingly, EC90 values 
recalculated from in vitro anti-SARS-CoV-2 activity data were expressed as a ratio to the achievable 
maximum plasma concentrations (Cmax) at an approved dose in humans (Cmax/EC90 ratio). Only 19 of 
the 66 analysed drugs achieved a Cmax/EC90 ratio above 1. A more in-depth assessment demonstrated 
that only nitazoxanide, nelfinavir, tipranavir (ritonavir-boosted) and sulfadoxine achieved plasma 
concentrations above their reported anti-SARS-CoV-2 activity across their entire approved dosing 
interval. An unbound lung to plasma tissue partition coefficient (KpUlung) was also simulated to derive 
a lung Cmax/EC50 as a better indicator of potential human efficacy. Hydroxychloroquine, chloroquine, 
mefloquine, atazanavir (ritonavir-boosted), tipranavir (ritonavir-boosted), ivermectin, azithromycin 
and lopinavir (ritonavir-boosted) were all predicted to achieve lung concentrations over 10-fold higher 
than their reported EC50. Nitazoxanide and sulfadoxine also exceeded their reported EC50 by 7.8- and 
1.5-fold in the lung, respectively. This analysis may be used to select potential candidates for further 
clinical testing, while deprioritising compounds unlikely to attain target concentrations for antiviral 
activity. Future studies should focus on EC90 values and discuss findings in the context of achievable 
exposures in humans, especially within target compartments such as the lung, to maximise the 




Coronavirus 2019 (COVID-19) is a respiratory disease caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) infection. Fever, a persistent cough and respiratory symptoms are 
common, with some patients reporting vomiting, nausea, abdominal pains and diarrhoea (Gu, Han, & 
Wang, 2020). To date, no specific treatment is available, and this has resulted in significant morbidity 
and mortality globally. According to the International Clinical Trials Registry Platform search portal, 
927 clinical trials for COVID-19 have been registered (World Health Organisation, 2020). This rapidly 
expanding pandemic warrants the urgent development of strategies, particularly to protect people at 
high risk of infection. Repurposing clinically evaluated drugs that have been utilised clinically with a 
known safety profile, is the quickest way to address this serious unmet clinical need. Antiviral drugs 
are urgently required for the treatment of patients with mild/moderate disease to prevent the 
worsening of symptoms and reduce the burden upon healthcare systems. However, a different 
approach is likely to be needed for patients that are already in a critical state, due to the immune 
dysregulation which is so apparent in severe cases (Qin et al., 2020).  
Previous investigations have shown that the entry by SARS-CoV-2 occurs via the angiotensin-
converting enzyme 2 (ACE2) receptor (W. Li et al., 2003). A study on normal lung tissue showed that 
83% of ACE2-expressing cells were alveolar epithelial type II cells (Zhao et al., 2020), highlighting the 
lungs as the primary target organ that facilitate viral invasion and replication. Furthermore, the ACE2 
receptor is also highly expressed in gastrointestinal epithelial cells, with SARS-CoV-2 RNA observed to 
be present in stool specimens of patients during infection (Gu et al., 2020; Wu et al., 2020). A recent 
retrospective analysis of 85 patients with laboratory-confirmed COVID-19 also indicated that SARS-
CoV-2 infects human kidney tubules and induces acute tubular damage in some patients (Diao et al., 
2020). Furthermore, 2–11% of patients with COVID-19 exhibit liver comorbidities (C. Zhang, Shi, & 
Wang, 2020). Of note is an observation of SARS and the Middle East respiratory syndrome (MERS) 
having a tropism to the gastrointestinal tract (Guo et al., 2020) and causing liver impairment in 
addition to respiratory disease. The genomic similarity between SARS-CoV-2 and SARS-CoV (79.6% 
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sequence identity) would imply that the current virus would act similarly and be present within the 
body systemically (Hoffmann et al., 2020; S. H. Wong, Lui, & Sung, 2020; H. Zhang et al., 2020). 
Therefore, treatment options that provide therapeutic concentrations of drug(s) within the systemic 
circulation and other affected organs are likely to be required. 
In the absence of a vaccine, antiviral drugs could also be deployed as chemoprophylaxis to protect 
against infection and would present an essential tool for protecting healthcare staff and other key 
workers, as well as household contacts of those already infected. Chemoprevention drugs will need 
to penetrate the multiple sites where SARS-CoV-2 infection occurs and do so in sufficient 
concentrations to inhibit viral replication (W. Zhang et al., 2020). This may include the mucous 
membranes present in the nasal cavity and throat, the ocular surface, tears and the upper respiratory 
tract/lungs (C. W. Lu, Liu, & Jia, 2020; Sun, Wang, Liu, & Liu, 2020). However, therapeutic 
concentrations may not be needed in the systemic circulation for chemoprophylaxis, but this is yet to 
be determined. Although difficult and scarcely studied, work in animals has shown that the size of the 
inoculum of other respiratory viruses such as influenza is associated with the severity of the resultant 
disease (D. S. Miller, Kok, & Li, 2013; C. A. Smith, Kulkarni, Chen, & Goldstein, 2019). Reports with 
SARS-CoV-2 indicate that higher viral loads are indicative of poorer prognosis and correlate with the 
severity of symptoms, with viral load in severe cases reported to be 60 times higher than that of mild 
cases (X. Chen et al., 2020; Y. Liu et al., 2020). In light of this, even if a chemoprophylactic drug reduced 
inoculum size without completely blocking transmission, major benefits for morbidity and mortality 
may still be achievable. 
Many ongoing global research efforts are focussed on screening the activity of existing compounds in 
vitro to identify candidates to repurpose for SARS-CoV-2. However, current data have not yet been 
systematically analysed in the context of the plasma and target site exposures that are achievable 
after administration of the approved doses to humans. The purpose of this work was to evaluate the 
existing in vitro anti-SARS-CoV-2 data to determine and prioritise drugs capable of reaching antiviral 
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concentrations within the blood plasma. Accepted physiologically based pharmacokinetic (PBPK) 
equation were also used to predict the expected concentration in the lung (Rodgers, Leahy, & 
Rowland, 2005; Rodgers & Rowland, 2006, 2007), to assess the potential of these drugs for therapy in 



















A.2.1 Candidate Analysis 
To identify compounds and their relevant potency and pharmacokinetic data, a literature search was 
performed on PubMed, Google Scholar, BioRxiv, MedRxiv, and ChemRxiv. The following search terms 
were used for in vitro activity data – (COVID-19 OR SARS-CoV-2) AND (EC50 OR IC50 OR antiviral). For 
pharmacokinetic data (Cmax OR pharmacokinetics) was used along with the drug name for drugs with 
reported anti-SARS-CoV-2 activity. Further clinical pharmacokinetic data were obtained from the Food 
and Drug Administration (FDA), the European Medicines Agency (EMA) and through publications 
available online. Inhaled medications were excluded from all analyses because the purpose was to 
assess systemically administered medicines. 
A.2.2 Lung Accumulation Prediction  
An indication of the degree to which candidate drugs are expected to accumulate in the lung (a 
presumed site of primary efficacy and for prevention of SARS-CoV-2 infection) was provided by 
calculation of unbound lung to plasma tissue partition coefficient (KpUlung) according to the 
methodology of Rodgers and Rowland (Rodgers et al., 2005; Rodgers & Rowland, 2006, 2007). 
Equations therein were implemented in the R programming environment (version 3.6.3). Briefly, the 
physicochemical properties of the drug (pKa, log P, classification as acid/base/neutral) and in vitro 
drug binding information (fraction unbound in plasma, blood to plasma ratio), in combination with 
tissue-specific data (lipid content, volumes of intra/extracellular water etc.) were used to predict 
tissue KpU values. Measured log P and pKa values were used where available but substituted with 
calculated values where necessary and all parameter values used for the calculations for each drug, 
and their references/sources, are provided in Table B.9. KpUlung values were converted to Kp_lung by 
multiplying by fraction unbound in plasma to allow estimation of lung exposure from in vivo 
measurements of plasma Cmax concentration. A similar analysis was conducted to assess the tissue 
distribution into other tissues. In the absence of observed tissue distribution data, the Rodgers and 
Rowland method is an accepted means to provide initial estimates of tissue partitioning for PBPK 
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modelling. However, there are known limits on accuracy with predicted KpU by the Rodgers and 
Rowland method generally reported to be within 2-3-fold of observed tissue KpU values (Rodgers et 
al., 2005; Rodgers & Rowland, 2006, 2007). This was confirmed for a limited number of drugs within 
the current dataset for which measure Kp values for lung were available from animal studies in the 
literature (see data analysis below). The lung accumulation prediction was performed by Henry 
Pertinez and Rajith Rajoli. 
A.2.3 Data Analysis and Interpretation 
Since in the majority of papers only an EC50 value was available, concentration-response data were 
digitised using the Web Plot Digitizer® software. Graphs were then replotted in SigmaPlot 14.0 (Systat 
Software, Inc.) and curves were fitted to confirm EC50 values and determine EC90 values. A Cmax/EC50 
and Cmax/EC90 ratio was then calculated for each drug for which previous evidence of clinical use in 
humans and the availability of human pharmacokinetic data were available. Lung and other tissue KpU 
values were used in combination with reported Cmax values to derive an estimate of lung exposure at 
Cmax for each drug. For a subset of molecules, the absence of available physicochemical or plasma 
protein binding parameters prohibited the derivation of a KpU estimate. For the remaining drugs, a 
lung (or other tissue) Cmax/EC50 and lung Cmax/EC90 were calculated. Published plasma concentration-
time data for the most promising candidates were then digitised (where available) and replotted to 
visually represent human pharmacokinetics relative to the calculated EC50 and EC90 data. Equivalence 
between values for the predicted lung Kp and those observed in vivo was undertaken for drugs with 
available animal lung and plasma concentration data. For this analysis, animal lung concentration data 
were available for anidulafungin (rat), bazedoxifene (rat), chloroquine (three albino rat studies), 
favipiravir (monkey), hydroxychloroquine (two albino rat studies), nitazoxanide (mouse), tamoxifen 
(rat), cyclosporine (rat), ritonavir (rat), azithromycin (mouse), dolutegravir (mouse), gilteritinib (albino 
rat), and lopinavir (rat) (Browning, 2014; Chandrasekaran et al., 2010; Damle, Stogniew, & Dowell, 
2008; Gupta, Tulsankar, Bhatta, & Misra, 2017; Kawai, Mathew, Tanaka, & Rowland, 1998; Lien, 
Solheim, & Ueland, 1991; McChesney, Banks, & Fabian, 1967; Moss et al., 2015; PMDA, 2018; Rivulgo 
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et al., 2013). Agreement between the predicted and measured Kp was assessed by simple linear 
regression and by constructing Bland-Altman plots, the limits of agreement (mean ± 2 standard 





















A.3 Results  
A.3.1 Identified Papers and Methods 
20 key studies that detailed the antiviral activity of 79 compounds were identified (Bojkova et al., 
2020; Bukreyeva et al., 2020; Caly, Druce, Catton, Jans, & Wagstaff, 2020; Choy et al., 2020; Fintelman-
Rodrigues et al., 2020; Nils C. Gassen et al., 2020; Ge et al., 2020; Gorshkov et al., 2020; S. Jeon et al., 
2020; Jin et al., 2020; Ko, Jeon, Ryu, & Kim, 2020; Lo et al., 2020; Ohashi et al., 2020; Touret et al., 
2020; M. Wang et al., 2020; Weston, Haupt, Logue, Matthews, & Frieman, 2020; T. Xu, Gao, Wu, 
Selinger, & Zhou, 2020; Yamamoto, Matsuyama, Hoshino, & Yamamoto, 2020; Yao et al., 2020; Zhijian 
et al., 2020). The majority of the in vitro SARS-CoV-2 infection experiments were performed in Vero 
E6 cells (ATCC 1586) maintained in either DMEM or MEM. Other studies utilised Vero-hSLAM cells, 
Calu-3, Vero E6 cells expressing TMPRSS2 and the CACO-2 cell line to cultivate the virus. The following 
SARS-CoV-2 strains were used across studies; WA-1 strain – BEI #NR-52281; Brazil/RJ-314/2020; C-
Tan-nCoV Wuhan strain 01; Wuhan/WIV04/2019; USA-WA1/2020; nCoV-
2019BetaCoV/Wuhan/WIV04/2019; BetaCoV/Hong Kong/VM20001061/2020; SARS-CoV-2 strain 
Munich; Australia/VIC01/2020; SARS-CoV-2/1/Human/2020/Frankfurt; βCoV/KOR/KCDC03/2020 and 
BavPat1/2020. Cells across all studies were infected with the virus with a multiplicity of infection (MOI) 
of 0.0005, 0.002, 0.01, 0.0125, 0.02, 0.05 and 0.1. Drugs were added at concentrations varying 
between 0.01μM - 500μM. A summary of the differences in methodologies between studies is 
presented in Table A.1. A ranking of included drugs based just on their EC50 and recalculated EC90 is 
presented in Figure B.11. 
A.3.2 Identification of Candidates Achieving Plasma Concentrations Expected to Exert 
Antiviral Activity (Cmax/EC50 Ratio) 
Seventeen molecules had a reported Cmax value greater than at least one of the reported EC50 values 
against SARS-CoV-2 and these were nelfinavir, chloroquine, remdesivir, lopinavir (ritonavir-boosted), 
eltrombopag, hydroxychloroquine, atazanavir (ritonavir-boosted), indomethacin, favipiravir, 
sulfadoxine, niclosamide, mefloquine, tipranavir (ritonavir-boosted), ritonavir, merimepodib, 
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anidulafungin and nitazoxanide. However, it should be noted that for amodiaquine, atazanavir, 
chloroquine, hydroxychloroquine, lopinavir, mefloquine, nelfinavir, remdesivir and toremifene, more 
than one EC50 value had been reported across the available literature and these were not always in 
agreement (Figure A.1a). Moreover, this variability in reported EC50 values sometimes resulted in 
Cmax/EC50 ratios giving a different estimation of the likely value of the molecule. Meaning that for the 
same drug, the Cmax/EC50 ratio could be above or below 1 (Figure A.1b). For amodiaquine and 
toremifene, all reported EC50 values were below their reported Cmax and only for nelfinavir was the 
reported Cmax value expected to exceed both reported EC50 values. For atazanavir, chloroquine, 
hydroxychloroquine, lopinavir, mefloquine and remdesivir, some EC50 values were above the Cmax 
whereas others were below. This observation dramatically highlights the sensitivity of the current 
analysis of the reported antiviral activity data, and this should be taken into account when interpreting 
the data presented hereafter. 
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Figure A.1 Assessment of the variation in reported EC50 values for SARS-CoV-2 across the drugs for which more 
than one value was available in the literature (a). The consequences of this variability in reported EC50 in terms 
of the Cmax/EC50 ratio is also provided (b). Amodiaquine and toremifene were estimated to exhibit sub-
therapeutic pharmacokinetics irrespective of which EC50 value was used. Similarly, nelfinavir was estimated to 
have Cmax value higher than its EC50 irrespective of which EC50 was used in the analysis. For the other drugs, 
interpretation was highly dependent upon which reported EC50 was utilised and this underscores the caution 







A.3.3 Identification of Candidates Achieving Plasma Concentrations Exceeding the SARS-Cov-
2 EC90 (Cmax/EC90 Ratio) 
For 66 of the reported antiviral activities, data covering a sufficient concentration range were available 
for digitisation and subsequent calculation of an EC90 value. For the remainder, it was not possible to 
calculate an EC90. Drugs with an available EC90 were ranked according to their Cmax/EC90 ratio (Figure 
A.2). Drugs with a value above 1.0 achieved plasma concentrations above the concentrations reported 
to inhibit 90% of SARS-CoV-2 replication. Only eltrombopag, favipiravir, lopinavir, remdesivir, 
nelfinavir, niclosamide, nitazoxanide and tipranavir were estimated to exceed at least one of their 
reported EC90 by 2-fold or more at Cmax concentrations. Anidulafungin, chloroquine and ritonavir were 
also reported to exceed at least one of their reported EC90 values at Cmax but by less than 2-fold. It was 




Figure A.2 A bar chart displaying Cmax/EC90 ratio for compounds studied for in vitro antiviral activity against SARS-
CoV-2 for which data were available to recalculate an EC90. Drugs with a ratio below 1 were deemed not to 
provide plasma concentrations at their approved doses to exert sufficient systemic antiviral activity. Those drugs 
with a ratio above 1 (shown in orange) were deemed to have potential to provide plasma concentrations 
sufficient to exert at least some antiviral activity for at least some of their dosing interval at their approved dose. 
Drugs shown in green were predicted to exceed plasma concentrations over their EC90 by more than 2-fold. 
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A.3.4 Detailed Interrogation of the Plasma Pharmacokinetics in Relation to Reported Anti-
SARS-Cov-2 Activity 
For drugs, with Cmax concentrations above at least one of their reported EC90 values that are not 
already in clinical trials for COVID-19, a detailed evaluation of concentrations across their approved 
dosing interval was undertaken. For this, published pharmacokinetic data were digitised and replotted 
relative to the calculated EC50 and EC90 data for SARS-CoV-2 (Figure A.3). For tipranavir (ritonavir-
boosted), nelfinavir, sulfadoxine and nitazoxanide, plasma concentrations after administration of the 
approved dose remained above SARS-CoV-2 effective concentrations across the entire dosing interval. 
For remdesivir, anidulafungin, eltrombopag, lopinavir (ritonavir-boosted), mefloquine and 
chloroquine, Cmax values were above EC90 at 1.15, 2-, 6-, 8- and 24-hours post-dose, respectively, but 
concentrations would be expected to dip below the EC50 at 1.3-, 3-, 8-, 10-, 72- and 120-hours post-
dose, respectively, when given at approved doses and schedules. An overview of these drugs is 




Figure A.3 Digitised pharmacokinetic interrogation of all drugs calculated to have a Cmax/EC50 ratio above 1. The 
lowest reported SARS-CoV-2 EC50 (dashed orange lines) and associated recalculated EC90 (dashed green lines) 
are also highlighted. References for the utilised data are nitazoxanide 500mg BID and 1000mg BID (Fox & 
Saravolatz, 2005), tipranavir 500mg BID with 200mg ritonavir (la Porte, Sabo, Beique, & Cameron, 2009), 
sulfadoxine 1500mg with 75mg pyrimethamine (de Kock et al., 2017), nelfinavir 1250mg BID (Kruse et al., 2005), 
indomethacin 50mg TID (Rainsford et al., 1992), atazanavir 300mg QD with 100mg ritonavir (Burger et al., 2006), 
hydroxychloroquine 2000mg hydroxychloroquine sulfate/1550mg base administered over 3 days (Tett, Cutler, 
Beck, & Day, 2000), eltrombopag 75mg single dose (Shida, Takahashi, Nohda, & Hirama, 2011), lopinavir 400 mg 
with 100mg ritonavir (FDA, 2020), chloroquine 1500mg administered over 3 days (Na-Bangchang, Limpaibul, 
Thanavibul, Tan-Ariya, & Karbwang, 1994), mefloquine 1200mg over 3 days (Krudsood et al., 2010), 
anidulafungin 100mg QD (P. Liu et al., 2013) and remdesivir 150mg OD for 7 days (Humeniuk et al., 2020). Robust 
pharmacokinetic data were unavailable for niclosamide 500mg, ritonavir 600mg and merimepodib 300mg to 
conduct this digitised interrogation of these molecules. 
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Table A.1 Summary of the top leads identified 




Atazanavir & Ritonavir 
REYATAZ® 
(Bristol-Myers Squibb) 










1.323 1.192 EMA FDA Invasive fungal infections Intravenous infusion 
200 mg QD + 







2.318 1.261 FDA Malaria Extraintestinal amebiasis Oral 1500 mg 
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Primary immune 
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Acquired severe aplastic 
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(Merck & Co) 
5.366 - EMA FDA Rheumatoid arthritis Oral 50 mg TID 
(Yeh, 1985) 
Lopinavir & Ritonavir 
Kaletra® 
(AbbVie) 
2.660 / 1.671 1.630 / 1.240 
EMA 












1.350 1.284 EMA FDA Malaria Oral 250 mg 
(R. N. Price 




1.629 0.638 Not clinically approved HCV Oral 300 mg TID 
(McHutchiso
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Infestation with 









13.823 6.315 FDA 
Diarrhoea caused by 
Giardia lamblia or 
Cryptosporidium parvum 













200 mg +  
100 mg 












6.577  FDA - discontinued Malaria Oral 1500/75 mg 
(K. D. Miller 
et al., 1986) 









*compassionate use programme 
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A.3.5 Simulated Exposure Relative to Reported Anti-SARS-Cov-2 Activity in Lung and Other 
Tissues 
Lung KpU was simulated for all molecules for which the necessary physicochemical properties and in 
vitro drug binding information were available. Regression and Bland–Altman plots were first used to 
assess the agreement between predicted lung Kp and that observed in previously published animal 
studies for drugs with available prior data. Good agreement was observed across the available drugs 
except for chloroquine. An r2=0.86 was observed in linear regression when chloroquine was excluded 
but decreased to r2=0.22 when included (Figure B.12A). Similarly, good agreement between measured 
and predicted Kp was observed by Bland-Altman analysis for all data points except for one chloroquine 
measurement (Figure B.12B). KpUlung was then used along with fraction unbound in plasma (Fu) and 




Figure A.4 A bar chart displaying the simulated lung Cmax/EC50. Drugs with a ratio below 1 were deemed not to 
provide lung concentrations at their approved doses to exert sufficient pulmonary antiviral activity for treatment 
or prevention strategies. Those drugs with a ratio above 1 (shown in orange) were estimated to provide lung 
concentrations sufficient to exert at least some antiviral activity at their approved dose. Drugs shown in green 
were predicted to exceed lung concentrations over their EC50 by more than 10-fold.  
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Tissue Cmax/EC50 ratios are also shown for other tissues in Figure A.5. For 4 drugs, ebselen, 
merimepodib, niclosamide and remdesivir, the fraction unbound data were unavailable. For 6 other 
drugs, benztropine, indinavir, loperamide, nelfinavir, saquinavir and toremifene, the blood to plasma 
ratios were unavailable. For a further 4 drugs, camostat, emetine, fluspirilene and umifenovir, both 
fraction unbound and blood to plasma ratios were unavailable. Therefore, these drugs were excluded 
from the analysis. A total of 18 drugs with available data were predicted to give concentrations in lung 
above at least one of their reported EC50 against SARS-CoV-2 (Figure A.4) and 8 of these were predicted 
to exceed their EC50 by more than 10-fold. The rank order of lung Cmax/EC90 ratio was chloroquine > 
hydroxychloroquine > atazanavir (ritonavir-boosted) > tipranavir (ritonavir-boosted) > lopinavir 
(ritonavir-boosted) > mefloquine > ivermectin > azithromycin > nitazoxanide > ritonavir > gilteritinib > 
amodiaquine > imatinib > oxprenolol (data excluded due to this analysis only being possible for 34 of 




Figure A.5 A heatmap displaying the simulated tissue Cmax/EC50 values for all drugs with available data. Those 
drugs with a ratio above 1 (shown in orange) were estimated to provide tissue concentrations sufficient to exert 
at least some antiviral activity at their approved dose. Drugs shown in green were predicted to exceed tissue 




The systematic development of mechanism-based inhibitors for key targets involved in viral 
replication or pathogenesis is likely to result in highly effective and safe medicines in the coming years. 
However, the repurposing of already approved medicines in antiviral treatment or chemoprevention 
strategies is undoubtedly the fastest way to bring forward therapeutic options against the urgent 
unmet need posed by SARS-CoV-2. A range of different drugs and drug classes have been 
demonstrated to display varying degrees of antiviral activity against SARS-CoV-2 in vitro, and many of 
these drugs are already licenced for use in humans for a range of indications. However, currently, the 
data emerging from global screening efforts are not being routinely benchmarked and prioritised 
against achievable concentrations after administration of doses proven to have acceptable safety 
profiles in humans.  
The current analysis indicates that only 13 drugs with reported antiviral activity are likely to achieve 
plasma exposures above that required for an antiviral activity for at least some of their dosing interval. 
Notably, neither chloroquine, hydroxychloroquine nor lopinavir/ritonavir exhibited a sustained 
plasma concentration above their reported SARS-CoV-2 EC90 across their reported dosing interval. This 
did raise some concerns for ongoing trials with these drugs (chloroquine: NCT04323527; 
NCT04333628, hydroxychloroquine: NCT04316377; NCT04333225; NCT04307693 and 
lopinavir/ritonavir: NCT04331834; NCT04255017; NCT04315948). Of late, it has been shown that 
chloroquine, hydroxychloroquine and lopinavir/ritonavir failed to deliver benefits in randomised 
controlled trials for mild/moderate and severe disease (Cao et al., 2020; Tang et al., 2020). A lack of 
efficacy was seen for lopinavir/ritonavir, and toxicity and safety concerns were present for the 
investigation of hydroxychloroquine for prophylaxis (Borba et al., 2020; P. Yang, Tekwani, & Martin, 
2020). This highlights the importance of systemic suppression (plasma exposure) as a prerequisite for 
a reduction in morbidity or mortality, and that predicted lung accumulation on its own does not 
provide any advantage as seen from the previous chemoprevention trials. 
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At least 8 of the 12 candidates achieving Cmax above one of their reported EC50 and derived EC90 are 
already in clinical evaluation for the treatment of SARS-CoV-2. These include remdesivir 
(NCT04292730; NCT04292899; NCT04257656; NCT04252664; NCT04315948), favipiravir 
(NCT04310228; NCT04319900), niclosamide (NCT04345419; NCT04436458), mefloquine 
(NCT04347031), nitazoxanide (NCT04459286; NCT04441398; NCT04351347; NCT04406246) 
lopinavir/ritonavir and chloroquine. A recent trial for favipiravir demonstrated some success with an 
improvement over arbidol from 56% to 71% (p = 0.02) in patients without risk factors (but not critical 
cases or patients with hypertension and/or diabetes) (C. Chen et al., 2020). The results of 
compassionate use of remdesivir in severely ill patients and a randomised placebo-controlled trial 
were also recently reported, both of which serve as further validation of the other candidates 
presented here (Grein et al., 2020; Y. Wang et al., 2020). Of particular interest, nitazoxanide, 
tipranavir, sulfadoxine and nelfinavir may be expected to sustain their plasma pharmacokinetic 
exposure above their lowest reported EC50 and derived EC90 (where available) for the duration of their 
approved dose and dosing interval.  
Nitazoxanide is an antiprotozoal drug that has previously been demonstrated to display broad antiviral 
activity against human and animal coronaviruses (Rossignol, 2016) as well as various strains of 
influenza (Haffizulla et al., 2014; D. Tilmanis, C. van Baalen, D. Y. Oh, J. F. Rossignol, & A. C. Hurt, 2017). 
Importantly, nitazoxanide is rapidly metabolised to tizoxanide in humans and this active metabolite is 
being investigated against SARS-CoV-2 (NCT04341493 and NCT04343248). Tizoxanide has been 
reported to exhibit similar activities to nitazoxanide for other viruses as well as other pathogens 
(Gekonge, Bardin, & Montaner, 2015; D. Tilmanis, C. van Baalen, D. Y. Oh, J.-F. Rossignol, & A. C. Hurt, 
2017; Trabattoni et al., 2016). The mechanism of antiviral action is not fully understood for 
nitazoxanide, but it has been reported to affect viral genome synthesis, prevent viral entry and 
interfere with the N-glycosylation and maturation of the influenza hemagglutinin (Hickson, 
Margineantu, Hockenbery, Simon, & Geballe, 2018; Rossignol, 2014; Rossignol, La Frazia, Chiappa, 
Ciucci, & Santoro, 2009; Y. M. Wang et al., 2016). Notably, the SARS-CoV-2 spike protein is also highly 
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N-glycosylated (Y. Zhang et al., 2020). This drug has also been shown to elicit an innate immune 
response that potentiates the production of type 1 interferons (Clerici, Trabattoni, Pacei, Biasin, & 
Rossignol, 2011; Rossignol, 2014) and a phase 2b/3 clinical trial demonstrated a reduction in 
symptoms and viral shedding in patients with uncomplicated influenza (Haffizulla et al., 2014). The 
safety of nitazoxanide is well understood, but it has not been fully investigated during renal or hepatic 
impairment. The antiviral activity of nitazoxanide for SARS-CoV-2 requires further study but the 
existing data for this drug are encouraging. Niclosamide is another antiprotozoal drug that exhibits 
broad antiviral activity due to its ability to perturb the pH-dependent membrane fusion required for 
virus entry (Jurgeit et al., 2012), but it was reported to have no impact upon the attachment and entry 
of SARS-CoV-2 (X. W. Zhang & Yap, 2004). For MERS-CoV, niclosamide was observed to inhibit SKP2 
activity impairing viral replication (N. C. Gassen et al., 2019). Niclosamide has been reported to be 
well-tolerated and does not influence vital organ functions (R. Li et al., 2013). However, it has low 
aqueous solubility and poor oral bioavailability (C. K. Lin et al., 2016) and, despite a higher reported 
SARS-CoV-2 potency (S. Jeon et al., 2020) than nitazoxanide (M. Wang et al., 2020), the Cmax/EC90 ratio 
was slightly lower. There is a paucity of published pharmacokinetic data for niclosamide and this 
prohibited a thorough investigation of exposures concerning activity over its entire dosing interval. 
Both nitazoxanide and niclosamide have also been reported to be potent antagonists of TMEM16A, 
calcium-activated chloride channels that modulate bronchodilation (Miner et al., 2019).  
Tipranavir and nelfinavir are HIV protease inhibitors (Lv, Chu, & Wang, 2015) and both drugs ranked 
highly in terms of their Cmax/EC90 ratio. Moreover, a more in-depth analysis demonstrated that the 
concentrations across the dosing interval for both these drugs remained above the calculated EC90 
values at approved doses and schedules. Unlike nelfinavir, tipranavir has to be co-administered with 
a low dose of ritonavir to boost its pharmacokinetics via CYP3A4 inhibition (Streeck & Rockstroh, 
2007). Since ritonavir itself has been reported to exert anti-SARS-CoV-2 activity, this could be 
advantageous but would need to be balanced against the much higher risk of drug-drug interactions 
that could negatively impact patient management. The implications of drug interactions have already 
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been raised for this reason with lopinavir/ritonavir use for COVID-19 (Sanders, Monogue, Jodlowski, 
& Cutrell, 2020) and are likely to be exacerbated with the higher ritonavir dose needed for tipranavir. 
Moreover, tipranavir has a black box warning from the FDA for fatal and nonfatal intracranial 
haemorrhage as well as severe hepatotoxicity (Chan-Tack, Struble, & Birnkrant, 2008; Flexner, Bate, 
& Kirkpatrick, 2005; Amy C. Justice et al., 2008). The major route of metabolic clearance for nelfinavir 
is via CYP2C19 and this pathway generates the M8 metabolite that retains activity against the HIV 
protease (Hirani, Raucy, & Lasker, 2004). No data are available for inhibition of SARS-CoV-2 replication 
by the M8 metabolite but if active, this could provide an advantage for nelfinavir over tipranavir for 
COVID-19. Conversely, while the analysis of pharmacokinetics relative to potency of these molecules 
against SARS-CoV-2 is encouraging, it should be noted that the reported in vitro activity for HIV (Lv et 
al., 2015; K. E. Zhang et al., 2001) is far higher than that against SARS-CoV-2 and both drugs are highly 
protein-bound (King & Acosta, 2006; Motoya et al., 2006). Given that tipranavir and nelfinavir are 
associated with long-term toxicities (A. C. Justice et al., 2008; Lv et al., 2015; Markowitz et al., 2007; 
Unis et al., 2016), there will be concern over giving even short-term exposure for COVID-19. 
Sulfadoxine is another antimalarial drug that is usually administered in combination with 
pyrimethamine as a folic acid antagonist combination (Lovegrove & Kain, 2008). Sulfadoxine inhibits 
the activity of dihydropteroate synthase within the malaria parasite, but its mechanism of action for 
SARS-CoV-2 is unclear. It should also be noted that the authors can find no data describing the antiviral 
activity of this drug against other viruses. Also, the concentrations used in the in vitro activity used in 
this analysis (Touret et al., 2020) were not high enough to reach or calculate an EC90 value. Therefore, 
like other molecules described in this manuscript, in vitro anti-SARS-CoV-2 activity should be repeated. 
Notwithstanding, sulfadoxine plasma concentrations far above the reported EC50 are maintained in 
patients receiving a single 1500mg dose (with 75mg pyrimethamine) for over 40 days (de Kock et al., 
2017). Compared to some other reported molecules, sulfadoxine is not expected to have as high an 
accumulation in the lungs, but concentrations higher than its EC50 are estimated from the analysis of 
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its lung KpU. Therefore, if the reported antiviral activity is confirmed, this drug may offer opportunities 
for therapy and/or chemoprophylaxis.  
Indomethacin is an Non-Steroidal Anti-Inflammatory Drug (NSAID) that is indicated for rheumatoid 
arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder or acute gouty arthritis. The 
recommended dose for acute gouty arthritis is 50mg three times a day and the pharmacokinetic 
exposure for this is shown in Figure A.3 relative to the reported EC50. Indomethacin mechanism of 
action for SARS-CoV-2 remains elusive, but it was shown to inhibit translation of the vesicular 
stomatitis virus by activating protein kinase R leading to the phosphorylation of eukaryotic initiation 
factor-2 α-subunit (Amici et al., 2015). This abrogated viral protein translation, leading to a dramatic 
inhibition of viral replication and infectious viral particle production. The reported in vitro antiviral 
activity data for indomethacin were insufficient to calculate an EC90 and this activity requires 
confirmation in other studies (T. Xu et al., 2020). Furthermore, the drug has a black box warning for 
serious cardiovascular and gastrointestinal events from the FDA so its use should be managed with 
caution (Nalamachu & Wortmann, 2014). 
Considering that most of the impact of the severe disease occurs in the lung and that this tissue may 
be a key site for transmission, the potential of candidate drugs to accumulate in lung tissue was 
considered. The lung Kp predictions were validated across 13 drugs for which previously reported 
animal plasma and lung concentrations were available and showed good agreement for all agents 
other than chloroquine. The poor fit for chloroquine does highlight that the predictions may not be 
accurate for all of the drugs listed and this should be considered in interpretation. Notwithstanding, 
the analysis of predicted lung Cmax/EC50 ratio revealed more candidates expected to exceed the 
concentrations needed for antiviral activity in this tissue. Hydroxychloroquine, chloroquine, 
mefloquine, atazanavir (ritonavir-boosted), tipranavir (ritonavir-boosted), ivermectin, azithromycin 
and lopinavir were all predicted to achieve lung concentrations over 10-fold higher than their reported 
EC50. All of these drugs were also predicted to exceed their EC90 in the lung by at least 3.4-fold. The 
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lung prediction was not possible for nelfinavir because insufficient data were available to calculate 
KpUlung, but nitazoxanide and sulfadoxine were also predicted to exceed their reported EC50 by 7.8- and 
1.5-fold in the lung, respectively. Nitazoxanide was predicted to exceed its EC90 by 3.6-fold in the lung 
but an EC90 was not calculable from the available data for sulfadoxine.  
Predictions for Cmax/EC50 ratio were also made for other tissues and were generally in agreement with 
observations in the lung with some important exceptions. Gliteritinib, amodiaquine, imatinib, 
indomethacin, oxprenolol, and sulfadoxine were predicted to be subtherapeutic in the brain and bone, 
with indomethacin and sulfadoxine being predicted to be subtherapeutic across most of the tissues in 
which Cmax was estimated. 
During inflammation or injury, changes to the vascular microenvironment could have a profound 
effect on the ability of these drugs to accumulate in lung cells. Due to the recruitment of neutrophils 
and leaky endothelial cells (Pober & Sessa, 2007), the lung inflammatory microenvironment is 
characterised by increased body temperature, excessive enzymatic activity and, most importantly, a 
low interstitial pH (R. Zhang et al., 2019). In the case of chloroquine and hydroxychloroquine, these 
diprotic weak bases are exquisitely dependent on a pH gradient to drive lysosomal uptake as a 
mechanism of lung accumulation. It has been demonstrated that cellular chloroquine uptake is 
diminished 100-fold for every pH unit of external acidification (Geary, Divo, Jensen, Zangwill, & 
Ginsburg, 1990). This situation is likely to deteriorate further on mechanical ventilation, which also 
induces acidification of the lung tissue, independently of inflammation (Drachman et al., 2017; Pugin 
et al., 2008). Therefore, the benefits of lung accumulation for many of these drugs may be lost during 
the treatment of severe SARS-CoV-2 infection. Conversely, mefloquine is monoprotic and more 
lipophilic than chloroquine, which may make it much less reliant on the pH gradient to drive cellular 
accumulation in the lung. The charged form of the drug is likely sufficiently lipophilic to allow 
movement across biological membranes along a concentration gradient (Ginsburg, Nissani, & Krugliak, 
1989). Only two studies have described mefloquine uptake into cells, one study suggested that 
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mefloquine uptake is not energy-dependent and the other suggested that mefloquine uptake is 
mediated by secondary active transport, rather than passive proton trapping (Fitch, Chevli, & 
Gonzalez, 1974; Vanderkooi, Prapunwattana, & Yuthavong, 1988). Mefloquine is known to cause 
severe psychiatric side effects in some patients and so the use of this drug should be managed with 
care (Ritchie, Block, & Nevin, 2013). Therefore, mefloquine may offer opportunities for treatment 
during severe disease that are not available with other drugs currently being tested for COVID-19 
therapy. If the high lung exposures are proven empirically for the drugs on this list, then some may 
also prove to be valuable for chemoprevention strategies. 
This study represents the first holistic view of drugs with reported activity against SARS-CoV-2 in the 
context of their achievable pharmacokinetic exposure in humans. While the analysis does provide a 
basis to rationally selected candidates for further analysis, there are some important limitations. 
Firstly, Cmax was the only pharmacokinetic parameter that was universally available for all of the 
candidate drugs, but Cmin values are generally accepted as a better marker of efficacy since they 
represent the lowest plasma concentration over the dosing interval. However, Cmax was only used to 
assess whether plasma concentration would exceed those required at any point in the dosing interval, 
and this was followed by a more in-depth analysis of the most promising candidates.  
Secondly, an EC50 value only equates to a concentration required to suppress 50% of the virus, and 
data were unavailable to calculate EC90 values for some of the drugs. EC90 values are a preferred 
marker of activity because the slope of the concentration-response curve can vary substantially 
between different molecules and between different mechanisms of action. Although EC90 values were 
not calculable for all drugs, molecules not achieving EC50 at Cmax in this analysis were deprioritised. 
Thirdly, the reported antiviral activities were conducted under different conditions (Table B.10) and 
in several cases varied between the same molecule assessed in different studies (Figure A.1). Also, 
some of the studied drugs (e.g. nitazoxanide and amodiaquine) are rapidly metabolised such that the 
major species systemically is a metabolite that has not been investigated for anti-SARS-CoV-2 activity. 
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No mitigation strategy was possible for these limitations and the data should be interpreted in the 
context that the quality of the available data may profoundly impact the conclusions. In vitro activity 
should be confirmed for the promising candidates and/or relevant metabolites.  
Fourthly, plasma protein binding can be an important factor in determining whether sufficient free 
drug concentrations are available to exert antiviral activity (Gonzalez, Schmidt, & Derendorf, 2013) 
and insufficient data were available across the dataset to determine protein binding-adjusted EC90 
values. This is important because for highly protein-bound drugs the antiviral activity in plasma may 
be lower than reported in vitro activity because protein concentrations used in culture media are 
lower than those in plasma. Fifthly, robust pharmacokinetic data were not available for all the 
molecules and subtle differences have been reported in the pharmacokinetics in different studies. 
Where possible, this analysis utilised the pharmacokinetics described at the highest doses approved 
for other indications and checked them to ensure that profound differences were not evident between 
different studies. However, in some cases, higher doses and/or more frequent dosing has been 
investigated for some of the drugs mentioned so higher exposures may be available for some drugs 
with off-label dosing. Sixthly, the digitised pharmacokinetic plots presented represent the mean or 
median profiles depending on what was presented in the original manuscripts. Many of the drugs 
presented are known to exhibit high inter-individual variability that is not captured within the 
presented analysis and it is possible that even for promising candidates, a significant proportion of 
patients may have sub-therapeutic concentrations despite population mean/median being higher 
than the Cmax. Advanced pharmacokinetics modelling approaches will be needed to unpick the 
exposure-response relationship and these studies are currently underway by the authors.  
Seventhly, the presented predictions for lung accumulation may offer a basis for ranking molecules 
for expected accumulation in that organ, but the ultimate effectiveness of a chemoprophylactic 
approach will likely depend upon penetration into other critical matrices in the upper airways, for 
which there are currently no robustly validated methods of prediction. Also, while a generally 
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accepted method for assessing KpU was employed, the predictions were only validated for a subset 
of drugs for which previous animal lung accumulation data were available. Also, the KpU method 
assumes all the processes are passive and perfusion limited, and the complexity of pulmonary tissue 
pharmacokinetics is not captured in this analysis. The lungs include different structures including 
airways, bronchioles and alveoli with different blood flow perfusion and more detailed modelling 
validated through animal experiments will be required to capture this complexity.  
Finally, this analysis assumes that drugs need to be active within the systemic compartment to have 
efficacy against SARS-CoV-2. Since current evidence suggests that the virus is widely disseminated 
throughout the body this is a logical assumption. However, the ultimate efficacy of any drug can only 
be demonstrated with robust clinical trial designs.  
 
A.5 Conclusion 
The current analysis reveals that many putative agents are never likely to achieve target 
concentrations necessary to adequately suppress SARS-CoV-2 under normal dosing conditions. 
Candidate medicines emerging from in vitro antiviral screening programmes must be considered in 
the context of their expected exposure in humans where possible. Clinical trials are extremely time-
consuming and expensive, and only the best options must be progressed for robust analysis as 
potential mono- or combination therapy or prevention options. Finally, it would be highly beneficial 
for activity data for SARS-CoV-2 to be performed with a standardised protocol and with activity 
reported as EC90 values as a better marker of the concentrations required to suppress the virus to 









Appendix B  
Table B.1 Origin, genetic and mutational characteristics of investigated human colorectal cancer cell lines 
 DLD-1 HCT116 LoVo 
Patient Male 48-Year-Old Male 56-Year-Old Male 
Site Colon Ascending Colon Colon 
Stage  Dukes’ D Dukes' C 
Source Primary Tumour Primary Tumour Left supraclavicular 
region 
Microsatellite Unstable Unstable Unstable 
CIMP + + - 
CIN - - - 
KRAS G13D G13D G13D; A14V 
BRAF WT WT WT 
PIK3CA E545K;D549N H1047R WT 
PTEN WT WT WT 
TP53 S241F WT WT 





Figure B.1 Morphology and appearance of colorectal cancer cell lines in monolayer (2D). Representative images 
of HCT116 and CT26 cells. Phase-contrast images were taken at 10x magnification using a phase-contrast 
microscope (ECLIPSE TS100/100-F, Nikon) Images were captured using a digital camera head (DS-Vi1, Nikon) 
and a stand-alone controller and display unit (DS-L3, Nikon). Scale bars shown are 100μm. For H&E, cells were 
grown on coverslips, stained and scanned using the Leica Aperio CS2 Slide Scanner. Images were then processed 





Figure B.2 Morphology of monolayer cells following drug treatment. Cells grown in monolayer on coverslips 
were treated with control (0.1% DMSO) or SN38 (predetermined IC50) for 72 hours. Coverslips were then 
processed, stained with H&E and mounted onto slides before scanning them with the Leica Aperio CS2 Slide 
Scanner. Images were then processed using the ImageScope software. Scale bars shown are 200μm. 
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Figure B.3 Concentration-response curves for (a) LoVo and (b) DLD-1 cells grown in 2d vs. 3d. ATP levels were 
measured in following treatment with SN-38 [nM], for 72 hours in 2D and 72/144 hours in 3D (n=3 using 6 
technical replicates, average ± %SD). Cell viability was calculated as a percentage of untreated vehicle control 
samples (DMSO – 0.1%). The dashed horizontal line represents the half-maximal inhibitory concentration (IC50).  
 
Figure B.4 Detection of topo I-DNA covalent complexes by fluorescence microscopy in HCT116 cells (2D). Time-
course experiment after treatment with SN-38 at previously determined IC50 concentrations. HCT116 cells were 
fixed, permeabilised, incubated with SDS and stained with α-TopoIcc antibody (green), γ-H2AX (red) and Hoechst 
33258 (blue). Images were taken on a Zeiss inverse Axio observer confocal microscope (Zeiss LSM 710, Carl Zeiss) 





Figure B.5 Detection of topo I-DNA covalent complexes by fluorescence microscopy in CT26 cells (2D). Time-
course experiment after treatment with SN-38 at previously determined IC50 concentrations. CT26 cells were 
fixed, permeabilised, incubated with SDS and stained with α-TopoIcc antibody (green), γ-H2AX (red) and Hoechst 
33258 (blue). Images were taken on a Zeiss inverse Axio observer confocal microscope (Zeiss LSM 710, Carl Zeiss) 





Figure B.6 Detection of topo I-DNA covalent complexes by fluorescence microscopy in microscopy following 
irinotecan treatment in 3D. After treatment for 24 hours with irinotecan at previously determined IC50 
concentrations or a nominal concentration of 100µM (A/C) HCT116 and (B) CT26 spheroids were fixed, 
permeabilised, incubated with SDS and stained with α-TopoIcc antibody (green), γ-H2AX (red) and Hoechst 
33258 (blue). Images A and B are spheroid sections and were taken on a Zeiss inverse Axio observer confocal 
microscope (Zeiss LSM 710, Carl Zeiss) using an x5 objective with apotome. Scale bars represent 100μm. For 






Figure B.7 Histological assessment of human tissue samples. Tissue samples from three patients were stained 
with H&E. Slides were scanned with the Leica Aperio CS2 Slide Scanner. Images were then processed using the 









Figure B.8 Drug release profiles SN-38 loaded nanoparticles, (a) SB1 and (b) CA16, in phosphate-buffered saline 





















































Figure B.9 Concentration-response curves for monolayer cells treated with select polymer nanomaterial’s. ATP 
levels were measured in monolayer (2D) cells treated with (a) SB1, (b) SB2, (c) SB3, (d) SB7, (e) SB8, (f) CA1, (g) 
CA14, (h) CA16, (i) CA18 and (j) CA19 [nM], between 24-72 hours (n=3 using 6 technical replicates, Average ± 
%SD). Cell viability was calculated as a percentage of untreated vehicle control samples (blank nanoparticles in 


























Figure B.10 ATP levels were measured in HCT116 and CT26 spheroids treated with SN-38 or (a) SB2, (b) SB3, (c) 
SB7, (d) SB8, (e) CA1 (f) CA14, (g) CA18 and (h) CA19 NPs, for 72 (i and iii) or 144 hours (ii and iv). Cell viability 
was calculated as a percentage of untreated vehicle control (DMSO – 0.1% or blank NP samples). Representative 
phase-contrast images (10x objective) are documented to capture spheroid integrity following treatment with 





Table B.2 SN-38 pharmacokinetic parameters after intravenous administration of irinotecan in BALB/c mice 
Parameter Unit Value 
Lambda_z 1/h 0.719390582 
t1/2 h 0.963519954 
Tmax h 0.5 
Cmax ng/ml 1189.407127 
C0 ng/ml 801.9322051 
Clast_obs/Cmax  0.031903685 
AUC 0-t ng/ml*h 2478.134565 
AUC 0-inf_obs ng/ml*h 2530.882642 
AUC 0-t/0-inf_obs  0.979158229 
AUMC 0-inf_obs ng/ml*h^2 3753.363652 
MRT 0-inf_obs h 1.483025562 
Vz_obs (mg/kg)/(ng/ml) 0.021969655 
Cl_obs (mg/kg)/(ng/ml)/h 0.015804763 
Vss_obs (mg/kg)/(ng/ml) 0.023438867 
 
Table B.3 SN-38 pharmacokinetic parameters after intravenous administration of SN-38 in BALB/c mice 
Parameter Unit Value 
Lambda_z 1/h 0.346483553 
t1/2 h 2.000519719 
Tmax h 0.08333 
Cmax ng/ml 7.410866071 
C0 ng/ml 8.191211344 
Clast_obs/Cmax  0.185840068 
AUC 0-t ng/ml*h 12.51392937 
AUC 0-inf_obs ng/ml*h 16.4888247 
AUC 0-t/0-inf_obs  0.758933981 
AUMC 0-inf_obs ng/ml*h^2 52.02464282 
MRT 0-inf_obs h 3.155145606 
Vz_obs (mg/kg)/(ng/ml) 0.350072237 
Cl_obs (mg/kg)/(ng/ml)/h 0.121294273 
Vss_obs (mg/kg)/(ng/ml) 0.382701092 
 
Table B.4 SN-38 pharmacokinetic parameters after intravenous administration of SB1 in BALB/c mice 
Parameter Unit Value 
Lambda_z 1/h 0.18494123 
t1/2 h 3.747932144 
Tmax h 0.25 
Cmax ng/ml 388.6866014 
C0 ng/ml 336.2519704 
Clast_obs/Cmax  0.011463756 
AUC 0-t ng/ml*h 170.6280618 
AUC 0-inf_obs ng/ml*h 194.7211667 
AUC 0-t/0-inf_obs  0.876268691 
AUMC 0-inf_obs ng/ml*h^2 266.1092272 
MRT 0-inf_obs h 1.366616849 
Vz_obs (mg/kg)/(ng/ml) 0.055537086 
Cl_obs (mg/kg)/(ng/ml)/h 0.010271097 




Table B.5 SN-38 pharmacokinetic parameters after intravenous administration of CA16 in BALB/c mice 
Parameter Unit Value 
Lambda_z 1/h 0.234685946 
t1/2 h 2.953509535 
Tmax h 0.0833 
Cmax ng/ml 47.97942206 
C0 ng/ml 122.0050613 
Clast_obs/Cmax  0.067072534 
AUC 0-t ng/ml*h 37.00648474 
AUC 0-inf_obs ng/ml*h 50.71885842 
AUC 0-t/0-inf_obs  0.729639544 
AUMC 0-inf_obs ng/ml*h^2 178.5947928 
MRT 0-inf_obs h 3.521269965 
Vz_obs (mg/kg)/(ng/ml) 0.168024821 
Cl_obs (mg/kg)/(ng/ml)/h 0.039433064 
Vss_obs (mg/kg)/(ng/ml) 0.138854465 
 
Table B.6 SN-38 glucuronide pharmacokinetic parameters after intravenous administration of irinotecan in 
BALB/c mice 
Parameter Unit Value 
Lambda_z 1/h 0.367042549 
t1/2 h 1.88846547 
Tmax h 0.5 
Cmax ng/ml 266.4015067 
C0 ng/ml 186.1051998 
Clast_obs/Cmax  0.131020915 
AUC 0-t ng/ml*h 521.2600514 
AUC 0-inf_obs ng/ml*h 616.3557543 
AUC 0-t/0-
inf_obs  0.845712963 
AUMC 0-inf_obs ng/ml*h^2 1503.670297 
MRT 0-inf_obs h 2.439614276 
Vz_obs (mg/kg)/(ng/ml) 0.176812158 
Cl_obs (mg/kg)/(ng/ml)/h 0.064897585 















Table B.7 SN-38 glucuronide pharmacokinetic parameters after intravenous administration of SB1 in BALB/c 
mice 
Parameter Unit Value 
Lambda_z 1/h 0.329293685 
t1/2 h 2.104951331 
Tmax h 0.25 
Cmax ng/ml 435.353171 
C0 ng/ml 328.8925898 
Clast_obs/Cmax  0.043130541 
AUC 0-t ng/ml*h 266.9049856 
AUC 0-inf_obs ng/ml*h 323.9270865 
AUC 0-t/0-
inf_obs  0.823966246 
AUMC 0-inf_obs ng/ml*h^2 498.8347173 
MRT 0-inf_obs h 1.53995988 
Vz_obs (mg/kg)/(ng/ml) 0.018749916 
Cl_obs (mg/kg)/(ng/ml)/h 0.006174229 
Vss_obs (mg/kg)/(ng/ml) 0.009508065 
 
Table B.8 SN-38 glucuronide pharmacokinetic parameters after intravenous administration of CA16 in BALB/c 
mice 
Parameter Unit Value 
Lambda_z 1/h 0.09433441 
t1/2 h 7.347766103 
Tmax h 0.5 
Cmax ng/ml 15.38037915 
C0 ng/ml 9.977672081 
Clast_obs/Cmax  0.257717227 
AUC 0-t ng/ml*h 37.55547812 
AUC 0-inf_obs ng/ml*h 79.57395956 
AUC 0-t/0-
inf_obs  0.471956885 
AUMC 0-inf_obs ng/ml*h^2 724.6456589 
MRT 0-inf_obs h 9.106567813 
Vz_obs (mg/kg)/(ng/ml) 0.266433536 
Cl_obs (mg/kg)/(ng/ml)/h 0.02513385 









Figure B.11 Reported EC50 and EC90 derived from in vitro anti-SARS-CoV-2 activity data. (A) The reported EC50 
values of various drugs against SARS-CoV-2 ranked from most potent to least potent (B) The recalculated EC90 




Figure B.12 (A) Scatter plot showing linear regression for predicted and measured lung Kp. Data are presented 
with (red) and without chloroquine (black). (B) A Bland-Altman plot displaying the relative differences of 
predicted and measured lung Kp for the 13 drugs for which previously reported animal lung concentrations were 
available. The 95% limits of agreement, defined as the mean difference plus and minus 2 times the standard 





















































Highest clinical dose 
approved Indication 
Population 


























BavPat1 0.6µM to 40µM RT-PCR 
360 ug QD (up to 







































plaque assay / 
TCID50/ qRT-
PCR 














plaque assay / 
TCID50/ qRT-
PCR 
450 mg QD Malaria Healthy Volunteers 
670.
3 
Amprenavir 0.01 VeroE6/TMPRSS2 No info 
0.01-


























Atazanavir 1 0.01 Vero E6 Brazil/RJ-314/2020 10- 1000 µM RT-PCR 
300/100 mg OD 






Atazanavir 2 0.01 VeroE6/TMPRSS2 No info 
0.01-
1000 uM RT-PCR 
300/100 mg OD 










BavPat1 0.6µM to 40µM RT-PCR 500 mg QD 



























Benztropine 0.01 Vero E6 cells 




plaque assay / 
TCID50/ qRT-
PCR 

































































Chloroquine 4 0.01 Vero cells C-Tan-nCoV Wuhan strain 01 
0.032 - 
100 uM RT-PCR 






Chloroquine 5 0.01 Vero E6 cells 




plaque assay / 
TCID50/ qRT-
PCR 














plaque assay / 
TCID50/ qRT-
PCR 






Clomipramine 0.01 Vero E6 cells 




plaque assay / 
TCID50/ qRT-
PCR 























Darunavir 0.01 VeroE6/TMPRSS2 No info 
0.01-
1000 uM RT-PCR 
600/100 mg BID 


































2 mg loading QD 



































scence 75 mg QD 
Idiopathic 
thrombocytope














No info TCID50 assay/ qRT-PCR 



















600 mg BID Ebola Healthy volunteers 
6150
0 
Fluphenazine 0.01 Vero E6 cells 




plaque assay / 
TCID50/ qRT-
PCR 









Fluspirilene 0.01 Vero E6 cells 




plaque assay / 
TCID50/ qRT-
PCR 















































quine 1 0.01 Vero cells 
C-Tan-nCoV 
Wuhan strain 01 
0.032 - 










quine 2 0.01 
Vero E6 
cells 




plaque assay / 
TCID50/ qRT-
PCR 
































250 mg IM (single 
dose) 
Reduces the 




Imatinib 0.01 Vero E6 cells 




plaque assay / 
TCID50/ qRT-
PCR 
400mg BID Cancer Healthy volunteers 
1907
.5 
Indinavir 0.01 VeroE6/TMPRSS2 No info 
0.01-










































scence 150 mg BID Cystic fibrosis 
Healthy 
volunteers 1962 































Lopinavir 1 0.01 VeroE6/TMPRSS2 No info 
0.01-
1000 uM RT-PCR 
400/100 mg 















































































aged 17 - 
50 
Mefloquine 2 0.01 Vero E6 cells 




plaque assay / 
TCID50/ qRT-
PCR 






aged 17 - 
50 
3279 




 300mg TID 








Nelfinavir 1 0.01 VeroE6/TMPRSS2 cells No info 
0.01-







Nelfinavir 2 0.01 VeroE6/TMPRSS2 No info 
0.01-

























Niclosamide 2 0.0005 VeroFM cells 
SARS-CoV-2 strain 
Munich 
0 - 100 

































































































500mg TID Herpes zoster Healthy Volunteers 3340 
246 
 
Promethazine 0.01 Vero E6 cells 




plaque assay / 
TCID50/ qRT-
PCR 
25mg BID Motion Sickness Healthy volunteers 18 












200mg IV loading 
dose, then 100mg 
IV daily for 5-10 
days 
covid-19 Healthy Volunteers 2600 




BavPat1 0.6µM to 40µM RT-PCR 
200mg IV loading 
dose, then 100mg 
IV daily for 5-10 
days                                                                                                  
covid-19 Healthy Volunteers 2600 









200mg IV loading 
dose, then 100mg 
IV daily for 5-10 
days                                                                                                                         
covid-19 Healthy Volunteers 2600 











200mg IV loading 
dose, then 100mg 
IV daily for 5-10 
days                                                                                                                                         
covid-19 Healthy Volunteers 2600 










200mg IV loading 
dose, then 100mg 
IV daily for 5-10 
days                                                                                                                         
covid-19 Healthy Volunteers 2600 





200mg IV loading 
dose, then 100mg 
IV daily for 5-10 
days                                                        
covid-19 Healthy Volunteers 2600 









200mg IV loading 
dose, then 100mg 
IV daily for 5-10 
days                                                                                                                         
covid-19 Healthy Volunteers 2600 
247 
 








200mg IV loading 
dose, then 100 mg 
IV daily for 5-10 
days                                               











1200mg OD HCV HCV+ patients 2748 
Ritonavir 0.01 VeroE6/TMPRSS2 No info 
0.01-





Saquinavir 0.01 VeroE6/TMPRSS2 No info 
0.01-
1000 uM RT-PCR 
1000/100mg BID 





















Tamoxifen 0.01 Vero E6 cells 




plaque assay / 
TCID50/ qRT-
PCR 






Tipranavir 0.01 VeroE6/TMPRSS2 No info 
0.01-
1000 uM RT-PCR 
500/200 mg BID 






21 - 58 
77,5
62 

















Toremifene 2 0.01 Vero E6 cells 




plaque assay / 
TCID50/ qRT-
PCR 













Russia and China 
Healthy 
Chinese 
subjects 
467 
 
 
 
 
 
